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Intercellular adhesion molecule 1 (ICAM-1) is a transmembrane protein found on the 
surface of vascular endothelial cells (ECs). Its expression is upregulated at inflammatory sites, 
allowing for targeted delivery of therapeutics using ICAM-1-binding drug carriers. Engagement 
of multiple copies of ICAM-1 by these drug carriers induces cell adhesion molecule (CAM)-
mediated endocytosis, which results in trafficking of carriers to lysosomes and across ECs. 
Knowledge about the regulation behind CAM-mediated endocytosis can help improve drug 
delivery, but questions remain about these regulatory mechanisms. Furthermore, little is known 
about the natural function of this endocytic pathway. To address these gaps in knowledge, we 
focused on two natural binding partners of ICAM-1 that potentially elicit CAM-mediated 
endocytosis: leukocytes (which bind ICAM-1 via β2 integrins) and fibrin polymers (a main 
component of blood clots which binds ICAM-1 via the γ3 sequence). First, inspired by properties 
 
 
of these natural binding partners, we varied the size and targeting moiety of model drug carriers 
to determine how these parameters affect CAM-mediated endocytosis. Increasing ICAM-1-
targeted carrier size slowed carrier uptake kinetics, reduced carrier trafficking to lysosomes, and 
increased carrier transport across ECs. Changing targeting moieties from antibodies to peptides 
decreased particle binding and uptake, lowered trafficking to lysosomes, and increased transport 
across ECs. Second, using cell culture models of leukocyte/EC interactions, inhibiting regulatory 
elements of the CAM-mediated pathway disrupted leukocyte sampling, a process crucial to 
leukocyte crossing of endothelial layers (transmigration). This inhibition also decreased 
leukocyte transmigration across ECs, specifically through the transcellular route, which occurs 
through a single EC without disassembly of cell-cell junctions. Third, fibrin meshes, which 
mimic blood clot fragments/remnants, bound to ECs at ICAM-1-enriched sites and were 
internalized by the endothelium. Inhibiting the CAM-mediated pathway disrupted this uptake. 
Following endocytosis, fibrin meshes trafficked to lysosomes where they were degraded. In 
mouse models, CAM-mediated endocytosis of fibrin meshes appeared to remove fibrin remnants 
at the endothelial surface, preventing re-initiation of the coagulation cascade. Overall, these 
results support a link between CAM-mediated endocytosis and leukocyte transmigration as well 
as uptake of fibrin materials by ECs. Furthermore, these results will guide the future design of 
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Chapter 1: Motivation and Goals 
 
Lining the interface between blood and tissues, vascular endothelial cells use a 
diverse set of molecules to achieve functions that are critical to organismal homeostasis 
[1]. One of these molecules is intercellular adhesion molecule 1 (ICAM-1), a 
glycoprotein of the immunoglobulin superfamily expressed on the surface of endothelial 
cells [2] that mediates recruitment of leukocytes to sites of inflammation [3]. Due to its 
localized upregulation during the inflammatory response [4], ICAM-1 has gained 
attention in the field of drug delivery; this molecule can be used to target therapeutics to 
diseased tissue by employing ICAM-1-binding drug delivery carriers [5]. The 
development of these targeting strategies has led to the discovery of a non-classical 
endocytic pathway known as cell adhesion molecule (CAM)-mediated endocytosis, 
which is activated when drug carriers bind multiple copies of ICAM-1 on the surface of 
endothelial cells [6]. Uptake of carriers through this pathway depends on Na+/H+ 
exchanger 1 (NHE1), acid sphingomyelinase (ASM)-driven production of ceramide, and 
rearrangement of actin into stress fibers [6-8]. After uptake, drug carriers undergo 
trafficking to lysosomes, as well as transcytosis across cell barriers [9-11]. 
Although significant efforts have been made to understand and optimize the use 
CAM-mediated endocytosis for drug delivery, several questions remain about the 
regulation of this pathway. Furthermore, CAM-mediated endocytosis has been associated 
with endocytic phenomena, such as recycling of this molecule at the immunological 
synapse [12] and entry of human rhinovirus into cells [13, 14], but the physiological role 
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of the CAM-mediated pathway in the endothelium is still obscure. The objective of the 
work presented in this dissertation was to expand our understanding of CAM-mediated 
endocytosis in the context of drug delivery, and to explore the physiological relevance of 
this pathway in the endothelium. 
To achieve this, we focused on two important natural ligands of ICAM-1: 
leukocytes, which bind to ICAM-1 via β2 integrins, and fibrin polymers, which bind to 
ICAM-1 via the fibrin(ogen) γ3 sequence. While αLβ2 is found in multiple copies on the 
surface of leukocytes [15], fibrin polymers are the main component of the blood clot 
matrix [16]. Thus, both leukocytes and blood clots have the potential to bind multiple 
copies of ICAM-1 on the surface of cells, similar to drug carriers that elicit the CAM-
mediated pathway. In addition to this, leukocyte or fibrin(ogen) interaction with 
endothelial cells elicits similar signaling and responses seen during CAM-mediated 
endocytosis [17, 18], including massive rearrangement of the actin cytoskeleton [19, 20]. 
In the case of leukocytes, this signaling has been linked to the process of transmigration 
across endothelial cells, which requires membrane and vesicular dynamics [21]. In the 
case of fibrin clots, it has been shown that interaction with endothelial cells leads to clot 
extravasation [22]. Thus, it is plausible that CAM-mediated endocytosis is activated upon 
binding of leukocytes and fibrin polymers to ICAM-1, and that this pathway is involved 
in endothelial functions associated with leukocytes and/or blood clots. 
Inspired by notable properties of these ICAM-1 natural binding partners, we first 
explored how the parameters of size and targeting moiety can affect binding, 
internalization and intracellular trafficking of drug carriers targeted to CAM-mediated 
endocytosis (Aim 1). Then, we explored the potential role of regulatory elements of the 
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CAM-mediated pathway in the interaction between the endothelium and leukocytes (Aim 
2) or fibrin polymers (Aim 3). Improving our understanding of CAM-mediated 
endocytosis can allow for the optimization of drug delivery strategies that use ICAM-1 as 
a target. Furthermore, increasing our knowledge of leukocyte and blood clot interaction 
with the endothelium may expand our basic understanding of endothelial cells and has 
important clinical relevance. 
The following section (Chapter 2) will provide a background on ICAM-1, CAM-
meditated endocytosis, and the interaction of the endothelium with leukocytes and blood 
clots. Chapter 3 will summarize the methodologies used in our studies. Then, chapters 4, 
5 and 6 will describe and discuss the results found for each respective aim. Finally, 
Chapter 7 will present the conclusions of this work, and provide future directions that 




Chapter 2: Background 
 
2.1. Intercellular Adhesion Molecule 1 (ICAM-1) 
Intercellular adhesion molecule 1 (ICAM-1; CD54) is a glycoprotein of the 
immunoglobulin superfamily first characterized in 1986 as a 90 kDa antigen necessary 
for homotypic aggregation of leukocytes [23]. Contemporary studies revealed that 
ICAM-1 was expressed on the surface of fibroblasts and endothelial cells (among others), 
and showed its role in lymphocyte adhesion to non-hematopoietic cells and its 
upregulation in the presence of several cytokines [2, 24], forecasting its importance in the 
inflammatory response. Within five years of its discovery, a variety of studies 
consolidated ICAM-1 as a molecule crucial to immune function, highlighting its role in T 
cell-mediated cytotoxicity [25] and B cell activation [26], T cell activation [27-30], 
lymphocyte-endothelium interactions [3, 26], and various pathologies [4, 31-34]. 
Structurally, ICAM-1 is a type I transmembrane protein, whose extracellular 
region consists of five Ig-like domains (D1 at the N-terminus, through D5 adjacent to the 
plasma membrane) [35-37]. These domains are arranged linearly in a kinked rod-like 
conformation that extends from the cell surface (Figure A), positioning ICAM-1 in a 
manner suitable for its function as an adhesive co-receptor for leukocytes on both 
hematopoietic and non-hematopoietic cells [26, 38]. The five extracellular domains are 
connected via a single transmembrane region to the cytosolic C-terminal tail of ICAM-1. 
Consisting of 28 residues [36], the ICAM-1 cytosolic domain lacks conventional protein-
protein interaction sequences. However, it contains several positively charged residues 
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and one tyrosine, which seem to account for its protein-binding and signaling activities 
[39-43], as described below. 
 
Figure A. ICAM-1 structure, binding and signaling. Intercellular adhesion molecule 1 (ICAM-1) on the 
plasma membrane (horizontal line). Domains D1 through D5 are found on the extracellular side of the 
plasmalemma and comprise 453 amino acids (a.a.). ICAM-1 can interact with integrins LFA-1 and Mac-1 
as well as fibrin(ogen). A transmembrane domain is followed by a C-terminal short cytosolic tail (28 a.a.), 
which can interact with cytosolic proteins (*NHE1 is not cytosolic, but transmembrane). ICAM-1 signals 
through a variety of molecules, most of which converge in rearrangement of the actin cytoskeleton, often 
associated with opening of endothelial cell-cell junctions. ICAM-1 signaling also induces overexpression of 
inflammatory molecules. Adapted from Serrano and Muro [5]. 
 
Endothelial expression of ICAM-1 is constitutive, yet low, but its expression is 
upregulated during inflammatory and thrombogenic states by cytokines and other factors, 
including TNFα, IFNγ, TGFβ, thrombin, fibrin and fibrinogen, and reactive oxygen 
species [2, 44-46]. In addition to being expressed on endothelial cells and leukocytes, 
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ICAM-1 is also found on dendritic and epithelial cells, fibroblasts, neurons, myocytes 
and other cell types [2, 47]. Furthermore, several isoforms of this protein have been 
identified, including splicing and post-translational glycosylation variants, along with a 
soluble form of ICAM-1 that can appear in circulation and corresponds to the full 
extracellular domain of this protein, and which is thought to compete against endothelial 
ICAM-1 for integrin binding as a means of regulating inflammatory events [34, 48]. 
Natural ligands that bind to ICAM-1 include leukocyte integrins αLβ2 
(lymphocyte function-associated antigen 1, LFA-1) and αMβ2 (macrophage-1 antigen, 
Mac-1) which bind, respectively, to the extracellular domains D1 and D3 of the molecule 
[38, 49]. Fibrinogen and fibrin also bind to domain D1 and serve as an additional bridge 
between leukocytes (macrophages) and endothelial cells, improving binding and 
transmigration [50, 51]. In addition, some pathogens exploit the prevalence and luminal 
binding availability of ICAM-1, including human rhinovirus [52], plasmodium 
falciparum-infected erythrocytes [53], and possibly polioviruses and HIV [54, 55]. 
Interaction with cytosolic molecules accounts for certain functions of ICAM-1. In 
particular, most proteins known to bind the cytosolic tail of ICAM-1 serve as 
cytoskeleton adaptors: α-actinin [41], β-tubulin [40], and erzin [56]. Radixin and moesin, 
the two other members of the ezrin-radixin-moesin (ERM) family of actin adaptors, have 
been found to colocalize with ICAM-1 [57, 58]. These interactions with members of the 
cytoskeleton or cytoskeleton-adaptor proteins appear to be important for ICAM-1 
distribution on the plasma membrane, as ICAM-1 is normally found enriched in 
microvilli structures, while deletion of its cytoplasmic domain results in homogeneous 
distribution on the cell surface [41, 56, 59]. Scanning electron microscopy reveals that 
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this redistribution is itself associated with a loss in microvilli structures [59], suggesting a 
link between ICAM-1 and the formation of membrane protrusions. 
Signal transduction is also associated with ICAM-1 cytosolic residues. 
Multivalent binding of ICAM-1 at the surface of endothelial cells using antibodies 
activates xanthine oxidase activity, generating reactive oxygen species (ROS) that in turn 
activate Src-kinases [60-63]. ICAM-1 cross-linking also activates small GTPase Rho [19, 
57, 58, 64], RhoA [58] and perhaps other Rho proteins [60, 65], and mitogen-activated 
protein kinases (MAPK) [63, 66]. In turn, p38 MAPK phosphorylates HSP27 and this 
leads to cytoskeletal rearrangement [67]. Along with MAPK, cytoskeleton-associated 
proteins ezrin, cortactin, focal adhesion kinase, paxillin, and p130Cas are also 
phosphorylated downstream of Src [60, 62, 63], consistent with multiple reports that 
cross-linking ICAM-1 elicits rearrangement of the actin cytoskeleton [6, 68-70]. 
Wittchen [17] as well as Lawson and Wolf [71] have recently summarized the current 
signaling paradigms associated with ICAM-1, which often converge in the opening of 
endothelial cell-cell junctions. 
These signaling events occur in parallel to ICAM-1 redistribution to detergent-
resistant membrane fractions, a phenomenon likely to be important for signaling through 
ICAM-1. For instance, Src activation seems to depend on Src-homology domain 2 
containing phosphatase 2 (SHP-2), which binds to ICAM-1 upon cross-linking and entry 
into detergent-resistant membrane fractions [39, 72]. This is followed by SHP-2-
dependent Src activation and ERK1/2 signaling, leading to increased expression of 
inflammation-related genes like IL-1β, RANTES, VCAM-1, and ICAM-1 itself [73, 74]. 
Specialized lipid domains might serve as rigid platforms required for localized 
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maintenance of ICAM-1-dependent signaling events and cytoskeletal remodeling [75]. 
Our recent findings also suggest that these cytoskeletal rearrangements depend on ICAM-
1-mediated production of ceramide [7], a signaling lipid also known to promote the 
formation of membrane microdomains [76]. Although a comprehensive mapping of the 
signals mediated by ICAM-1 and their respective functional significance remains to be 
performed, the following sections will illustrate the several of the cascades mentioned 
above can be ascribed to the functions of this protein. 
 
2.2. Cell Adhesion Molecule (CAM)-Mediated Endocytosis 
ICAM-1 was initially thought to serve only as an adhesive molecule, but 
subsequent work revealed signaling properties associated with it [71]. In addition, studies 
on the use of ICAM-1 for endothelium-targeted delivery of therapeutics led to the 
discovery of its endocytic activity: a pathway known as cell adhesion molecule (CAM)-
mediated endocytosis is activated upon engagement of multiple copies of ICAM-1 by 
ICAM-1-targeted drug carriers (Figure B) [6]. This multivalent engagement, which can 
be achieved by the interaction between antibody-coated nano- or microparticles and 
ICAM-1 on the endothelial cell surface, elicits the recruitment of Na+/H+ exchanger 1 
(NHE1) to particle binding sites [8]. This occurs with concomitant mobilization of acid 
sphingomyelinase from perinuclear regions of the cell and enrichment of this enzyme at 
NHE1- and ICAM-1-rich sites of the plasma membrane where particles bind [7]. The 
activity of acid sphingomyelinase is responsible for subsequent enrichment of ceramide 
at sites of binding, which results in endocytosis of drug carriers as small as 100 nm and as 
large as 10 µm in diameter [7, 77]. The mechanism that results in uptake is dependent on 
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vesicle formation and rearrangement of the actin cytoskeleton, both of which were 
initially mapped downstream of Rho and rho-dependent kinase (ROCK), protein kinase C 
(PKC) and Src, as well as dynamin [6], and now are also attributed to sphingomyelinase 
activity [7]. Such signaling cascades are in agreement with historical reports using 
antibodies to cross-link ICAM-1 [68, 78, 79]. 
 
Figure B. The CAM-mediated pathway of endocytosis. CAM-mediated endocytosis is initiated upon 
multivalent engagement of ICAM-1 by ICAM-1-binding drug carriers. ICAM-1 engagement elicits the 
recruitment of NHE1, which is itself an adaptor of the actin cytoskeleton. Concomitant mobilization of acid 
sphingomyelinase to sites of carrier binding leads to conversion of sphingomyelin to ceramide. This leads 
to vesicle formation and rearrangement of actin. Signaling through Rho/ROCK, PKC, and Src elicits actin 
rearrangement and dynamin-dependent endocytosis. Internalized vesicles fuse into early endosomes, where 
ICAM-1 dissociates from anti-ICAM particles and recycles back to the plasma membrane. Early 
endosomes maturate into/fuse with lysosomes in an NHE6-dependent manner. The final trafficking 
destination of particles is the lysosome. In addition to lysosome trafficking, transport of carriers across cells 
occurs. Inhibitors of NHE1 include amiloride and EIPA. Inhibitors of acid sphingomyelinase include 
imipramine. Not shown, CAM-mediated endocytosis also occurs with PECAM-1-binding carriers. Adapted 
from Ding et al. [80]. 
 
Although the biophysical properties that promote vesicle detachment from the 
plasma membrane and/or fusion into larger compartments to internalize both nanometric 
and micron-sized objects have not been fully elucidated, they are likely associated with 
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the involvement of ceramide in this pathway. In other systems, generation of ceramide 
produces changes in the plasma membrane suitable for flexible uptake, such as promotion 
of large lipid domains [81, 82], modification of the membrane curvature resulting in 
ATP-independent vesiculation [81, 83, 84], vesicular fusion [85, 86], and also 
cytoskeletal rearrangement [87, 88]. 
Following CAM-mediated uptake, drug carriers are trafficked to early endosomes 
in a microtubule-dependent manner, and later colocalize with lysosomes, reaching 
maximum accumulation at approximately 3 hours after internalization [6, 9, 89]. This 
trafficking pattern is slow compared to typical pathways such as pinocytosis, where 
accumulation in lysosomes can occur as early as 15 minutes after uptake [89]. 
Meanwhile, it appears that ICAM-1 detaches from carriers in maturing endosomes [8] 
and recycles to the plasma membrane [9]. Recent studies also indicate that a fraction of 
carriers internalized by CAM-mediated endocytosis undergo transport across epithelial 
and endothelial cells [10, 11], but the trafficking itinerary followed within cells during 
this transport remains unexplored. It should be noted that although the majority of work 
regarding CAM-mediated endocytosis has focused on ICAM-1, the engagement of 
multiple copies of another immunoglobulin superfamily protein, platelet/endothelial cell 
molecule 1 (PECAM-1), on endothelial cells also leads to this endocytic pathway [6]. 
Whether or not other immunoglobulin superfamily CAMs elicit CAM-mediated 
endocytosis remains unknown. 
CAM-mediated uptake is categorized as a non-classical endocytic pathway (Table 
1). The pathway is unrelated to clathrin- and caveolae-dependent uptake, as 
pharmacological inhibitors of caveolae- (filipin and genistein) or clathrin-mediated (K+ 
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depletion and monodansylcadaverine) endocytosis do not inhibit internalization elicited 
by multivalent binding of ICAM-1 [6]. Furthermore, fluorescently labeled anti-ICAM 
particles do not colocalize with clathrin heavy chain or caveolin-1 during the process of 
internalization or intracellular trafficking [6]. This is confirmed by transmission electron 
microscopy images of the mouse pulmonary endothelium, which show that anti-ICAM 
particles are contained in endothelial cell invaginations and vesicles not associated with 
typical morphological features of these two classical endocytic pathways, such as 
caveolar pits and clathrin coats [77]. Furthermore, endocytosis of anti-ICAM particles is 
not inhibited in caveolin knockout mice [7]. 
Due to the close association between CAM-mediated endocytosis and the actin 
cytoskeleton, this pathway shares certain features with macropinocytosis and 
phagocytosis, in particular PKC dependence, as PKC inhibitors bisindolylmaleimide-1 
(BIM-1) and 1-(5-isoquinoline-sulphonyl)-2-methylpiperazine (H-7) reduce, and PKC 
stimulator phorbol 12-myristate 13-acetate (PMA) increases, internalization of anti-
ICAM particles [6]. However, CAM-mediated endocytosis does not exhibit the formation 
of phagocytic actin cups or membrane ruffling, as the two other pathways [6]. 
Furthermore, CAM-mediated endocytosis is independent of microtubules for 
internalization to occur, unlike macropinocytosis, and of phosphatidylinositol 3-
phosphate kinase (PI3K) signaling, unlike phagocytosis, but depends on dynamin [6]. 
Further differentiation between CAM-mediated uptake and classical pathways of 
endocytosis comes from its association with acid-sphingomyelinase-driven generation of 
ceramide [7], although growing evidence is connecting sphingomyelinases and ceramide 
to many modes of endocytosis [90, 91]. 
 
 
Table 1. Comparison of endocytic pathways. 
 












>1µm + + + - - + Cav, Clat 
Receptor-mediated + + - + + + M 
Dynamin-2 + + - + + + M 
NHE - - + - - + C, F, Cav, Clat 
PKC + + + + + + n 
Actin + + + + + + n 
Actin cup + + + - - - C, F, M 
Microtubules + - + + + - C, M, Cav, Clat 
Src kinase - + + + + + C 
PI3 kinase + + + ? - - C, F, M 
Rho/ROCK + - ? ? ? + F 
Caveolin-1 - - - + - - Cav 
Sensitive to 
MDC/K+ depletion - - - - + - Clat 
Sensitive to 
filipin/genistein ? ? - + - - Cav 
Sensitive to 
LatA/CytD + + + + + 
+ (LatA) / 
- (CytD) 
C, F, M, 
Cav, Clat 
Sphingomyelinase/ 
ceramide pathway - + - ? ? + C, M 
Adapted from Caron and Hall [92], and Muro et al [6] 
+, required for uptake/event observed; –, not required for uptake/event not observed; ?, no definitive data found in the literature/not previously tested. 
MDC, monodansylcadaverine; LatA, latrunculin A; CytD, cytochalasin D;  C, complement receptor (CR)-mediated phagocytosis; F, FcR-mediated phagocytosis; 
M, macropinocytosis;  Cav, caveolae-mediated endocytosis; Clat, clathrin-mediated endocytosis; CME, CAM-mediated endocytosis; n, none. 
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An important aspect differentiating CAM-mediated uptake from other modes of 
endocytosis is its promiscuity regarding the size of drug carriers internalized. While 
clathrin- and caveolae-mediated endocytosis are mechanically restricted to internalize 
objects below a few hundred nanometers in diameter [93], macropinocytosis and 
phagocytosis are associated with uptake of micron-sized objects [94, 95]. A clear 
example of these limitations of this comes from the internalization of IgG-coated 
particles by macrophages, where increasing particle size shifts the uptake mechanism 
from clathrin-dependent to phagocytic [96]. In the case of CAM-mediated endocytosis, 
particles that bind ICAM-1 use this mechanism regardless of their size. These particles 
can range between 100 nm and 10 µm in diameter, and still share signaling features as 
well as uptake kinetics, efficiencies, and molecular dependencies [77]. 
With its flexible limitations on particle size for uptake, CAM-mediated 
endocytosis has been a suitable tool for understanding the role of size and shape on post-
endocytic trafficking. This is important, as the field of drug delivery aims to understand 
the role of geometry on endocytic outcomes in order to optimize therapeutic strategies 
[77, 97-100]. Following CAM-mediated entry into cells, large ligands, such as those 1 
µm and 3 µm in diameter traffic to lysosomes more slowly than nanometric counterparts 
and they reach a plateau of lower colocalization with lysosomes [77], indicating 
differences in trafficking for objects of different sizes. Furthermore, disc-shaped carriers 
exhibit lower uptake efficiencies compared to spherical carriers of a similar diameter 
[77], implicating object shape in the outcomes that follow CAM-mediated uptake. 
Other evidence indicates that besides ligand geometry, the receptor epitope 
targeted by a drug carrier can also affect CAM-mediated endocytic outcomes [101]. 
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Particles coated with antibodies to different epitopes of PECAM-1 exhibit different 
binding properties, with some antibodies providing low, while others providing high, 
carrier binding to endothelial cells despite the fact that all antibodies behaved similarly 
when presented as free molecules in solution [101]. Out of the population of antibodies 
that elicit substantial carrier binding, some reveal efficient CAM-mediated uptake, while 
others are not internalized by cells. Finally, out of the population of anti-PECAM carriers 
that induce similar endocytosis, some undergo efficient trafficking of carriers to 
endothelial lysosomes, while others do not, depending on the PECAM-1 epitope bound 
[101]. 
As illustrated here, a large body of work has described the properties of drug 
carrier-induced CAM-mediated endocytosis. However, gaps in knowledge remain 
regarding its biological function. If cells are equipped with the machinery necessary to 
induce an endocytic pathway upon the binding of ICAM-1, it is likely that this 
mechanism occurs in nature and has a relevant physiological significance. As will be 
described, understanding the phenomena behind ICAM-1 binding to its natural ligands 
can guide the efforts to fill this gap. 
 
2.3. Leukocyte Transendothelial Migration 
Two notable natural ligands of ICAM-1 are leukocyte integrins αLβ2 (LFA-1) and 
αMβ2 (Mac-1) [38, 49, 102], which bind at domains D1 and D3, respectively [103, 104]. 
Initially, these interactions were thought to contribute only to the firm adhesion of 
leukocytes to the endothelium, but signaling functions have now been attributed to 
ICAM-1-integrin binding. Since a single leukocyte exhibits multiple copies of these 
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integrins, it can engage multiple copies of ICAM-1 on the same endothelial cell. Thus, 
some of the signaling events observed during ICAM-1 multivalent binding by antibodies, 
as described in Section 2.1, and by antibody-coated drug carriers (Section 2.2) match 
with those associated with leukocyte binding to endothelial cells [71]. ICAM-1 
engagement by leukocytes mediates signaling involving Ca2+, Src kinases and PKC, 
Rho/ROCK-mediated formation of actin stress fibers, and binding of actin crosslinkers to 
the cytosolic domain of ICAM-1 [105-107]. These signaling events are important for 
leukocytes to move from the bloodstream into tissues, a process known as transmigration. 
Since leukocytes must perform a variety of functions outside of their sites of 
origin and beyond the circulation, transmigration is crucial for proper functioning of the 
immune system. This process can occur both under normal conditions for surveillance, 
and during abnormal conditions, such as the inflammatory response [108, 109]. In both 
cases, it is necessary for leukocytes to travel outside of the bloodstream in a regulated 
manner to minimize or prevent pathology [110]. This regulated recruitment of leukocytes 
into tissues is described as a sequential series of events that results in transmigration 
(Figure C) [111]. In this model, leukocytes undergo tethering, followed by rolling 
interactions, strong adhesion, lateral crawling, and finally transmigration, which can 




Figure C. Leukocyte recruitment at the endothelium and transmigration. Leukocytes (white blood 
cells, WBC) undergo selectin-mediated tethering and rolling, followed by integrin-mediated firm adhesion, 
which leads to formation of endothelial docking structures (star). After firm adhesion, crawling (not shown) 
involves lateral migration of leukocytes to sites suitable for transmigration. Finally, transendothelial 
migration can occur by two means. The transcellular route involves tractive forces by docking structures, 
and endothelial cell vesicular fusion into transcellular pores. The paracellular route involves opening of 
endothelial cell-cell junctions and crossing of the endothelium through these junction openings. Taken from 
Serrano [113]. 
 
The initial steps of tethering and rolling involve the interaction of leukocyte L-
selectin or endothelial cell P-selectins with PSGL1 (P-selectin glycoprotein ligand 1) and 
other glycosylated ligands complementarily expressed on either leukocytes or endothelial 
cells [111, 114-116]. At sites of inflammation, activated endothelial cells additionally 
express E-selectin, which supports slow leukocyte rolling [117]. 
The transient leukocyte-endothelial cell interaction imparted by rolling 
mechanisms allows for activation of leukocyte integrins, which leads to firm adhesion 
[109]. The most commonly studied interactions in firm adhesion are those of leukocyte 
integrins αLβ2 (LFA-1) and α4β1 (very late antigen 4, VLA-4) with ICAM-1 and vascular 
adhesion molecule 1 (VCAM-1), respectively [38, 118]. Despite its name, firm adhesion 
does not imply absolute immobilization of the leukocyte on the endothelial surface. 
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Instead, lateral movement of the leukocyte, even against blood flow, occurs prior to 
crossing of the endothelial barrier [109]. 
The step of transmigration features notable signaling cascades, as well as 
membrane changes at the protein/lipid composition and morphological levels in both the 
leukocyte and the endothelium. For instance, the lateral crawling of leukocytes on the 
endothelial surface changes leukocyte morphology from round to flattened [59, 119, 
120]. Along with this, leukocytes extend protrusions (~0.2-1 µm in diameter and up to 
several microns in length [121]) against the plasmalemma of endothelial cells, which is 
thought to allow for the leukocyte to probe for sites suitable for transmigration [121, 
122]. 
Interestingly, the process of transmigration is also dependent on active 
participation by the endothelial cell. This reflects the regulated nature of the event, where 
the leukocyte does not force itself across the endothelial barrier, but must instead be 
granted access. At sites of leukocyte probing, endothelial cells develop ICAM-1-enriched 
invaginations and vesicles from 200 nm to 1 µm in diameter that coalesce to form pores 
through which leukocytes transmigrate [121]. Simultaneously to leukocyte probing, 
endothelial cells extend protrusions around leukocytes, which form a structure known as 
the transmigratory cup, or docking structure, whose presence is necessary for 
transmigration [105, 123, 124]. These structures can form by a single endothelial cell, or 
be composed of contributing adjacent endothelial cells, and could serve as a directional 
track for the leukocyte to follow, or a plug to prevent crossing of blood components into 
tissue [123, 125]. The formation of the transmigratory cup, which is enriched in ICAM-1 
and VCAM-1 likely due to profuse integrin-CAM interactions, is associated with 
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rearrangement of the actin cytoskeleton to form stress fibers, and depends on the 
cytosolic tail of ICAM-1 [59, 105, 123, 126, 127]. The maintenance of these large 
regions of specific molecular enrichment is associated with protein/lipid rearrangement to 
form specialized lipid domains at the plasma membrane that allow for ICAM-1-
dependent signaling events. This is manifested in the enrichment of ICAM-1, VCAM-1, 
tetraspanin CD9, actin, RhoG, ezrin, and moesin [105, 123, 124, 126], and a 
redistribution of ICAM-1 to detergent-resistant membrane fractions [128]. 
In addition to VCAM-1 and ICAM-1, PECAM-1 also has a role in transmigration. 
This molecule is expressed on endothelial junctions, and its homophilic interaction serves 
in the maintenance of monolayer integrity [129]. During transmigration, PECAM-1 
contained in so-called lateral border recycling compartments traffics to sites of leukocyte 
interaction with endothelial cells, and promotes crossing of the endothelial barrier [109, 
130]. The mechanism of involvement by PECAM-1 remains to be fully understood, but it 
is thought that transient leukocyte PECAM-1 interactions with endothelial PECAM-1 
may serve as a track for crossing through the endothelium. In addition, it may be possible 
that multivalent homophilic interactions induce vesicle formation to open a path in the 
endothelial barrier, possibly implicating PECAM-1 in the opening of endothelial pores 
[6, 130-132]. 
 
2.4. Route of Leukocyte Transmigration 
For decades, transmigration was accepted to occur solely through the paracellular 
pathway, which involves dissociation of cell junctions between endothelial cells, and 
passage of leukocytes in between these opened junctions [111, 133]. This satisfies a 
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model in which leukocytes transmigrate through a path of least resistance, and is in 
agreement with many of the signaling events ascribed to ICAM-1 and VCAM-1, which 
are associated with disassembly of endothelial cell-cell junctions [134, 135]. 
However, even early studies suggested an alternative route of transmigration 
independent of junctional disruption, with electron micrographs showing lymphocytes 
inside the endothelial cytoplasm or in vacuoles [136, 137]. This evidence was treated 
cautiously until cell culture studies proved the crossing of endothelial layers by 
leukocytes not only without disruption of cell-cell junctions, but also at sites distant from 
the endothelial border [123, 127, 138]. In this route, a leukocyte moves across the body 
of an individual endothelial cell through a process that involves fusion of endothelial 
vesicles into a so-called transcellular pore, whose dimensions vary but can be as large as 
several microns in diameter [122, 123, 138]. Recent evidence suggests that the 
mechanisms behind the transcellular and paracellular pathways might be similar, as 
junctional proteins migrate from cell-cell junctions to sites of transcellular transmigration 
[130], but this has not been seen in all instances of transmigration [139]. 
The extent to which the two routes of transmigration are used by leukocytes, the 
conditions in which one is favored over the other, and the regulation between para- 
versus transcellular migration remain controversial [111, 133, 140]. Despite 
methodological difficulties in characterizing these phenomena and a lack of systematic 
studies attempting to define their regulation, it is likely that the differences in route 
preference rates observed in different studies depend on factors such as endothelial and 
white blood cell type, flow conditions, and cell activation states. For instance, the 
transcellular route can be as low as 10% or as high as 100% of all transmigration events, 
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depending on the conditions used [17]. In addition, only recent studies have successfully 
quantified transcellular transmigration in vivo [141], agreeing with the lower rate found 
in cell culture studies (less than 10%), yet this technique remains to be used to categorize 
transmigration in a variety of endothelial beds and leukocyte types. 
Despite discrepancies, the role of ICAM-1 in leukocyte transcellular 
transmigration is well recognized. TNFα-activation of HUVECs to induce ICAM-1 
overexpression increases the percentage of polymorphonuclear leukocytes that migrate 
using the transcellular route [127]. Further, blocking or deleting the cytoplasmic domain 
of ICAM-1 reduces primarily transcellular transmigration events, suggesting that 
transcellular migration depends on ICAM-1 signaling and/or association with actin [127]. 
During the transcellular pathway, ICAM-1 becomes internalized and undergoes 
transcytosis to the basal membrane of endothelial cells [138], which is likely a 
manifestation of transcellular pore aperture. 
Some works suggest a contribution of caveolar endocytosis [138, 142] and/or the 
related vesiculo-vacuolar organelle [143] in the formation of the transcellular pore. Other 
works, however, have shown more partial association between ICAM-1 and caveolin-1 in 
structures that form during transmigration [121, 123]. Thus, although there is consensus 
on the key role of ICAM-1 and vesicle formation in leukocyte transcellular migration, the 
nature of the transcellular pore and the vesicular pathway regulating its dynamic 
formation is still unclear. Due to similarities in signaling and features such as vesicle 
formation/fusion and transcytosis, it is possible that CAM-mediated endocytosis could 




2.5. Coagulation and Fibrinolysis  
The second known ICAM-1 physiological ligand is fibrinogen, a molecule central 
in the coagulation cascade, which is crucial for maintenance of fluid within the 
vasculature upon injury. Fibrinogen is a 340 kDa protein made up of two identical dimers 
linked by multiple disulfide bonds (Figure D) [16]. Each subunit is in turn composed of 
three chains (Aα, Bβ and γ) also stabilized by disulfide bonds [144]. A binding site for 
ICAM-1 is found in the γ chains, so that one fibrinogen molecule has binding potential 
for two molecules of ICAM-1 [145]. Cleavage of fibrinogen by thrombin generates 
fibrin, which polymerizes to form the matrix of blood clots. Since this cleavage removes 
small peptides at the N-terminus of fibrinogen, the γ chains and the ICAM-1-binding site 
are retained when fibrin is formed [146]. Due to polymerization of fibrin into a mesh 
during blood clot formation, ICAM-1 binding capacity is increased, allowing for 
engagement of multiple copies of ICAM-1 during interaction with endothelial cells. 
 
Figure D. Structure of fibrin(ogen). Fibrinogen consists of two identical dimers, each composed of three 
chains (Aα, Bβ, and γ). Waved lines versus ovals represent coiled coil versus globular structure, 
respectively. Straight lines between chains represent disulfide linkages. Red dashed lines represent the 
cleavage sites for fibrin generation. Arrows point at binding sites of molecules as indicated. VE-cadherin 
and ICAM-1 are found on endothelial cells. αVβ3 (also found on endothelial cells) and αMβ2 are leukocyte 




Fibrinogen can also interact directly with vascular endothelial (VE)-cadherin and 
integrin αVβ3, both of which are found on the surface of endothelial cells, like ICAM-1 
[147-149]. Finally, fibrin(ogen) can interact indirectly with endothelial cells by binding 
to receptors of tissue plasminogen activator (tPA) or urokinase (u)PA, or 
thrombomodulin [150, 151]. Besides the endothelium, fibrin(ogen) can interact with 
leukocytes through αVβ3 and αMβ2 (Mac-1) [152], and platelets through αIIbβ3 [149]. 
Although fibrinogen and fibrin are central elements of the coagulation cascade, 
this mechanism is composed of a large number of molecules that interact in a complex 
manner [153]. This is due to the required balance between formation of fibrin to create 
clot polymers, and degradation of these polymers in order to spatially and temporally 
confine the gelatinization of blood and cell aggregation [154]. Biochemical 
characterization of the clotting cascade is thorough and well documented [155, 156], 
whereby the phenomenon is described as a two-branched mechanism depending on the 
signal that ignites coagulation: a) exposure to tissue factor (the extrinsic pathway), or b) 
contact activation by exposure to a negatively-charged surface (the intrinsic pathway). 
The two branches converge in the hydrolysis of prothrombin to thrombin, the protease 
responsible for generating fibrin, the main protein component of the clot (the common 
pathway). Current views on this system emphasize the interconnectedness of the two 
branches and the importance of cellular surfaces on which the biochemical reactions can 
occur and be compartmentalized. Three phases are recognized in the process of 





Figure E. Coagulation and fibrinolysis. The model of coagulation has three stages. Initiation involves 
exposure of tissue factor (TF) to components of the blood. TF complexes with active factor VII (‘a’ 
indicates activation) to activate factors IX and X. Factors Xa and Va complex to generate small thrombin 
quantities. Amplification involves thrombin-mediated generation of factors Va, VIIIa, and XIa. IXa from 
initiation (and from XIa activity) complexes with VIIIa to generate more Xa. Propagation occurs when 
sufficient Xa and Va are produced to induce a thrombin burst. After wound repair, plasminogen is 
converted to plasmin by tPA (and uPA), which leads to clot fibrinolysis. Blood clot remnants become 
soluble and are cleared by blood flow and endocytosed by macrophages downstream. It is unknown what 
happens to clot remnants still attached to the endothelium. 
 
After injury and platelet plug formation, initiation proceeds when the ubiquitous 
transmembrane protein tissue factor, normally confined to the non-circulating 
environment, is exposed to blood. This occurs due to vessel injury, or due to induced 
expression of tissue factor on endothelial or blood cells [157-159]. Tissue factor forms a 
complex with factor VII, leading to activation of factors IX and X. At this point, active 
factor IX is not crucial, but instead diffuses and comes into play during propagation. 
Interaction of active factors X and V results in the formation of small quantities of 
thrombin [156]. Amplification involves the thrombin-mediated activation of platelets and 
also factors V, VIII and XI. This is coupled with deposition of circulating fibrinogen on 
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the endothelial cell surface, which induces the production of pro-inflammatory and pro-
coagulant molecules, leading to recruitment of leukocytes and platelets, and increased 
binding of fibrinogen [160, 161]. Active factor XI can generate more active factor IX, 
which interacts with active factor VIII to generate more active factor X. Sufficient 
concentration of active factors V and X leads to propagation, which involves a massive 
burst of thrombin production, cleaving sufficient fibrinogen to generate fibrin polymers 
 Cleavage by thrombin involves the proteolysis of 16 residues at the N-terminal 
region of fibrinogen, exposing polymerization sites that allow for the initial formation of 
simple double-stranded fibrils [146]. Cleavage of a second 14-residue fragment allows 
for inter-fibril associations to produce more complex, branching networks of fibrin, 
creating the blood clot matrix, whose porosity and architecture depend on fibrinogen and 
thrombin concentrations [162]. In parallel, the polymerization of fibrin is consolidated by 
factor XIII, which generates covalent bonds between fibrin molecules, generating the 
fibrin meshes tethered to the endothelial surface. These meshes serve as docks for 
platelets and erythrocytes in the growth of a blood clot. 
The specific endothelial responses to interaction with these fibrin polymers have 
been documented for over three decades, yet they remain relatively sparse. Contact of 
polymerized fibrin with endothelial cells in culture causes disorganization of the 
monolayer, cell retraction, junction disassembly, and migrational behavior of endothelial 
cells. This was proposed as a mechanism for delivery of tPA to sites where fibrin clots 
are present, or a potentiator of coagulation itself by opening of the endothelial barrier and 
exposure to tissue factor [163], yet to our knowledge these hypotheses have not been 
formally tested. In addition to this, fibrin induces release of von Willebrand factor [164], 
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a molecule crucial for clotting due to its role in platelet recruitment and factor VIII 
regulation [165, 166]. Fibrin also increases endothelial expression of ICAM-1 [167], 
supporting the role of clots in self-propagation and promotion of inflammation. 
In terms of molecule-specific responses, VE-cadherin interaction with fibrin 
induces the rearrangement of endothelial cell cultures into capillary-like tubes [168] 
through effects on endothelial cytoskeleton [169]. Binding of fibrinogen to αVβ3 on the 
endothelium induces the production of prostacyclin by endothelial cells (which inhibits 
platelet activation) [170], and this interaction has also been linked to disorganization of 
the endothelial layer and formation of capillary-like structures [171]. 
The interaction between endothelial ICAM-1 and fibrin(ogen) has been more 
thoroughly characterized. First, it is known that fibrinogen can serve as a bridging 
molecule between ICAM-1 on the surface of lymphocytes and ICAM-1 on endothelial 
cells (or Mac-1 on monocytes and ICAM-1 on endothelial cells), increasing the adhesion 
between these two cell types [172]. It was later found that the interaction between 
fibrinogen and ICAM-1 on endothelial cells requires the clustering of ICAM-1 (which is 
actin-dependent), indicating that fibrinogen might not constitutively bind to the 
endothelium, but requires a surface of activated (i.e.: inflamed) endothelium for binding 
[173], and binding occurs at domain D1 of ICAM-1 [50], at an epitope different from 
those responsible for integrin binding [51]. It also appears that fibrinogen and fibrin may 
interact differently with ICAM-1. Fibrin, but not fibrinogen, binding to endothelial cells 
induces overexpression of ICAM-1 to similar levels as potent cytokines [44]. This 
phenomenon is dependent not only on thrombin-mediated cleavage of fibrinogen, but 
polymerization of fibrin into meshes. Thus, although it has not been formally shown, 
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fibrin-dependent upregulation of ICAM-1 is likely mediated by ICAM-1 itself, as the 
kinetics and degree of activation mimic those seen in ICAM-1 autoregulation after 
clustering [44]. In addition to this, fibrinogen interaction with ICAM-1 is known to 
induce mitogenic and proliferative pathways [72, 174]. 
 
2.6. Clot Dissolution and Remnant Clearance 
Following vascular repair, fibrinolysis is required for dissolution of clots (Figure 
E). The fibrinolytic machinery consists of plasmin and plasminogen activators, which are 
active even during clot formation, so a shift in equilibrium is required to favor clot 
degradation. Here, the abundant circulating molecule plasminogen (which can embed 
itself in the clot during clot formation [175]) is converted to plasmin by uPA or tPA, both 
of which can be secreted by endothelial cells [176, 177], and factor XII. Both 
plasminogen and tPA can bind fibrin, localizing the fibrinolytic reaction, while plasmin 
can cleave uPA and tPA to generate more active forms, serving as a positive feedback 
mechanism [178]. In turn, platelets in the vicinity of the clot can release plasminogen 
activator inhibitor 1 (PAI-1), to keep fibrinolytic reactions in check [179]. 
A series of fragments result from plasmin fibrinolytic activity depending on the 
cleavage site within the complex mesh [180]. The best characterized fragments are the D-
dimer, the E fragment, and Bβ15-42, which are known to have pro-and anti-inflammatory 
as well as pro- and anti-coagulant activities [181], highlighting the complex regulation of 
the clotting system up to its final steps. Yet these smaller fragments comprise a small 
percentage of the total plasmin-derived fibrin mesh products. In vitro studies show that a 
heterogeneous selection of less-characterized fragments of larger size are produced, and 
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their size distribution can range by two orders of magnitude in molecular weight [180]. 
Indeed, since complete clot solubilization requires cleavage of only 25% of the fragment 
D-fragment E connections, it is expected that a majority of fibrinolysis material is 
composed of large fibrin polymer meshes. This is supported by the lateral (and not 
outside-in) mode in which clot digestion occurs [182] and electron microscopy studies 
characterizing the released clot fragments which can be up to 400 nm in diameter [183]. 
Despite a clear understanding of the biochemical features of fibrinolysis, and 
some aspects of clot architecture during this process in vitro [178], the interactions of this 
system within a cellular context are not fully understood. For instance, it is not known 
how the binding between clots and endothelial surface molecules, such as ICAM-1, can 
affect their degradation, or retention of clot fragments on the endothelial wall. The 
solubilized fragments that shed from the degrading clot may be removed by blood flow 
[160, 184, 185], followed by off-site uptake by neutrophils through pinocytosis and 
monocytes through integrin Mac-1, and lysosomal degradation [186, 187]. However, the 
postfibrinolytic clot fragments that remain bound to the endothelial surface could be 
responsible for re-ignition of the coagulation cascade, unless they are removed. Under 
pathological conditions this may be the cause of disease, as suggested by the 
consequences of hypofibrinolysis, where there is an increased risk of venous thrombosis 
[188]. Indeed, it appears that the healthy endothelium is equipped to transport blood clots 
from the vasculature into tissue in a process that involves formation of endothelial cell 
membrane protrusions similar to those observed during leukocyte transmigration [22]. 
Thus, if endothelial cells are equipped with mechanisms to perform clearance of these 
fibrin meshes, ICAM-1-dependent CAM-mediated endocytosis could be a possible 
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candidate. Indeed, there is similarity in binding to ICAM-1 and subsequent signaling 





Chapter 3: Methods 
 
3.1. Antibodies and Reagents. 
Monoclonal antibodies used in these studies were: mouse anti-ceramide (IgM; 
Sigma-Aldrich, Inc., Saint Louis, MO), mouse anti-human fibrin β chain (Sekisui 
Diagnostics, Lexington, MA), mouse anti-human ICAM-1 clone LB-2 (Santa Cruz 
Biotechnology, Inc., Santa Cruz, CA), mouse anti-human ICAM-1 clone R6.5 (ATCC, 
Manassas, VA), mouse anti-human integrin α4β1 (VLA-4; Millipore, Billerica, MA), 
mouse anti-human integrin αLβ2 (LFA-1; Millipore), mouse anti-human integrin β3 
(Millipore), mouse anti-human mannose 6-phosphate receptor (M6PR) clone 2G11 
(Novus Biologicals, Littleton, CO), mouse anti-human thrombomodulin (Abcam, 
Cambridge, MA), mouse anti-human tPA receptor (BD Biosciences, , Franklin Lakes, 
NJ), mouse anti-human uPA receptor (Sekisui Diagnostics), mouse anti-human VCAM-1 
(Millipore), and mouse anti-human VE-cadherin clone BV9 (Abcam). Polyclonal 
antibodies were: rabbit anti-human acid sphingomyelinase (Santa Cruz), rabbit anti-
human NHE1 (Santa Cruz), and rabbit anti-human VE-cadherin clone H-72 (Santa Cruz). 
All non-labeled and labeled secondary antibodies were from Jackson Immunoresearch 
Laboratories, Inc. (West Grove, PA), except for FITC-labeled rabbit anti-mouse IgM 
from Santa Cruz. The 17-residue peptide containing the ICAM-1-binding sequence of 
fibrin(ogen) (NNQKIVNLKEKVAQLEA [145]), known as γ3, and a peptide containing 
the corresponding scrambled sequence ALENAEVQNLVKKIQKN (γ3S) were 
synthesized by United Biochemical Research, Inc. (Seattle, WA). Calcein AM, AF594 
phalloidin, DAPI, AF594 or AF488 fibrinogen, and Texas Red dextran (10,000 MW) 
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were from Life Technologies (Grand Island, NY). Polystyrene latex beads were from 
Polysciences, Inc. (Warrington, PA). Na125I was from Perkin Elmer (Waltham, MA) and 
Pierce iodination tubes were from Thermo Scientific (Rockford, IL). Unless otherwise 
stated, all other reagents were from Sigma-Aldrich. 
 
3.2. Microscopy Equipment and Software. 
Phase-contrast and epifluorescence microscopy were performed using an 
Olympus IX81 inverted microscope (Olympus, Inc., Center Valley, PA) with 40× or 60× 
oil immersion objectives (UPlanApo; Olympus, Inc.) and filters in the red (excitation 
BP360-370 nm, dichroic DM570 nm, emission BA590-800+ nm; Semrock, Rochester, 
NY), green (excitation BP460-490 nm, dichroic DM505 nm, emission BA515-550 nm; 
Semrock), or blue (excitation 355-375 nm, dichroic 380 nm, emission 400-480 nm; 
Chroma, Bellows Falls, VT) channels. Micrographs were taken with an ORCA-ER 
camera (Hamamatsu Corporation, Bridgewater, NJ) and SlideBook™ 4.2 (Intelligent 
Imaging Innovations, Inc., Denver, CO). Confocal microcopy was performed on a Zeiss 
LSM700 confocal laser scanning microscope (Zeiss, Thornwood, NY) equipped with 
555, 405, and 488 lasers, using a 40× air or a 63× oil immersion objective (Zeiss). 
Micrographs were captured using Zen 2012 (Zeiss). Two-photon microscopy was 
performed using a two-photon microscope system equipped with a Ti:sapphire laser 
(Mira 900F; Coherent Inc., Santa Clara, CA) operating at 785 nm wavelength, 165 fs 
pulse width, and 76 MHz repetition rate. The excitation laser beam was focused with a 
40×/1.0NA oil immersion objective (Olympus) and the fluorescence signal was detected 
with a photomultiplier (PMT) after a 572-642 nm optical band-pass filter. 
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Epifluorescence and two-photon image processing analysis were performed using 
Image-Pro Analyzer 6.3 or 7.0 (MediaCybernetics, Rockville, MD), while confocal 
processing and analysis were performed using Zen 2012. 
 
3.3. Iodination of Proteins for Radiotracing. 
Proteins were labeled with 125I for radiotracing by mixing 100 µg of 1 µg/µL 
protein with 2 µCi of Na125I in iodination tubes for 5 minutes. The reaction mixture was 
passed through Tris buffer size-exclusion polyacrylamide bead columns of molecular 
weight limit 6 kDa (Bio-Spin® P-6; Bio-Rad) 4 minutes at 1,000 g to separate free 125I. 
To determine the protein activity, iodinated protein was mixed with 3% bovine serum 
albumin (BSA) in phosphate-buffered saline (PBS) and (1-to-6 volume/volume) 
trichloroacetic acid (TCA). This precipitates protein, leaving free 125I in the supernatant, 
which allows for determination of the radioactive counts per minute (CPM) only in the 
protein fraction using a gamma counter (PerkinElmer Wizard2, Waltham, MA). Then, the 
concentration of iodinated protein was determined using a standard Bradford assay. 
Using protein concentration and activity, the specific activity of the iodinated protein was 
calculated as CPM per µg of protein. 
 
3.4. Preparation of ICAM-1- or M6PR-Targeted Particles. 
Particles targeting ICAM-1, associated with CAM-mediated endocytosis, or 
M6PR, associated with clathrin-mediated endocytosis (as an example of an endocytic 
receptor associated to a non-CAM-mediated pathway [189]), were used for this thesis. 
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Particles were prepared by adsorbing antibodies to ICAM-1 (clone R6.5; hereby referred 
to as anti-ICAM particles), peptide γ3, or antibodies to M6PR (anti-M6PR) on the surface 
of 100 nm, 500 nm, 1 µm or 4.5 µm polystyrene-latex particles, as described [6, 77]. As 
controls for binding specificity, particles were coated with non-specific mouse IgG, or 
γ3S (scrambled γ3). Particles of 100 nm and 500 nm in diameter had a green fluorescent 
FITC-derived labeled core to allow for detection via microscopy. 
In the case of anti-ICAM and γ3 particles, the adsorption reaction only contained 
each respective molecule, yielding a particle whose surface coverage was 100% antibody 
or peptide. In the case of anti-M6PR particles, they were coated in three different 
manners: (a) 100% with the antibody, (b) 80% with anti-M6PR and 20% with IgG (anti-
M6PR:IgG) or neutral sphingomyelinase (NSM; anti-M6PR:NSM), or (c) 50% with anti-
M6PR and 50% with IgG or neutral sphingomyelinase [189, 190, 191]. We have 
previously titrated the molar ratios to which antibodies and enzyme need to be combined 
in the adsorption reaction mixture in order to achieve these values [191]. 
After adsorption, non-coated antibodies or peptides were separated by 
centrifugation and coated particles were resuspended using 1% BSA in PBS and 
sonicated to prevent particle aggregation. The effective diameter of antibody- or peptide-
coated particles was measured by dynamic light scattering (for nanometric particles; 
Malvern Zetasizer Nano-ZS90, Westborough, MA) or phase-contrast microscopy (for 
micron-sized particles). Particles 100 nm in diameter ranged from 230-260 nm after 
coating; hence, they are referred to as 200 nm in diameter. 
Antibodies, γ3 or neutral sphingomyelinase used for coating were 125I-labeled for 
determination of the antibody or peptide density on particles using a gamma counter as 
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previously described [189, 191]. Briefly, a known concentration particles coated with 
125I-labeled protein (whose specific activity is known) is passed through a gamma counter 
to determine the CPMs per particle. Since CPM/µg of protein is known, one can calculate 
the µg of protein (and, by extension, the number of molecules) associated per particle. 
This number divided by the surface area of the particle yields the coating density. 
Antibodies were also 125I-labeled for radiotracing in transport experiments. Also, 
in certain cases as indicated, it was necessary to add a fraction of non-specific mouse IgG 
to the surface of γ3 particles in order to allow for immunostaining or radiotracing (125I-
IgG). The fraction of IgG was small (1,000 γ3 to 1 IgG by mass) and preliminary data 
showed no effects of this IgG on the binding of γ3 particles. The characterization of used 
formulations is provided below: 
 
Table 2. Characterization of ICAM-1- or M6PR-binding particles. 
Size Coat Surface coverage Molecules/µm2 of particle Diameter (µm) 
   Antibody IgG or NSM  
200 nm Anti-ICAM 100 7,393 - 0.264 
500 nm Anti-ICAM 100 25,944 - 0.561 
1 µm Anti-ICAM 100 30,564 - 1.098 
4.5 µm Anti-ICAM 100 25,827 - 4.410 
200 nm γ3 100 262,384 - 0.239 
1 µm γ3 100 4,953,739 - 1.001 
4.5 µm γ3 100 34,153,702 - 4.394 
1 µm Anti-M6PR 100 23,544 - 1.144 
1 µm Anti-M6PR:IgG 80:20 19,608 1,632 1.156 
1 µm Anti-M6PR:IgG 50:50 12,616 4,328 1.095 
1 µm Anti-M6PR:NSM 80:20 16,052 2,532 1.051 
1 µm Anti-M6PR:NSM 50:50 11,498 5,658 1.142 
NSM = Neutral sphingomyelinase; Surface coverage = approximate fraction of particle surface that a 




3.5. Cell Culture. 
Human umbilical vein endothelial cells (HUVECs) purchased from Lonza 
Walkersville, Inc. (Walkersville, MD) were cultured in M-199 basal medium 
supplemented with 15% fetal bovine serum (FBS), 15 µg/mL endothelial cell growth 
supplement, 2 mM L-glutamine, 100 µg/mL heparin, 100 U/mL penicillin, and 100 
µg/mL streptomycin. Human brain microvascular endothelial cells (HBMECs) from 
Applied Cell Biology Research Institute (Kirkland, WA) were cultured in RPMI-1640 
medium supplemented with 20% FBS, 2 mM glutamine, 30 µg/mL endothelial cell 
growth supplement, 100 µg/mL heparin, 100 U/mL penicillin, and 100 µg/mL 
streptomycin. For microscopy, HUVECs were seeded on 12-mm2 1%-gelatin-coated 
glass cover slips in 24-well plates. For SDS-PAGE (sodium dodecyl sulfate 
polyacrylamide gel electrophoresis), HUVECs were seeded on 1%-gelatin-coated 6-well 
plates. For lymphocyte transmigration, HUVECs were seeded on 8-µm pore Transwell® 
filters (Corning, Inc., Lowell, MA). For particle transcytosis, HBMECs were seeded on 
3-µm pore Transwell® filters (Corning, Inc.). In all cases, endothelial cells were grown to 
confluence at 37°C, 5% CO2, and 95% relative humidity, and treated for 16 hours with 10 
ng/mL TNFα (BD Biosciences) to induce endothelial activation and up-regulate ICAM-1 
expression.  
Lymphocytes were obtained from the blood of healthy volunteers (under 
International Review Board approval) using standard protocols [192]. Briefly, blood was 
extracted into sodium citrate-coated tubes followed by density gradient centrifugation 
over Ficoll-PaqueTM PLUS (GE Healthcare Amersham Biosciences Corp., Piscataway, 
NJ) or Polymorphprep (Accurate Chemical & Scientific Corporation, Westbury, NY). 
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The layer of peripheral blood mononuclear cells was isolated and washed, followed by 
incubation on gelatin-coated culture bottles to separate adherent monocytes. Non-
adherent cells were cultured in RPMI-1640 supplemented with 10% FBS (Mediatech, 
Inc., Manassas, VA) in the presence of 0.5 µg/mL phytohemagglutinin for 48 hours to 
activate and differentiate T lymphocytes into T lymphoblasts, followed by addition of 10 
U/mL interleukin 2 (IL-2) for 8-12 days for continued enrichment and activation. Non-
migratory K562 erythroid leukemia cells were obtained from Sigma-Aldrich (Inc., Saint 
Louis, MO) and cultured as done with lymphocytes. 
 
3.6. Binding of ICAM-1- or M6PR-Targeted Particles to Endothelial Cells. 
For binding experiments, TNFα-activated HUVECs growing on glass cover slips 
were fixed to prevent confounding results due to concomitant endocytosis. After fixation, 
cells were incubated for 30 minutes, 3 or 24 hours with 200 nm, 1 µm, or 4.5 µm anti-
ICAM, γ3, anti-M6PR, anti-M6PR:IgG (50:50 or 80:20), or anti-M6PR:NSM (50:50 or 
80:20) particles, followed by washing of non-bound particles. Phase-contrast and 
epifluorescence microscopy were used to determine the number of particles bound per 
cell. For fluorescent particles, a custom-made algorithm was used that detects and counts 
fluorescent objects regardless of their intensity as long as they are above a specified 
background fluorescence threshold [6]. 
Alternatively, for experiments on live cells, HUVECs were not fixed, and were 
incubated for 30 minutes, 3 or 24 hours with 200 nm, 1 µm, or 4.5 µm anti-ICAM or γ3 




3.7. Uptake of ICAM-1 or M6PR-Targeted Particles by Endothelial Cells. 
For uptake studies, TNFα-activated HUVECs growing on glass cover slips were 
incubated with 200 nm, 1 µm, or 4.5 µm anti-ICAM, γ3, anti-M6PR, anti-M6PR:IgG 
(50:50 or 80:20), or anti-M6PR:NSM (50:50 or 80:20) particles at 37˚C for 30 minutes or 
3 hours. Cells were washed and fixed, followed by staining with Texas Red-labeled goat 
anti-mouse, which can recognize the antibodies coated on the particle. This labels 
surface-bound, but not internalized, particles since antibodies cannot cross the cell 
membrane. This allows differentiation between particles inside versus those outside of 
cells for quantification of percent uptake through microscopy as described before [6, 
189]. Briefly, for 1 µm or 4.5 µm particles, total particles were counted using phase 
contrast and surface-bound non-internalized particles were counted using Texas Red 
fluorescence. For 200 nm particles, total particles versus non-internalized particles were 
counted using green and Texas Red fluorescence, respectively using the same algorithm 
as Section 3.6 [189]. Internalized particles were calculated by subtracting non-
internalized particles (Texas Red immunostained) from total particles. Percent 
internalization was calculated as: internalized particles divided by total particles × 100. 
 
3.8. Actin Staining and Ceramide Enrichment at Sites of ICAM-1 or M6PR-Targeted 
Particle Interaction with Endothelial Cells. 
TNFα-activated HUVECs growing on cover slips were incubated for 30 minutes 
at 37°C with 200 nm, 1 µm or 4.5 µm anti-ICAM, γ3, anti-M6PR:IgG, or anti-
M6PR:NSM particles. When indicated, HUVECs were pre-incubated for 30 minutes in 
the presence of 20 µM imipramine to inhibit acid sphingomyelinase, and imipramine was 
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kept during the binding incubation. Non-bound particles were washed, and cells were 
fixed and blocked overnight with 2% BSA in PBS. Cells were permeabilized with 0.2% 
Triton X-100 and then F-actin was stained with red AF594 phalloidin or ceramide was 
immunostained using mouse anti-ceramide (IgM) followed by green FITC-labeled goat 
anti-mouse IgM [7]. For ceramide staining experiments, 200 nm particles had a red, not 
green, fluorescent core for detection. 
Microparticles were located using phase-contrast, while nanoparticles were 
located using epifluorescence microscopy. Fluorescence micrographs at these positions 
were then obtained to visualize ceramide or actin. Semi-quantitative analysis of ceramide 
enrichment at binding sites was performed as described previously [7]. Briefly, a 
reference line of 5 µm was drawn crossing the equatorial axis of the identified particle 
(and also centered with the center of the particle). The fluorescence intensity was 
obtained for every pixel found on this line. This was done for ≥ 30 particle binding sites 
and averaged. Enrichment was then calculated as the fold increase (represented as Δ in 
graphs) between the average intensity of surrounding background areas of the plasma 
membrane and the average intensity where particles bound the HUVEC membrane. 
In order to graph the relationship between ceramide enrichment and ICAM-1 
binding density, we estimated the potential ICAM-1-binding capacity of each particle as 
the antibody density (determined through radiolabeling, as described in Section 3.4, 




3.9 Lysosomal Transport of ICAM-1-Targeted Particles. 
TNFα-activated HUVECs grown on cover slips were incubated with Texas Red-
labeled dextran (10,000 MW) for 45 minutes, followed by washing and incubation for 45 
minutes to label lysosomes. This ensures that internalized dextran has fully trafficked to 
lysosomes, a technique shown to be a suitable alternative to lysosomal-associated 
membrane protein 1 (LAMP-1) immunostaining [9, 89, 193]. Then, cells were incubated 
with 200 nm, 1 µm or 4.5 µm anti-ICAM or γ3 particles for 1 hour (pulse, to allow for 
synchronized binding and uptake), followed by washing and incubation for 0, 2, or 4 
hours (chase, to allow for intracellular trafficking). After fixation, surface-bound, non-
internalized particles were immunostained. Epifluorescence microscopy was used to 
determine the percentage of internalized particles (obtained by subtracting non-
internalized particles from the total particle count) that colocalized with Texas Red-
labeled lysosomes as done previously [9]. Briefly, green fluorescent pixels (total 
particles) above a given intensity threshold are counted. Then, then red pixels above the 
same intensity threshold, but only those overlapping with green (only red lysosomes that 
colocalize with green particles), are counted. Percent colocalization is the area of yellow 
pixels (green pixels that overlap with red) divided by the area of total pixels (all green 
pixels) × 100. 
 
3.10. Transport of ICAM-1-Targeted Particles Across Endothelial Cells. 
TNFα-activated HBMECs grown on 3-µm pore Transwell® filters were incubated 
with 200 nm, 500 nm, or 1 µm 125I-anti-ICAM or γ3:125I-IgG particles for 30 minutes 
(pulse, to allow for binding), followed by washing of both apical and basal chambers, and 
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incubation for 4.5 hours (chase, to allow for internalization and transport). Washing of 
both apical and basal chambers removes non-bound particles from the medium to ensure 
that the transport observed after chase only originates from ICAM-1-bound particles. 
This washing minimizes confounding results due to leakage of non-bound particles. 
Apical and basal fractions were collected and the porous membrane was excised 
and incubated in 1% Triton X-100 to lyse cells, freeing internalized particles. All 
fractions were quantified using a gamma counter (to obtain total CPMs), followed by 
precipitation of proteins in TCA (1-to-6 volume/volume). The non-precipitated fractions 
were quantified using a gamma counter in order to determine the free (non-protein-
bound) iodine CPMs. This allows to calculate the counts in each fraction contributed only 
by proteins (by subtracting the free iodine CPMs from the original total CPMs). Protein 
CPM values of each fraction can be divided by the pre-established CPM/particle values 
to determine how many particles are in each fraction. Detailed protocols of this procedure 
are published [194]. 
Although this technique does not trace the particle itself but antibodies coating the 
particle surface, it is acceptable to assume that the detected free-iodine-corrected CPMs 
are from non-degraded proteins on the particle surface [10, 195]: previous data show high 
antibody coating stability of anti-ICAM particles in different solutions (including cell 
medium and blood serum) and pH for extended periods of time [195], while microscopy 
evidence shows that these particles retain their antibody coat inside cells before they 




3.11. Imaging of Lymphocyte Adhesion and Pre-transmigratory Interactions with 
Endothelial Cells. 
IL-2-activated lymphocytes were stained with 4 µM (green fluorescent) calcein 
AM, washed, and added over TNFα-activated HUVECs growing on glass cover slips at 
1.5-lymphocyte to 1-HUVEC ratio. Cells were incubated for 30 minutes at 37°C, 
followed by fixation with 2% paraformaldehyde, and washing to remove non-adhered 
lymphocytes. For inhibition, HUVECs were pre-treated for 30 minutes with 1 µg/mL 
filipin to inhibit caveolae-mediated endocytosis, 5 mM methyl-β-cyclodextrin (Cdx) to 
chelate cholesterol and disrupt lipid domains, 3 mM amiloride or 20 µM 5-(N-Ethyl-N-
isopropyl)amiloride (EIPA) to inhibit NHE1, or 50 µM imipramine to inhibit acid 
sphingomyelinase. The inhibitors were either washed away before adding lymphocytes or 
maintained through the experiment, as indicated. After fixing, samples were 
permeabilized with 0.2% Triton X-100 and stained using anti-VE-cadherin, anti-ICAM, 
anti-NHE1, anti-acid sphingomyelinase, or anti-ceramide, plus fluorescently labeled 
secondary antibodies as indicated (ceramide immunostaining involved an overnight pre-
blocking at 4˚C in 2% BSA PBS). 
Samples were analyzed by phase-contrast and epifluorescence microscopy with a 
40× objective. The total number of lymphocytes left on the HUVEC monolayer firmly 
bound after washing was quantified to obtain binding data. Lymphocytes exhibiting flat, 
spread-out morphologies, suggestive of lateral movement on the endothelium or pre-
transmigratory probing, were scored as ‘sampling’ cells. Meanwhile, lymphocytes 
showing round morphologies, indicative of no transmigration, were scored as simply 
‘adhered’ cells. Both adhered and sampling lymphocytes were additionally spatially 
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scored at either the HUVEC border (in contact with or within 1 µm of HUVEC borders) 
or away from it (HUVEC ‘body’; ≥ 1 µm away from the cell border). Location of 
lymphocytes at these sites and presence of podosome-like structures in sampling 
lymphocytes were visualized in parallel by scanning electron microscopy.  
 
3.12. Quantification of Lymphocyte Transmigration Across Endothelial Cell Monolayers. 
IL-2-activated lymphocytes (or the erythroid leukemia cell line K562, which does 
not transmigrate) were added at a 1.5-lymphocyte to 1-HUVEC ratio to the apical 
chamber above a confluent monolayer of TNFα-activated HUVECs grown on 8-µm pore 
Transwell® filters. Recombinant lymphocyte chemoattractant stromal cell-derived factor 
1-alpha (SDF-1α; R&D Systems, Inc., Minneapolis, MN) was added at 200 ng/mL to the 
basal chamber under HUVECs. Transmigration was assessed by counting lymphocytes in 
the bottom chamber after incubation with HUVECs for 30 minutes at 37°C. For 
inhibition, HUVECs were pre-treated with 1 µg/mL filipin, 5 mM Cdx, 3 mM amiloride, 
20 µM EIPA, or 50 µM imipramine, and the inhibitors were either washed before 
addition of lymphocytes or maintained through the experiment. Alternatively, 
lymphocytes were pre-treated with 40 ng/µL anti-α4β1 (to block binding to VCAM-1) or 
anti-αLβ2 (to block binding to ICAM-1), then washed and incubated over HUVECs. 
Experiments were also performed in the absence of a HUVEC monolayer to determine 





3.13. Quantification of the Route of Lymphocyte Transmigration Across Endothelial 
Cells. 
IL-2-activated lymphocytes were added over TNFα-activated HUVECs growing 
on glass cover slips at a 1.5-lymphocyte to 1-HUVEC ratio. Cells were incubated for 15 
minutes at 37°C, followed by fixation with 2% cold paraformaldehyde and then washing 
to remove non-bound lymphocytes. For inhibition, HUVECs were pre-treated with 1 
µg/mL filipin, 5 mM Cdx, 3 mM amiloride, 20 µM EIPA, or 50 µM imipramine for 30 
minutes, and the inhibitors were washed away before adding lymphocytes. Samples were 
stained (after fixation and permeabilization) using DAPI (to identify nuclei), AF594 
phalloidin (to identify endothelial and lymphocyte actin), and anti-VE-cadherin followed 
by green fluorescent secondary antibody (to identify cell-cell junctions).  
Samples were analyzed by confocal microscopy using a 63× objective by 
obtaining 1024×1024 pixel z-sections starting at the bottom of the HUVEC monolayer in 
contact with the cover slip, and reaching the top of the monolayer, where endothelial 
actin cannot be detected, but adhered lymphocyte actin is still visible (total thickness ~5 
µm, 6-7 stacks). Micrographs were used to quantify the total number of lymphocytes, and 
those transmigrating (lymphocyte actin observed on top of and beneath HUVECs) versus 
those not transmigrating (lymphocyte actin observed only on top of HUVECs). All 
transmigration events not occurring directly on cell-cell borders were counted as 
transcellular. In addition, the population of transmigrating lymphocytes on borders was 
classified as transcellular if VE-cadherin staining was intact at the transmigration site, or 




3.14. Interaction of Fibrin Meshes or Microemboli with Endothelial Cells. 
TNFα-activated HUVECs growing on glass cover slips were incubated in the 
presence of 0.5 µM AF488 (green fluorescently labeled) fibrinogen, 2 mM CaCl2, 0.063 
nM plasminogen, and 0.034 nM thrombin in 25 mM (4-(2-hydroxyethyl)-1-
piperazineethanesulfonic acid (HEPES) Hank’s balanced salt solution (HBSS), hereby 
referred to as fibrin mesh forming mixture, for 30 minutes at 37°C to form fibrin meshes 
[196]. Fibrin mesh formation was also performed in the presence of 40 U/mL hirudin 
(EMD Chemicals, Gibbstown, NJ) to inhibit thrombin, and, thus, production of fibrin, or 
3 mM glycine-proline-arginine-proline (GPRP; EMD Chemicals) to inhibit fibrin 
polymerization. For blocking of endothelial surface molecules, HUVECs were pre-
treated with 33.3 µg/mL of mouse IgG, anti-ICAM-1 (LB-2 clone), anti-VE-cadherin 
(BV9 clone), anti-integrin β3, anti-tPA receptor, anti-uPA receptor, or anti-
thrombomodulin at 4˚C 15 minutes prior to mesh formation, and antibodies were 
maintained during the assay. This was also done with 0.33 µg/µL or 0.067 µg/µL γ3 or 
γ3S to directly block the ICAM-1 fibrin(ogen) epitope. 
Alternatively, fibrin mesh forming mixture was pre-incubated in test tubes for 30 
minutes and then added to HUVECs (final concentration of fibrin was equivalent to the 
meshes formed in situ as described above) for 30 minutes to allow binding. These are 
referred to as fibrin microemboli, as the fibrin mesh polymers are formed prior to coming 
in contact with endothelial cells, mimicking the interaction between a circulating pre-
formed fibrin polymer and the endothelium. 
Cells were washed, fixed and permeabilized, followed by immunostaining of 
ICAM-1, NHE1, acid sphingomyelinase, or VCAM-1, as done in Section 3.11. Analysis 
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was done by epifluorescence microscopy and images were used to quantify the binding of 
fibrin meshes (calculated as the total number of fluorescent objects (meshes or 
microemboli) detected in the green channel), as well as their mean diameter. Enrichment 
of the described molecules at binding sites of fibrin meshes was also determined using 
custom-made algorithms that determine the percent colocalization between green and red 
staining as done previously [89]. Briefly, green fluorescent pixels (total fibrin meshes) 
above a given intensity threshold are counted. Then, then red pixels (immunostained 
membrane proteins) above the same intensity threshold, but only those overlapping with 
green, are counted. Percent colocalization is the area of yellow pixels (green pixels that 
overlap with red) divided by the area of total pixels (all green pixels) × 100. 
 
3.15.Uptake of Fibrin Meshes or Microemboli by Endothelial Cells. 
TNFα-activated HUVECs growing on glass cover slips were incubated in the 
presence of fibrin mesh forming mixture or fibrin microemboli for 30 minutes at 37°C. 
Cells were washed and incubated in complete medium for 0, 30 minutes, 1, 3, 5 or 24 
hours (chase). Incubation at 3 hours was also performed in the presence of 0.15 U/mL 
aprotinin and 50 ng/mL PAI-1 (EMD Chemicals) to inhibit serine proteases and tPA, 
respectively. To probe mechanisms of endocytosis, incubation at 3 hours was performed 
in the presence of 1 µg/mL filipin to inhibit caveolae-mediated uptake, 50 µM 
monodansylcadaverine (MDC) to inhibit clathrin-mediated endocytosis, 3 mM amiloride 
to inhibit NHE1, 50 µM imipramine to inhibit acid sphingomyelinase, or 0.5 µM 
wortmannin to inhibit PI3K-dependent uptake (which is associated with 
macropinocytosis and phagocytosis). 
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After washing and fixing, cells were incubated with anti-fibrin β chain, followed 
by a red fluorescent secondary antibody to label only surface-bound, non-internalized 
fibrin meshes for percent internalization analysis. Samples were analyzed by phase-
contrast and epifluorescence microscopy using a 40× objective. Using this technique, 
micrographs reveal non-internalized fibrin meshes as green and red (yellow), while 
internalized meshes are only green. Images were used to quantify percent internalization 
as green meshes divided by total (green and yellow) meshes × 100 (as done with particles 
in Section 3.7). 
Alternatively, cells were permeabilized prior to staining to determine the 
immunolabeling by anti-fibrin of internalized fibrin meshes. Analysis was performed on 
micrographs to quantify the percent immunolabeling, calculated as follows: 
Immunolabeled fibrin meshes (green meshes that are immunolabeled in red, appearing as 
yellow) divided by total fibrin meshes (all green meshes) × 100. 
 
3.16. Lysosome Trafficking of Fibrin Meshes in Endothelial Cells. 
TNFα-activated HUVECs growing on glass cover slips were pre-treated with 
Texas Red labeled dextran (10,000 MW) for 45 minutes, followed by washing and 
incubation for 45 minutes in dextran-free medium. This ensures that dextran fully traffics 
to lysosomes. Then, cells were incubated in the presence of fibrin mesh forming mixture 
30 minutes at 37°C. Cells were washed and incubated in complete medium for 0, 30 
minutes, 1, 3, 5, or 24 hours (chase). Alternatively, cells were not pre-treated with 
dextran, but instead were permeabilized after fixing, followed by incubation with anti-
fibrin β chain and red fluorescently labeled secondary antibody. When noted, cells were 
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treated with 10 µM chloroquine (to disrupt lysosome-mediated hydrolysis), 0.15 U/mL 
aprotinin plus 50 ng/mL PAI-1 (to inhibit non-specific and tPA-mediated proteolysis), or 
all three reagents. 
Epifluorescence microscopy was used to analyze the colocalization between green 
fibrin meshes and red lysosomes (as done in Section 3.9 for particles), or green fibrin 
meshes and red anti-fibrin immunostaining (as done in Section 3.15). 
 
3.17. SDS-PAGE and Western Blotting of Fibrin Meshes. 
TNFα-activated HUVECs growing on 6-well plates were incubated in the 
presence of fibrin mesh mixture 30 minutes at 37°C. Cells were washed and incubated in 
complete medium for 4.5 hours under control conditions, or in the presence of 3 mM 
amiloride, 10 µM chloroquine, 50 ng/mL PAI-1 plus 0.15 U/mL aprotinin, amiloride with 
PAI-1 plus aprotinin, or chloroquine with PAI-1 plus aprotinin. Wells were washed in 
PBS, followed by HUVEC lysis with radio-immunoprecipitation (RIPA) buffer in the 
presence of protease inhibitor cocktail (AEBSF, aprotinin, bestatin, E-64, leupeptin, 
pepstatin A; Thermo Scientific). Cell residue was separated by centrifugation (13,300 g 
for 15 minutes) and the protein fraction was prepared for reducing SDS-PAGE by 
incubating at 70˚C in the presence of 0.1 M dithiothreitol for 10 minutes to denature 
protein and reduce disulfide linkages. Gel electrophoresis was done in TrisHCl 4%-15% 
polyacrylamide gels (Bio-Rad Laboratories, Inc., Hercules, CA) at 60 V (constant 
voltage), TrisHCl buffer. After PAGE, gels were directly imaged using fluorescence 
detection in a Typhoon Trio imager (GE Healthcare Life Sciences, Pittsburgh, PA). 
Alternatively, protein was transferred to polyvinyl difluoride membranes at 250 mA 
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(constant current) in 80% TrisHCl:20% methanol. This was followed by Western blotting 
with anti-fibrin β chain, followed by horse radish peroxidase (HRP)-conjugated 
secondary, and detection by chemiluminescence. Densitometry analysis was performed 
using ImageJ (National Institutes of Health, Bethesda, MD). 
In order to test the activity of PAI-1, we incubated fibrin mesh mixture in the 
absence (control) or presence of tPA or tPA plus PAI-1 plus aprotinin in test tubes. After 
8 hours of incubation, fibrin mesh mixtures were processed for SDS-PAGE and Western 
blotting with anti-fibrinogen as done above. 
 
3.18. Visualization of Fibrin Microemboli in Mice. 
For confocal microscopy of pulmonary emboli models, wild-type C57BL/6 
(Jackson Laboratory, Bar Harbor, ME), ICAM-1 knockout (B6.129S4-Icam1tm1Jcgr/J, 
Jackson Laboratory), or acid sphingomyelinase (ASM) knockout (kindly provided by Dr. 
Edward Schuchman, Mount Sinai School of Medicine, New York, NY [197]) mice were 
anesthetized and injected via jugular vein with pre-formed green fibrin microemboli 
(made by incubating fibrin mesh mixture for 30 minutes in test tubes, see Section 3.14). 
After 1.5 hours, mice were injected with 50 µg AF594 (red fluorescently labeled) 
fibrinogen. One hour later, mice were sacrificed and lungs were dissected, followed by 
fixation overnight in 4% paraformaldehyde. Lungs were submerged in DAPI for 1 hour, 
and washed. Confocal microscopy was used to identify fibrin microemboli found in 
alveolar regions. Then, individual frames were selected to obtain z-stacks starting at the 
top of the fibrin microembolus of interest, and ending at the plane of the nuclei in the 
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same frame. Images were used to determine overlap between green fibrin microemboli 
and red fibrinogen. 
For two-photon microscopy of brain emboli models, C57BL/6, ICAM-1 
knockout, or ASM knockout mice were anesthetized and injected with one of the 
treatments indicated in Table 3. 
Table 3. Injection treatments used for microscopy of mouse emboli models. 
 
NF = Non-fluorescent, FnMe = fibrin microemboli 
 
After the last injection, mice were sacrificed and brains were dissected and fixed 
in 4% paraformaldehyde overnight prior to imaging using two-photon fluorescence 
microscopy. For each mouse, the brain surface was scanned to find a region where blood 
vessels could be clearly identified. At this location, an image was obtained ~100 µm deep 
into the tissue, where preliminary experiments consistently showed abundant brain 
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capillaries. Then, four more images were similarly obtained above, below, left, and right 
of this central location. The process was repeated at 2 different brain regions, yielding 15 
images per mouse, each image comprising a field of 400 µm by 400 µm of tissue. 
Analysis was performed on each image to quantify the number and mean diameter of 
fluorescent fibrin microemboli above a background fluorescence threshold in each field. 
All animal studies were performed according to the Guide for the Care and Use of 
Laboratory Animals, as well as Institutional Animal Care and Use Committee-approved 
protocols and University regulations. 
 
3.19. Statistics. 
For microscopy, each experiment was repeated at minimum two times and 
contained duplicate cover slips per treatment (≥ 4 cover slips total). From each cover slip, 
with a population of ~105 cells under confluence, a minimum of 5 frames containing 
confluent cells (~5-10 cells per field) were obtained randomly. Depending on the 
analysis, frames were analyzed as a whole (≥ 20 frames total), or a minimum of 2 cells 
were analyzed per frame (≥ 40 cells total). For Transwell® experiments, each experiment 
was repeated at minimum two times and contained four replicate wells per treatment (≥ 8 
wells total). Mouse experiments used a minimum of two mice per treatment, and a 
minimum of 15 images were obtained per organ (≥ 30 frames total). Data were calculated 
as mean ± standard error of the mean. For two-way comparisons, statistical significance 
was determined using Student’s t-test with a threshold of p<0.05. For multiple 
comparisons, statistical significance was determined using One-way ANOVA followed 
by Tukey’s test (p<0.05).  
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Chapter 4: Role of Particle Size and Targeting Moiety on the 
Outcomes of ICAM-1-Mediated Endocytosis 
 
4.1. Background 
A major goal in the field of drug delivery is to optimize the therapeutic effect of a 
cargo drug, which can be achieved by varying parameters such as dose, administration 
route, cell- or tissue-targeting capacities, etc. [198, 199], and a clear understanding of 
biological systems often facilitates these optimizations [200]. When intracellular drug 
delivery relies on endocytic receptors, knowledge about the mechanism of endocytosis 
associated with a given targeted receptor can inform drug carrier design. For instance, 
clathrin- and caveolae-mediated endocytosis are adapted for the uptake of nanometric 
nutrients, proteins and other small molecules, and thus internalize objects no larger than 
~70-200 nm in diameter due to the physical limitations in their vesicular machineries [93, 
201]. Drug carriers targeted to receptors associated with these pathways must be below 
200 nm in diameter to achieve efficient intracellular delivery. Conversely, it can result 
beneficial to use drug carriers above 200 nm if delivery is desired in the vicinity of, but 
not inside, cells that express said receptors. 
In a similar fashion, tools used in the field of drug delivery can help elucidate 
natural phenomena thanks to the ability to generate mimicking entities, and modulate 
physical and chemical properties of these objects when they interact with biological 
systems. An example of this is the use of spherical inert particles coated with selectin-
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binding and/or Ig-like CAM-binding molecules that have given insight into the binding 
properties behind leukocyte interaction with the endothelium [202-205]. 
The characterization of cell adhesion molecule (CAM)-mediated endocytosis, 
which occurs when drug carriers bind multiple copies of ICAM-1 on the cell surface, has 
thus far only occurred in the context of drug delivery [6-8]. Therefore, the design 
parameters used for drug delivery through this pathway have not benefitted from in-depth 
biological knowledge of the mechanism, but rather have served to elucidate its regulation. 
Furthermore, no systematic studies have been performed to link ICAM-1 binding and 
subsequent endocytosis to a physiological function. However, since binding ICAM-1 is 
the initial driving step of CAM-mediated uptake, it is possible that the properties of 
natural binding partners of ICAM-1 could shed light on this endocytic mechanism. 
With this in mind, the first goal of this work was to study how two physical 
parameters can affect CAM-mediated endocytosis of drug carriers, based on knowledge 
about two important natural ICAM-1 ligands: integrin αLβ2, found on the surface of 
leukocytes, and fibrin, the main component of blood clot polymers. As suggested above, 
this strategy could provide two-fold benefits: first, to gain knowledge about CAM-
mediated endocytosis that can be applied for the optimization of drug delivery; second, to 
gain insight into the possible mechanisms that regulate the physiological functions of the 
CAM-mediated pathway. 
The two parameters we selected were drug carrier size and the targeting moiety 
used to bind ICAM-1. Regarding size, leukocytes range from 5 to 20 µm diameter before 
spreading on the endothelial cell surface [206], and they produce podosomes against the 
endothelial cell plasmalemma which range from 0.2 to 1 µm in diameter [123]. Blood 
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clots range from hundreds of nanometers to hundreds of microns [207], so that blood clot 
degradation (fibrinolytic) fibrin mesh remnants can be expected to fall within a wider 
range compared to leukocytes, but exhibiting smaller sizes at the lower (nanometric) end 
[183]. This makes it plausible for outcomes of CAM-mediated endocytosis elicited by 
ICAM-1 binding to depend on ligand size. 
Regarding targeting moiety, leukocytes and fibrin(ogen) bind ICAM-1 through 
different means. First, leukocytes use integrin-mediated binding, which depends on 
integrin activation states [208, 209] and is regulated by changing the distribution of 
integrins on the leukocyte plasma membrane, generating changes in avidity [210]. 
Meanwhile, fibrin(ogen) has a binding site for ICAM-1 on its γ chain [145] and the 
density of fibrin clots could affect how these binding sites are presented to ICAM-1. In 
addition to this, while both leukocytes and fibrin bind domain D1 of ICAM-1, they do so 
at different epitopes. Certain antibodies that bind/disrupt D1 of ICAM-1, such as clone 
LB-2, can block binding of both αLβ2 and fibrin(ogen), while others, such as clone R6.5, 
inhibit αLβ2, but not fibrinogen, binding [51]. Use of ICAM-1 peptides for competition 
experiments, mutagenesis, and crystallography, also suggests that the sites for αLβ2 and 
fibrin(ogen) binding both reside near the N terminus of D1, but are different and might 
slightly overlap at most [50]. Thus, if natural systems are in place to bind different 
regions of ICAM-1 and with potential variety of binding strengths, it is possible the 
CAM-mediated pathway can be regulated based on the used ICAM-1-targeting moiety 
that coats drug carriers. 
In support of these ideas, previous evidence shows that size and bound epitope 
can significantly affect aspects of CAM-mediated endocytosis of drug carriers. For 
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example, spherical carriers of a wide range of sizes (100 nm to 10 µm) enter cells with 
similar efficiency, yet trafficking to lysosomes is slower and less efficient for 1 µm 
carriers compared to 100 nm carriers [77]. In a different scenario, carriers targeted to 
PECAM-1 to induce CAM-mediated endocytosis have different uptake and trafficking 
efficiencies depending on the epitope on PECAM-1 bound by antibodies coating drug 
carriers [101]. 
Drug carrier size and targeting moiety appear to be important factors that could 
help modulate CAM-mediated drug delivery strategies, and they represent easily 
manipulatable parameters in the design of drug carriers. Thus, in this chapter we examine 
how ligand size and targeting moiety affect binding, uptake, ceramide enrichment, and 
intracellular trafficking associated with CAM-mediated endocytosis. 
 
4.2. Results 
4.2.1. Model to study the role of particle size and targeting moiety on CAM-mediated 
pathway outcomes. 
In order to perform our studies, we used inert polystyrene-latex spherical 
particles, a ubiquitous and economical model to study targeting and intracellular transport 
of ICAM-1-targeted polymer drug carriers. These particles behave in a similar fashion as 
the clinically relevant biodegradable poly(lactic-co-glycolic acid) (PLGA) drug carriers, 
yet they do not introduce confounding effects of degradation [190]. We chose particles of 
four sizes, spanning the range in which typical drug carriers, leukocytes, and fibrin 
meshes fall (200 nm, 500 nm, 1 µm, and 4.5 µm). To differentiate targeting moieties, we 
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coated on the surface of these particles either of two targeting molecules: Antibodies to 
ICAM-1 (clone R6.5) bind the same epitope as integrin αLβ2 without blocking 
fibrin(ogen) binding, while the 17-residue peptide γ3 is directly derived from the ICAM-
1-binding sequence of fibrinogen. While anti-ICAM is a divalent 150 kDa molecule, γ3 is 
a monovalent 1.93 kDa peptide, such that differences in size and valency between these 
two molecules could affect CAM-mediated uptake. 
The properties of particles used in each section will be detailed correspondingly, 
but Table 2 in the Methods section (page 33) serves as an overall reference. 
 
4.2.2. Role of particle size and targeting moiety on binding of ICAM-1-targeted particles. 
The induction of CAM-mediated endocytosis depends on initial binding of drug 
carriers to ICAM-1. As shown in other scenarios, the efficiency of endocytosis may be 
dependent on the total number of receptors bound, strength of binding, and other 
phenomena at the interface between ligands (e.g.: drug carriers, leukocytes, or fibrin 
meshes) and the plasma membrane [211]. Thus, it is important to understand binding 
events separately from subsequent endocytosis. In order to achieve this, we first 
examined binding of ICAM-1-targeted particles using fixed endothelial cells, where 
uptake and membrane dynamics are abolished. We chose particles of three sizes spanning 
the range in which typical drug carriers and ICAM-1 natural binding partners fall: 200 
nm, 1 µm, and 4.5 µm. In order to better determine the effect of size, we adjusted the 
concentration of each size formulation in order to normalize the total particle surface area 
added to cells. That is, each cell was exposed to the same net particle surface area 
regardless of particle size. 
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As shown in Figure 1A, anti-ICAM particles of 200 nm, 1 µm and 4.5 µm in 
diameter all bound to fixed TNFα-activated HUVECs. This binding was specific, as 
determined by comparing binding levels of anti-ICAM particles to those of particles 
coated with non-specific IgG (fold-increase in binding between IgG and anti-ICAM was 
87±3, 92.3±6.1, and 45.3±3.2 for 200 nm, 1 µm and 4.5 µm particles, respectively). 
Although all particle sizes bound specifically, the total number of anti-ICAM particles 
bound per cell was lower with increasing particle size at all time-points (Figure 1B). 
 
Figure 1. Binding of anti-ICAM particles to fixed endothelial cells. (A) Fluorescence (top) or phase-
contrast (middle, bottom) microscopy showing binding of 200 nm, 1 µm or 4.5 µm anti-ICAM particles 
after 30 minutes, 3 hours or 24 hours incubation at room temperature with fixed activated HUVECs. Scale 
bar = 20 µm. Green = particles. Blue = nuclei. (B) Quantification of total particles bound per cell. (C) Total 
(top-down) cell surface area occupied by bound particles on each cell. Data represent mean ± standard error 
of the mean. * compares 200 nm to 1 µm, # compares 200nm to 4.5 µm, and ^ compares 1 µm to 4.5 µm 
(p<0.05 by Tukey’s test after One-way ANOVA). 
 
This result is not surprising since each individual particle of a larger size occupies 
more surface area than a smaller counterpart. Thus, in order to better compare binding, 
we calculated the top-down cell surface area occupied by all the particles bound per cell 
(Figure 1C). This revealed that at 30 minutes and 3 hours, micron-sized particles 
occupied a larger surface area of the cell compared to nanoparticles. However, allowing 
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sufficient binding time (24 hours incubation) led to equal occupancy by particles of all 
three sizes (~370 µm2), which may represent a saturation level. Since we originally 
exposed cells to equal particle surface areas regardless of size, this indicated that particles 
of larger sizes exhibit earlier stronger binding than those in the nanoscale. This result is in 
line with the additive binding properties of antibodies since each individual particle of 
larger size exhibits more antibody-ICAM-1 interactions than a smaller counterpart, likely 
making its avidity higher. However, it appears from these data, that given sufficient time, 
the binding interactions become stabilized regardless of size. 
When we examined binding of γ3 particles, they also bound specifically as 
compared to particles coated with γ3S, a γ3 scrambled peptide sequence (binding for 200 
nm γ3S particles was not quantifiable, while 1 µm γ3 particles bound 3.6±0.3-fold more 
than γ3S). Similar to anti-ICAM particles, there was a size-dependent pattern in terms of 
binding to HUVECs (Figure 2A and B). However, binding was much lower for both sizes 
of γ3 particles even though the γ3 peptide density on the particle surface (and, thus, 
potential for binding a number of ICAM-1 molecules) far surpassed that of antibodies 
(Table 2, page 33). This result might be expected since the dissociation constant of R6.5 
for ICAM-1 is 4 orders of magnitude lower than that of γ3 in solution (6.3 nM vs 34 µM 
[145, 212]), so the affinity of γ3 for ICAM-1 is predicted to be lower compared to an 




Figure 2. Binding of γ3 particles to fixed endothelial cells. (A) Fluorescence (top) or phase-contrast 
(bottom) microscopy showing binding of 200 nm or 1 µm γ3 particles after 30 minutes, 3 hours or 24 hours 
incubation at room temperature with fixed activated HUVECs. Scale bar = 20 µm. Green = particles. Blue 
= nuclei. (B) Quantification of total particles bound per cell. (C) Total (top-down) cell surface area 
occupied by bound particles on each cell. Data represent mean ± standard error of the mean. * compares 
200 nm to 1 µm (p<0.05 by Student’s t-test). 
 
We also observed that the difference in binding between 200 nm versus 1 µm 
particles was much larger for γ3 than for anti-ICAM particles. Even after calculating the 
total cell surface area occupied by particles per cell, γ3 nanometer-sized particles 
occupied a larger surface area than γ3 microparticles (compare black versus dashed 
columns in Figures 1C and 2C). This suggested that, unlike anti-ICAM, there was not 
such an acute increase in particle avidity as size (and, thus, number of ICAM-1 engaged 
per particle) increased. Due to this, it seemed that binding through γ3 is more sensitive to 
increasing particle size compared to anti-ICAM, a reflection of the differences in binding 
potential between the two molecules coating the particles. It is also possible that a small 
peptide such as γ3 might have more difficulty accessing its ICAM-1 binding epitope than 
a large antibody when presented on a large particle compared to a small one. 
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Next, we repeated binding experiments using live HUVECs to verify these results 
and in order to understand how membrane dynamics and concomitant endocytosis may 
affect particle association with endothelial cells. Important factors that may affect this are 
(a) lateral mobility of proteins in the plasma membrane, which could allow particles to 
bind more molecules of ICAM-1 and increase avidity, (b) concomitant endocytosis that 
may retain carriers inside cellular compartments regardless of how firmly bound they are 
to ICAM-1, and/or (c) internalization of ICAM-1 molecules, reducing the available 
binding pool of this molecule. As shown in Figure 3A and B, the pattern of total anti-
ICAM particle binding levels was the same as that seen with fixed cells, where fewer 
microparticles bound per cell compared to nanoparticles. Despite this similar trend, there 
were differences in the total number of particles associated with cells between fixed 
versus live cells depending on particle size. Submicrometer-sized particles showed an 
enhancement in cell association when cells were live, in agreement with the expected 
particle accumulation within cells due to concomitant endocytosis, while this was not the 
case (or less dramatic) for microparticles (Figure 3C). Specifically, at 30 minutes, 200 nm 
particles showed a 2.9-fold enhancement in association with cells, while 1 µm and 4.5 
µm showed comparatively no/lower enhancement (0.97-fold and a 1.79-fold 
enhancement, respectively). Even by 3 hours, 200 nm particles retained a 1.7-fold 





Figure 3. Association of anti-ICAM particles to live endothelial cells. (A) Fluorescence (right) or phase- 
contrast (middle and left) microscopy showing association of 200 nm, 1 µm or 4.5 µm anti-ICAM particles 
after 30 minutes or 3 hours incubation at 37˚C with activated HUVECs. Scale bar = 20 µm. Green = 
particles. Blue = nuclei. (B) Quantification of total particle binding per cell. (C) Ratio of particles per cell 
in living versus fixed HUVECs. Dashed line = 1. Data represent mean ± standard error of the mean. In B, * 
compares 200 nm to 1 µm, # compares 200 nm to 4.5 µm, and ^ compares 1 µm to 4.5 µm (p<0.05 by 
Tukey’s test after One-way ANOVA). 
 
A lower enhancement between fixed and live cells for micron-sized particles 
suggests that perhaps endocytosis for this size is not as efficient as that observed for 200 
nm particles. However, previous evidence shows that the CAM-mediated pathway is 
capable of internalizing drug carriers of a wide range of sizes [77]. Thus, it is possible 
that the concomitant endocytosis of anti-ICAM particles led to a depletion of ICAM-1 at 
the cell surface, preventing new particles in solution from engaging the cell. Although 
previous work has shown that ICAM-1 rapidly recycles back to the plasma membrane 
after drug carrier uptake [9], this was only explored in the case of nanocarriers (which 
agrees with our data showing binding enhancement even after 3 hours in live cells for 
200 nm particles). It may be possible that ICAM-1 recycling kinetics are slower or 
trafficking itinerary differs for micron-sized particles, preventing replenishment of the 
60 
 
receptor on the plasma membrane. This could also be associated with different trafficking 
patterns for internalized particles depending on size after CAM-mediated uptake, which 
we explore in subsequent sections. 
The idea that γ3 particles may exhibit lower avidity compared to anti-ICAM 
particles was further supported after examining their binding in live cells (Figure 4A). 
Similar to anti-ICAM particles, micron-sized γ3 particles bound to live HUVECs at lower 
levels than nanometric counterparts (Figures 4B). However, the enhancement in cell 
association for γ3 particles between fixed and living cells was quite prevalent, for both 
particle sizes and at both time-points (compare Figures 3C and 4C). For a particle 
exhibiting low binding strength, it may have been of greater benefit to allow for the 
lateral migration and clustering of more ICAM-1 molecules at the particle binding site 
compared to high-affinity antibody particles. It may also be possible that endocytic 
retention of particles increased their association with cells. Furthermore, it should be 
noted that unlike 1 µm anti-ICAM particles, 1 µm γ3 particles bound more in live versus 
fixed cells even after 3 hours. This suggests that γ3 particles might not deplete ICAM-1 
from the plasma membrane, as could be expected from their lower binding levels, or that 






Figure 4. Association of γ3 particles to live endothelial cells. (A) Fluorescence (left) or phase-contrast 
(right) microscopy showing association of 200 nm or 1 µm γ3 particles after 30 minutes or 3 hours 
incubation at 37˚C with activated HUVECs. Scale bar = 20 µm. Green = particles. Blue = nuclei. (B) 
Quantification of total particle binding per cell. (C) Ratio of particles per cell in living versus fixed 
HUVECs. Dashed line = 1. Data represent mean ± standard error of the mean. In B, * compares 200 nm to 
1 µm at each time-point (p<0.05 by Student’s t-test). 
 
When comparing the binding levels, anti-ICAM particles always bound at higher 
levels than γ3 counterparts regardless of size (anti-ICAM particles per cell divided by γ3 
particles per cell > 1 for all cases; Figure 5A). Also, this difference was always higher for 
1 µm versus 200 nm particles, supporting the idea that γ3 particles are more sensitive to 
increasing particle size regarding binding outcomes. It was interesting to note that this 
difference was mitigated over time even in fixed cells, suggesting that initial weak 
interactions between γ3 and ICAM-1 are stabilized over time to a greater degree than the 
originally strong antibody-ICAM-1 interaction. 
As mentioned earlier, endocytic entrapment of particles or ICAM-1 membrane 
mobility may also enhance cell association. Indeed, the difference in binding between 
anti-ICAM and γ3 particles was further reduced in living cells (Figure 5B). Furthermore, 
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the gap between 200 nm and 1 µm particle binding was lower in living cells than fixed 
cells (compare the jump between black columns and dashed columns in Figure 5A versus 
5B), suggesting endocytic accumulation (or increased avidity due to ICAM-1 lateral 
mobility) can mitigate the size-dependent binding sensitivity of γ3 particles. 
 
Figure 5. Comparison of binding of anti-ICAM versus γ3 particles to endothelial cells. (A) Ratio of 
binding of 200 nm or 1 µm anti-ICAM versus γ3 particles after 30 minutes, 3 hours or 24 hours incubation 
at room temperature with fixed activated HUVECs. (B) Ratio of cell association of 200 nm or 1 µm anti-
ICAM versus γ3 particles after 30 minutes or 3h incubation at 37˚C with activated HUVECs. Data 
represent mean ± standard error of the mean. 
 
In short, these results provide insight into the optimization of drug delivery 
strategies that target ICAM-1, where overall lower binding of γ3 particles may affect 
their performance compared to antibody particles, especially for larger particle sizes. 
Although pure binding data showed that γ3 particles may not be as advantageous as anti-
ICAM counterparts for high levels of therapeutic delivery, their association with cells 
thanks to membrane dynamics and/or CAM-mediated endocytic retention reduces these 
binding deficiencies and makes them similarly suitable for ICAM-1-targeted intracellular 
drug delivery. The apparent differences in binding strength between these two targeting 
moieties call for in-depth examination of the behavior of these particles under the shear 
stress of blood flow. This will be particularly important because drug carriers with lower 
affinity/avidity may accumulate more acutely at desired delivery sites, since they are less 
likely to interact and be retained at sites with low expression of the targeted molecule. 
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4.2.3. Role of particle size and targeting moiety on endothelial uptake of ICAM-1-
targeted particles. 
Next, we determined the role of size and targeting moiety on CAM-mediated 
uptake by incubating anti-ICAM or γ3 particles with HUVECs for 30 minutes or 3 hours, 
followed by fixing and immunostaining to differentiate surface-bound from internalized 
particles (see Methods, Section 3.7). Since particles of different sizes and targeting 
moieties associated with cells at different total numbers, we calculated their rate of 
uptake (percent internalized particles out of the total cell-associated), which has been 
shown to be unaffected by how many particles are bound per cell in the case of CAM-
mediated endocytosis [7]. 
As shown in Figure 6, we found that at initial time-points, the percent 
internalization for anti-ICAM particles was dependent on particle size (~70% for 200 nm 
and 1 µm versus 31.9% for 4.5 µm). Nonetheless, by 3 hours, uptake of all particles was 
the same regardless of size, in agreement with previous reports [77], and showing that 
given enough time, CAM-mediated endocytosis is capable of internalizing a wide range 
of object sizes with high efficiency. These internalization patterns shed some light on our 
results seen with binding fixed versus live cells. The fact that by 3 hours all particles 
showed levels of uptake near 100%, yet only nanoparticles exhibited enhanced binding in 
live versus fixed cells, as discussed above (recall Figure 3C), is intriguing. This supports 
the idea that large particles a) might have depleted ICAM-1 from the cell membrane more 
readily than small particles and/or b) may elicit different trafficking patterns that do not 
recycle ICAM-1 back to the plasma membrane as readily as nano-meter sized particles. 
Such properties of CAM-mediated uptake could hold importance in the design of drug 
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delivery strategies as, for instance, previous studies have shown that ICAM-1 recycling 
following CAM-mediated endocytosis can be exploited for the administration of multiple 
therapeutic doses [9]. Thus, it will be important for future work to study the ICAM-1 
plasma membrane depletion/recycling properties of large versus small ICAM-1-targeted 
particles. 
 
Figure 6. Uptake of anti-ICAM particles by endothelial cells. Activated HUVECs were incubated with 
200 nm, 1 µm or 4.5 µm anti-ICAM particles for 30 minutes or 3 hours at 37˚C. Surface-bound, but not 
internalized, particles were immunostained to quantify percent uptake. (A) Sample micrographs showing 
total particles (top panels for each time-point) or only surface-bound non-internalized particles (bottom 
panels for each time-point). Arrows indicate internalized particles and arrowheads indicate non-internalized 
particles. Scale bar = 20 µm. Green = particles. Blue = nuclei. (B) Quantification of uptake expressed as the 
percent of particles inside cells out the total cell-associated particles. Data represent mean ± standard error 
of the mean. # compares 200 nm to 4.5 µm, and ^ compares 1 µm to 4.5 µm (p<0.05 by Tukey’s test after 
One-way ANOVA). 
 
Compared to anti-ICAM particles, which showed similar uptake for 200 nm and 1 
µm particles by 30 minutes, the endocytosis of γ3 particles appeared to be more sensitive 
to size. Particles 1 µm in diameter showed significantly lower levels of uptake at 30 
minutes compared to 200 nm particles (Figure 7A and B). As seen with anti-ICAM 
particles, the uptake efficiency of nano- and micro-particles was brought closer over time, 
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indicating that CAM-mediated uptake is equipped for internalization of objects of a wide 
range of sizes, regardless of the ICAM-1-targeting moiety used to elicit the pathway. 
However, since the percent uptake of 200 nm versus 1 µm γ3 particles at 3 hours was still 
significantly higher, this suggests that binding ICAM-1 via γ3, slower, or weaker particle 
binding, may lead to more size-sensitive CAM-mediated uptake rates. 
 
Figure 7. Uptake of γ3 particles by endothelial cells and comparison with anti-ICAM particle uptake. 
Activated HUVECs were incubated with 200 nm or 1 µm γ3 or anti-ICAM particles for 30 minutes or 3 
hours at 37˚C. Surface-bound, but not internalized, particles were immunostained (see Methods) to quantify 
percent uptake. (A) Sample micrographs showing total particles (top panels for each time-point) or only 
surface-bound non-internalized particles (bottom panels for each time-point). Arrows indicate internalized 
particles and arrowheads indicate non-internalized particles. Scale bar = 20 µm. Green = particles. Blue = 
nuclei. (B) Quantification of uptake expressed as the percent of particles inside cells out of the total cell-
associated particles. (C) Ratio of uptake of anti-ICAM versus γ3 particles. Data represent mean ± standard 
error of the mean. * compares 200 nm to 1 µm at each time-point (p<0.05 by Student’s t-test). 
 
In support of these targeting moiety differences regarding particle size, a 
comparison of the uptake levels of anti-ICAM versus γ3 particles, showed only a slight 
(1.5-fold) higher efficiency of uptake for 200 nm as early as 30 minutes, yet 1 µm 
particles took 3 hours to reach this level (from an original 8-fold difference; Figure 7C). 
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This suggests that in addition to particle size, the CAM-mediated endocytic machinery is 
sensitive to targeting moiety, particularly at early time-points. 
These results should be considered in the development of ICAM-1-targeted 
carrier-assisted drug delivery, as the use of peptides instead of antibodies could prove 
beneficial in order to prevent potential effects on the immune system [213], yet our data 
indicate generally lower uptake efficiency of γ3 versus anti-ICAM model drug carriers, 
and specifically slower uptake with micron-sized formulations. For instance, increasing 
the concentration of γ3 carriers administered may attenuate these differences. 
 
4.2.4. Role of particle size and targeting moiety of ICAM-1-targeted particles on 
ceramide enrichment during CAM-mediated endocytosis. 
Thus far, our data showed that particle size and targeting moiety affect particle 
binding outcomes, suggesting differences in ICAM-1 engagement. Since ICAM-1 
signaling depends on the multivalent engagement of this molecule [6], it is possible that 
these particle size and targeting moiety differences affect signaling properties of CAM-
mediated uptake. Such differences in signaling could be manifested in the downstream 
events of membrane deformability and actin rearrangement, both of which are likely to 
affect the efficiency of internalization, particularly in a size-dependent manner. Our 
published data show that ICAM-1 signaling leads to acid sphingomyelinase recruitment 
and production of ceramide during CAM-mediated uptake, and this is a major aspect in 
the regulation of membrane deformability and actin rearrangement [7]. With that in mind, 
we next explored ceramide in the context of size and targeting moiety. 
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In order to compare ceramide production for particles of different sizes, we 
incubated HUVECs with 200 nm, 1 µm, and 4.5 µm anti-ICAM or γ3 particles for 30 
minutes. Then, we immunostained ceramide (Figure 8A, left) and measured the fold 
increase (Δ) between background levels of plasma membrane ceramide at the vicinity of 










Figure 8. Ceramide enrichment at sites of binding of ICAM-1-targeted particles to endothelial cells 
and effect on uptake. Activated HUVECs were incubated with 200 nm, 1 µm or 4.5 µm anti-ICAM or γ3 
particles for 30 minutes at 37°C in the absence (control) or presence of imipramine. After fixing, ceramide 
was immunostained for fluorescence microscopy. (A) Left: Example of a 4.5 µm anti-ICAM particle 
(phase-contrast; upper panel) colocalizing with enriched ceramide (fluorescence; bottom panel) at the 
endothelial plasma membrane. Right: Quantification of ceramide enrichment, where Δ indicates fold 
increase in fluorescence intensity over background levels (adjacent plasmalemma). (B) Ceramide 
enrichment at sites of 200 nm, 1 µm or 4.5 µm anti-ICAM particle binding in the absence or presence of 
imipramine. (C) Left: Example of a 4.5 µm γ3 particle (upper panel) colocalizing with enriched ceramide 
(bottom panel) at the endothelial plasma membrane. Right: Quantification of ceramide enrichment, where 
Δ indicates fold increase in fluorescence intensity over background levels. (D) Plot of fold increase in 
ceramide intensity normalized to background (imipramine) versus the density of ICAM-1 engagement for 
each particle size (see Methods, Section 3.8). (E) Percent uptake normalized to ceramide enrichment. Scale 
bars = 10 µm. Data represent mean ± standard error of the mean. * compares control versus imipramine for 
each size, # compares 200 nm to 1 µm, ! compares 200 nm to 4.5 µm, and & compares 1 µm to 4.5 µm 
(p<0.05 by Student’s t-test). 
 
As seen in Figure 8B, binding sites for anti-ICAM particles of all sizes were 
enriched in ceramide (Δ > 1), yet these levels were higher for both micron-sized particle 
groups compared to nanoparticles. In addition to this, all particle sizes exhibited specific 
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ceramide production, indicated by decreased enrichment in the presence of imipramine, 
an inhibitor of acid sphingomyelinase activity. The level of enrichment in the presence of 
imipramine was still substantial and similar for all sizes, suggesting that this lipid, which 
is an inherent resident of the plasma membrane, is present to a certain extent at particle 
binding sites even in the absence of enzymatic activity. Interestingly, the production of 
ceramide at sites of 200 nm particle binding was much lower (although significantly 
different from imipramine-treated) compared to micron-sized particles. This suggests that 
smaller particles have a lower requirement for ceramide production than micron-sized 
counterparts, because despite lower ceramide enrichment, they exhibited higher initial 
uptake rates (recall Figure 6). 
Since γ3 particles had lower uptake than anti-ICAM particles, we also determined 
ceramide enrichment upon engagement of the ICAM-1 with γ3-targeting. The particle 
sizes used for binding and uptake studies did not elicit detectable levels of ceramide at 
binding sites (data not shown). Thus, we also used γ3 4.5 µm particles for this purpose. 
Detection of enrichment is typically more straightforward in this size of particles, and this 
size presented the highest density of γ3 on its surface (Table 2, page 33), which should 
elicit the highest ceramide response (refer to Figure 8D results below). Even this particle 
size failed to produce ceramide enrichment above the background levels seen in the 
presence of imipramine for anti-ICAM particles (Figure 8C). This lower level of 
ceramide may be due to lower binding avidity of γ3 particles than anti-ICAM 
counterparts, which could essentially elicit weaker signaling. However, this effect could 
also be due to differential epitope binding between the two types of particles (recall that 
anti-ICAM and γ3 particles bind distinct ICAM-1 epitopes), as binding of different 
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epitopes on the same molecule can differentially affect allosteric responses [214, 215]. 
Regardless of the reason behind this lower ceramide production, this fact could explain 
why γ3 particles exhibited a higher sensitivity to increasing particle size with respect to 
uptake efficiency compared to anti-ICAM particles. Lower production of ceramide to 
drive vesiculation and actin rearrangement, even for large particles, would generate this 
outcome. Nonetheless, it will be necessary to further explore the relationship between 
ceramide production, vesiculation, and actin rearrangement, as previous data show that 
despite no detectable levels of ceramide, γ3 particles engage ICAM-1 sufficiently to 
generate signaling for actin stress fiber formation [216]. Co-coating sphingomyelinases 
on the surface of γ3 drug carriers could enhance ceramide signaling and, hence, uptake, 
as in the case of carriers targeted to the M6PR (shown below in Section 4.2.5). 
Our working model for CAM-mediated uptake proposes that binding of ICAM-1 
triggers exocytosis of acid sphingomyelinase, leading to ceramide production [7]. Since 
the number of ICAM-1 molecules engaged could affect the degree of sphingomyelinase 
recruitment, we determined the relationship between ceramide production and potential 
ICAM-1 binding density for each particle (based on the number of antibodies per µm2 of 
particle; see Methods, Section 3.8). As seen in Figure 8D, the fold increase in ceramide 
enrichment was directly proportional to potential ICAM-1 binding density of each 
particle at the cell surface. This shows that although drug carriers of larger sizes could 
require higher ceramide production for uptake as suggested by our uptake data, their size 
may not inherently signal for this higher ceramide production. Instead, the density at 
which ligands engage ICAM-1 on the cell surface is likely to control this signaling 
output. Although not shown, the relationship between ceramide enrichment and density 
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of potential ICAM-1 engagement for γ3 particles was not linear. Instead, there was equal 
production of ceramide (close to imipramine levels) regardless of γ3 density on the 
particle surface. This suggests fundamental differences in the way which anti-ICAM 
particles engage ICAM-1 compared to γ3 particles, which may affect CAM-mediated 
signaling. 
Due to the linear relationship between engagement density and ceramide 
enrichment for anti-ICAM particles, we also determined the internalization of each anti-
ICAM particle size as a function of ceramide enrichment (Figure 8E). This revealed that 
nanoparticles exhibited higher percent uptake per unit of ceramide enrichment compared 
to micron-sized counterparts. Once again, this suggests that uptake through CAM-
mediated endocytosis depends on ceramide production in a size-dependent manner. 
Overall, for drug delivery purposes, nano-sized particles seem to have lower 
requirements for ceramide production to achieve earlier uptake, so nano-carriers would 
be beneficial when the main goal is high and quick intracellular drug delivery. However, 
an anti-ICAM drug carrier with larger surface area would exhibit more flexibility for 
controlling the density of ICAM-1 targeting molecules on its surface. This makes 
microparticles more suitable for manipulating ceramide enrichment and possibly control 
the efficiency of endocytosis, providing wider modulation of the therapeutic outcome that 




4.2.5. Role of particle size on the requirement for sphingomyelinase activity during 
endocytosis. 
In order to verify the possible size dependency that connected ceramide 
production and uptake of anti-ICAM particles (recall Figure 8E), we used a system that 
allowed us to control the level of sphingomyelinase present. This consisted of 200 nm, 1 
µm or 4.5 µm particles coated with antibodies to mannose 6-phosphate receptor (M6PR) 
along with varying levels of neutral sphingomyelinase (NSM; Table 4). 
Table 4. Particles used for the study of sphingomyelinase requirements in 
endocytosis. 
Size Coat Surface coverage 
1 µm Non-specific IgG 100% 
1 µm Anti-ICAM:IgG 50:50 
1 um Anti-M6PR 100% 
1 um Anti-M6PR:IgG 80:20 
1 um Anti-M6PR:IgG 50:50 
1 um Anti-M6PR:NSM 80:20 
1 um Anti-M6PR:NSM 50:50 
NSM = Neutral sphingomyelinase; Surface coverage = approximate fraction of particle surface that a 
molecule type occupies. 
 
We selected M6PR because this receptor associates with clathrin-mediated 
endocytosis, does not associate with ceramide production and is independent of 
sphingomyelinase for internalization, and anti-M6PR carriers do not associate with 
CAM-mediated uptake [189]. We used neutral sphingomyelinase as a substitute for acid 
sphingomyelinase, because unlike engagement of ICAM-1, engagement of M6PR by 
antibody-coated particles does not recruit NHE1, thought to be necessary for acidification 
of the microenvironment to permit acid sphingomyelinase activity [7]. 
Anti-M6PR:NSM particles, at both concentrations of sphingomyelinase used, 
showed a substantial increase in internalization by cells compared to control anti-M6PR 
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particles lacking neutral sphingomyelinase (Figure 9A and B), also reflected when we 
calculated percent uptake (Figure 9C). When compared to CAM-mediated uptake of anti-
ICAM particles (dashed line in Figure 9C), this NSM-enhanced uptake was less efficient, 
but substantial (approximately ~60-65% of putative CAM-mediated uptake). 
 
Figure 9. Uptake of anti-M6PR particles coated with neutral sphingomyelinase. Activated HUVECs 
were incubated with 1 µm anti-ICAM:IgG, anti-M6PR:IgG or anti-M6PR:NSM (50:50 or 80:20 surface 
coverage), or anti-M6PR or non-specific IgG (100% surface coverage) particles for 3 hours at 37°C. 
Surface-bound, but not internalized, particles were immunostained to quantify percent uptake. A) Sample 
micrographs of anti-M6PR:IgG or anti-M6PR:NSM particles. Phase contrast shows total particles bound 
and internalized. Fluorescence images show surface-bound, non-internalized particles. Arrowheads indicate 
non-internalized particles and arrows indicate endocytosed ones. Scale bar = 10 µm. (B) Total number of 
particles internalized per cell. Dotted line represents non-specific IgG particles. (C) Percent of particles 
internalized out of the total numbers of particles associated to cells (bound plus internalized). Dashed line 
represents anti-ICAM particles. Data represent mean ± standard error of the mean. * compares to 100% 
anti-M6PR particles (continuous line in both graphs); ^ compares to non-specific IgG particles; # compares 
to anti-M6PR:IgG particles (p<0.05 by Student’s t-test). 
 
In support of similar mechanisms of uptake, antiM6PR:NSM particles specifically 
(as opposed to anti-M6PR particles with no NSM) elicited enrichment of ceramide, as 
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well as rearrangement of actin into stress fibers, seen with anti-ICAM particles that 
undergo CAM-mediated endocytosis (Figure 10). 
 
Figure 10. Role of neutral sphingomyelinase on ceramide enrichment and actin for anti-M6PR 
particles. Activated HUVECs were incubated with 1 µm anti-ICAM:IgG, anti-M6PR:IgG or anti-
M6PR:NSM particles (all 50:50 surface coverage) for 30 minutes at 37°C (A) Ceramide was 
immunostained for fluorescence microscopy. Particles (arrowheads) are shown in phase-contrast and 
ceramide is shown in the fluorescent channel. (B) F-actin was stained with fluorescent phalloidin. Arrows 
indicate stress fibers. Scale bars = 10 µm. 
 
Due to the size restrictions of clathrin-mediated uptake, internalization efficiency 
of anti-M6PR particles lacking neutral sphingomyelinase expectedly decreased with 
increasing particle size (Figure 11A). As predicted from the central role that ceramide has 
in creating an environment suitable for uptake in CAM-mediated endocytosis, the 
presence of sphingomyelinase increased the efficiency of anti-M6PR particle 
internalization for all sizes (Δ > 1; Figure 11B). More importantly, and supporting the 
notion that ceramide plays a role in the size-dependency of CAM-mediated uptake, the 
sphingomyelinase-dependent improvement in uptake was larger for micron-sized 
particles than for nanoparticles. Additionally, increasing sphingomyelinase from 20% to 
50% of the particle surface did not change this improvement in the case of 200 nm or 1 
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µm particles (∼1-1.5-fold difference comparing 50% versus 20% sphingomyelinase; 
Figure 11C), but it did for 4.5 µm particles (by 3-fold). Therefore, for larger particles 
there was a larger dependence for sphingomyelinase activity, likely to be reflected in the 
original CAM-mediated pathway, as our uptake and ceramide enrichment data suggested 
(recall Figures 6 and 8). 
 
Figure 11. Role of particle size on neutral sphingomyelinase dependency for uptake. Activated 
HUVECs were incubated with 200 nm, 1 µm, or 4.5 µm anti-M6PR:IgG or anti-M6PR:NSM (either 50:50 
or 80:20 surface coverage) for 3 hours at 37°C. (A) Percent of anti-M6PR:IgG (50:50) particles internalized 
out of the total number of particles associated to cells (bound plus internalized). (B) Fold increase (Δ) in the 
percent uptake of anti-M6PR:NSM particles over control anti-M6PR:IgG particles (both 50:50) for each 
particle size. (C) Comparative improvement in endocytosis (Δ in B) for anti-M6PR:NSM particles bearing 
50% NSM particle-surface coverage (50:50) over that of particles bearing 20% coverage (80:20). Data 
represent mean ± standard error of the mean. * compares microparticles to 200 nm particles; # compares 
anti-M6PR:NSM particles to anti-M6PR:IgG particles, ^ compares anti-M6PR:NSM/anti-M6PR:IgG of 
50:50 surface-coverage to that of 80:20 particles for each given size (p<0.05 by Student’s t-test). 
 
Overall, these data support a role for ceramide in the particle size- and targeting moiety-
dependent differences observed for CAM-mediated endocytosis. Namely, larger particles 
require higher (or more prolonged) sphingomyelinase activity (and, thus, ceramide 
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enrichment) for efficient internalization. Meanwhile, binding of γ3 particles elicits lower 
enrichment levels of ceramide compared to anti-ICAM particles (which may be a result 
of differential epitope binding or extent of ICAM-1 binding/engagement), leading to 
lower uptake levels of γ3 particles. The understanding of this mechanism opens our 
ability to further modulate CAM-mediated endocytosis of drug carriers. As said, particles 
of large sizes, or particles coated with γ3 instead of anti-ICAM, can be co-functionalized 
with sphingomyelinase as a means to aid their uptake efficiency, if desired. Furthermore, 
a collateral benefit of this study is that evidently uptake of drug carriers targeted to 
receptors that normally do not internalize micron-sized objects, such as M6PR, can be 
enhanced with the presence of sphingomyelinase in order to achieve intracellular uptake. 
 
4.2.6. Role of size and targeting moiety on intracellular trafficking of ICAM-1-targeted 
particles. 
Next, in order to determine the role of size and targeting moiety on the 
intracellular fate of particles internalized by CAM-mediated endocytosis, we first 
explored their trafficking to lysosomes. To do this, we pre-incubated HUVECs with 
Texas Red-labeled dextran for 45 minutes, followed by a 45-minute chase. This allows 
for dextran to be endocytosed and fully transported to lysosomes, which has been 
confirmed using LAMP-1 staining [9, 193]. After pre-labeling of lysosomes, cells were 
incubated with 200 nm, 1 µm or 4.5 µm anti-ICAM or γ3 particles for 1 hour to allow 
binding, and 0, 2 or 4 hours (chase), to allow uptake and trafficking (Figure 12A). 
Surface-bound particles were immunostained and subtracted during analysis, such that 
percent colocalization with lysosomes only accounts for internalized particles. Analysis 
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after microscopy revealed, confirming historical data [77], that 200 nm anti-ICAM 
particles trafficked to lysosomes reaching a plateau of ~80% colocalization at 3 hours. 
Meanwhile, 1 µm and 4.5 µm particles reached a plateau of ~30% colocalization, 
indicative of less efficient trafficking to lysosomes for larger sizes (Figure 12B). 
 
Figure 12. Lysosome trafficking of anti-ICAM particles. Activated HUVECs were pre-incubated for 45 
minutes with Texas Red-labeled dextran, followed by a 45 minutes chase to label lysosomes. Then, cells 
were incubated with 200 nm, 1 µm, or 4.5 µm anti-ICAM particles for 1 hour, followed by washing and a 
chase of 0, 2 or 4 hours at 37˚C. (A) Sample micrographs for each time-point for 200 nm green particles, 
which appear as yellow when colocalizing with red lysosomes. Scale bar = 20 µm. (B) Quantification of the 
percent of internalized particles that colocalize with lysosomes per cell. (C) Quantification of the absolute 
number of particles that colocalize with lysosomes per cell. (D) Quantification of the absolute number of 
particles per cell. Data represent mean ± standard error of the mean. * compares 3 hours to 5 h; # compares 
1 hour to 3 hours (p<0.05 by Student’s t-test). 
 
Curiously, the colocalization of 4.5 µm particles decreased (although not 
significantly) between 3 and 5 hours (Figure 12B). This led us to examine the absolute 
values of lysosome-colocalized particles. Figure 12C shows that for 200 nm particles, 
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there was no change in the number of particles in lysosomes between 3 and 5 hours, 
similar to its percent values. Surprisingly, for both 1 µm and 4.5 µm particles, there was a 
decrease in the number of particles in lysosomes between these two time-points (only 
statistically significant for 4.5 µm particles). Thus, it appeared that while lysosomes were 
the terminal compartment for nanometric particles, micron-sized objects not only traffic 
poorly here, but might divert from these compartments. This finding agrees with recent 
models that identify the lysosome as a dynamic organelle that does not necessarily serve 
as a terminal trafficking destination [217], and it points at a regulatory role for object size 
with respect to the dynamics of these trafficking events. 
Since this suggested that post-endocytic trafficking, particularly for large 
particles, may not be terminal, we also determined the total number of particles 
associated with cells over time. As shown in Figure 12D, between 3 and 5 hours, there 
was no change in 200 nm cell-associated particles, as would be expected from a 
pulse/chase treatment. Meanwhile, both micron-sized particles showed a decrease in cell-
associated particles between these time-points. Although these changes were small, they 
were significant and suggested a release of micron-sized particles from cells, which 
would coincide with a tendency of these particles to escape lysosomes or avoid lysosome 
trafficking altogether. Thus, overall, these data pointed at a role in particle size with 
respect to intracellular trafficking, suggesting that after CAM-mediated endocytosis and 
trafficking, large particles may be secreted from lysosomes and also from cells. 
We also compared anti-ICAM and γ3 particle trafficking. We focused on 200 nm 
particles only in order to minimize issues with the slower binding and uptake, especially 
for larger particles, that could confound kinetics of lysosome colocalization (refer to our 
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binding and uptake data in Figures 3-7). As seen in Figure 13A, γ3 particles exhibited 
consistently lower levels of percent colocalization with lysosomes compared to anti-
ICAM particles. Unlike micron-sized anti-ICAM particles which showed a similar 
behavior (recall Figure 12), however, γ3 particles did not appear to exit lysosomes or 
cells (Figure 13B and C). 
 
Figure 13. Lysosome trafficking of anti-ICAM versus γ3 particles. Activated HUVECs were pre-
incubated for 45 minutes with Texas Red-labeled dextran, followed by a 45 minutes chase to label 
lysosomes. Then, cells were incubated with 200 nm anti-ICAM or γ3 particles for 1 hour, followed by 
washing and incubation (chase) for 0, 2, 4, or 23 hours at 37˚C. (A) Quantification of the percent of 
internalized particles that colocalize with lysosomes per cell. (B) Quantification of the absolute number of 
particles that colocalize with lysosomes per cell. (C) Quantification of the absolute number of particles per 
cell. Data represent mean ± standard error of the mean. 
 
Since γ3 particles in general showed slower internalization kinetics compared to 
anti-ICAM particles, we extended the lysosome colocalization to 24 hours (where uptake 
was near 100% for both types). Even after this long period of time, γ3 particles still 
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exhibited lower percent colocalization than anti-ICAM counterparts (90.7±2.2% and 
72.4±5.6% for anti-ICAM and γ3 particles, respectively). This suggested that binding to 
ICAM-1 through the γ3-associated epitope, or lower binding strengths, led to lower 
trafficking to lysosomes. 
Since anti-ICAM nanocarriers exhibit high levels of lysosome trafficking, a major 
focus of CAM-mediated uptake strategies has been the delivery of drug carriers for 
treatment of lysosomal storage disorders. However, the discovery that changing anti-
ICAM particle size can impede or delay lysosome trafficking has been explored to permit 
delivery of drugs to other intracellular compartments. The data presented here 
corroborate these ideas regarding size, and add a novel component in the use of γ3 to 
achieve lower rates of trafficking to lysosomes. This targeting moiety concept, which was 
already explored in PECAM-1-binding drug carriers, holds potential for the expansion of 
drug delivery techniques through CAM-mediated endocytosis. 
 
4.2.7. Size and targeting moiety of ICAM-1-targeted particles affect transport across 
endothelial cells. 
Finally, with data suggesting differential intracellular trafficking after CAM-
mediated endocytosis depending on size and targeting moiety, we examined particle 
transport across endothelial cells. We used human brain microvascular endothelial cell 
(HBMEC) monolayers plated on porous membranes, as the brain endothelium is an 
important target for transport of drug carriers, and we have previously shown similar 
patterns of binding and CAM-mediated uptake in HUVECs versus HBMECs [195]. 
Particles of 200 nm, 500 nm or 1 µm diameter coated with 125I-anti-ICAM or γ3 
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(containing a small fraction of 125I-IgG, that does not affect binding, for tracing purposes; 
see Methods, Section 3.4) were added to HBMECs for 30 minutes to allow binding, 
followed by washing of both apical and basal fractions, and further incubation for 4.5 
hours to allow for transport. After the assay, the basal and cell fractions were collected 
for quantification using a gamma counter. These readings consist of both intact proteins 
labeled with 125I, or free (non-protein-associated) iodine resulting from protein 
degradation. Thus, the free iodine content from each collected fraction was also 
determined and it was subtracted from the original readings to obtain numbers that only 
account for intact particles that associate with cells or cross from the apical to the basal 
chamber without being degraded. It is assumed that all intact radiolabeled proteins are 
retained on the particle surface, as historical data show [195] (see Methods, Section 3.4). 
Similar to our microscopy studies, ICAM-1-targeted particle association with 
HBMECs grown on porous membranes was specific as compared to control non-specific 
IgG or γ3S particles (Figure 14A, ICAM-1-targeted/Non-specific > 1, dashed line, in all 
cases). Free iodine for both targeted and non-specific formulations were similar and close 
to the background levels found in original particle formulations (~10%), which suggests 
that the readings obtained in the cell fraction are mostly representative of cell-bound 
particles (Figure 14B). Similar to our previous data, particle association with cells (after 
correcting for free iodine to only account for intact particles) was dependent on particle 
size and targeting moiety, with lower binding levels for anti-ICAM micron-sized particles 
and γ3 nanoparticles, compared to anti-ICAM nanoparticles (Figure 14C). 
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Figure 14. Association of ICAM-1-targeted particles to endothelial cells on porous membranes. 
Activated HBMECs grown on 3-µm pore-size porous membranes were incubated in the presence of anti-
ICAM, IgG, γ3, or γ3S 200 nm, 500 nm, or 1 µm particles (coated with radiolabeled proteins for tracing) 
for 30 minutes, followed by washing of both chambers and incubation (chase) for 4.5 hours at 37˚C. Cell 
fraction and basal fraction were quantified with a gamma counter. (A) Quantification of cell-association 
specificity (cell fraction of anti-ICAM or γ3 particles divided by cell fraction of IgG or γ3S particles). 
Dashed line = 1. (B) Quantification of the cell fraction free (non-protein-associated) iodine in each 
formulation. (C) Quantification of total cell-associated particles per mm2 of cell surface after subtracting 
free iodine. Data represent mean ± standard error of the mean. 
 
Transport of ICAM-1-targeted particles was also specific compared to IgG and 
γ3S (Figure 15A). Meanwhile, free iodine levels were above particle formulation 
backgrounds, indicating protein degradation (Figure 15B). However, the free iodine 
levels of ICAM-1-targeted particles were higher than those of non-specific counterparts. 
This shows that specific interaction with ICAM-1 elicits degradation of particle protein 
coats, and based on our microscopy data, this is likely due to intracellular trafficking of 
these particles, and particularly due to degradation in lysosomes. 
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Figure 15. Transport of ICAM-1-targeted particles across endothelial cells. Activated HBMECs grown 
on 3-µm pore-size porous membranes were incubated in the presence of anti-ICAM, IgG, γ3, or γ3S 200 
nm, 500 nm, or 1 µm particles (coated with radiolabeled proteins for tracing) for 30 minutes, followed by 
washing of both chambers and incubation (chase) for 4.5 hours at 37˚C. Cell fraction and basal fraction 
were quantified with a gamma counter. (A) Quantification of transport specificity (basal fraction of anti-
ICAM or γ3 particles divided by basal fraction of IgG or γ3S particles). Dashed line = 1. (B) Quantification 
of the basal free (non-protein-associated) iodine in each formulation. (C) Quantification of percent 
transport, calculated as (basal fraction)/(cell plus basal fraction) × 100. Data represent mean ± standard 
error of the mean. 
 
Finally, as shown in Figure 15C, the transport efficiency of ICAM-1-targeted 
particles was dependent on particle size and targeting moiety. For anti-ICAM particles, 
transport efficiency increased with increasing size. For the same size of particles (200 
nm), γ3 particles showed higher percent transport compared to anti-ICAM particles. 
These effects correlate with our lysosome colocalization data (recall Figures 12 and 13), 
supporting higher avoidance of terminal lysosome trafficking (as seen by microscopy), 
accompanied by higher rates of transcytosis with increasing object size after CAM-
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mediated uptake. A similar conclusion can be made for particles binding via γ3 versus 
those binding via anti-ICAM. 
Thus, these data show that CAM-mediated transport across barriers can be 
modulated by changing particle size and targeting moiety. Larger drug microcarriers 
versus nanometric counterparts may benefit the delivery of therapeutics into tissue as 




Using knowledge about the natural binding partners of ICAM-1, we selected two 
parameters to determine their effect on the outcomes of CAM-mediated endocytosis: 
particle size and ICAM-1-targeting moiety (which may affect binding epitope, avidity, 
etc.). Here, we present evidence showing that these parameters of ICAM-1-targeted 
particles affects the binding, uptake, ceramide enrichment and trafficking outcomes of 
CAM-mediated endocytosis, potentially guiding the future design of drug delivery 
carriers. As will be addressed later, these results may also shed light on the regulation of 
the physiological functions of the CAM-mediated pathway. 
In summary, we have found that large ICAM-1-binding particles bind at faster 
initial rates than small counterparts, but in activated cells expressing high levels of 
ICAM-1, binding is saturated to similar values of cell surface occupancy over time. 
Furthermore, the role of ceramide production during CAM-mediated endocytosis makes 
this pathway sensitive to large objects, which require higher levels of sphingomyelinase 
activity for efficient uptake. In turn, ceramide enrichment appears to depend on the 
density of ICAM-1 engagement per individual particle. Despite a possible initial barrier 
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for uptake due to this ceramide dependence, objects even the size of a cell can be 
internalized by the endothelium through the CAM-mediated pathway. This may relate to 
the role of ICAM-1 on lymphocyte interaction and transmigration. Finally, after 
internalization, the size of particles affects their rate of trafficking to lysosomes, with 
larger particles avoiding lysosomal compartments, and possibly escaping these 
compartments and exiting the cell. This may be reflected in the higher rates of 
transendothelial transport observed for micron-sized particles versus nanometer-sized 
ones. Meanwhile, binding to ICAM-1 by γ3 particles, as opposed to anti-ICAM ones, 
leads to slower binding, lower ceramide production, lower internalization, and also lower 
trafficking to lysosomes, with higher transport across cells. 
Thus, these data support the use of small high-affinity ICAM-1-targeted drug 
carriers for fast and efficient terminal delivery into cells (specifically lysosomes), while 
large carriers for transport across barriers. In addition, the inclusion of exogenous 





Chapter 5: Contribution of Regulatory Elements of the CAM-




Crossing of endothelial cells by leukocytes (transmigration) is a process that 
requires an active role by both cell types involved. That is, despite the leukocyte being 
motile, it cannot by itself penetrate the endothelial layer. Instead, the endothelium must 
grant regulated access, which involves signaling and structural changes in both the 
membrane and the cytoskeleton of endothelial cells [109, 111]. For instance, when 
endothelial PECAM-1 is blocked by antibodies, leukocytes migrate laterally on the 
endothelial surface, but cannot transverse the endothelial cell layer [218]. More 
strikingly, when endothelial cells express and ICAM-1 mutant that lacks its cytosolic tail, 
leukocytes adhere to the endothelium but remain immobile and cannot migrate laterally 
or transversally [59], which also occurs if cells do not express ICAM-1 at all [219]. 
Leukocyte interaction with this ICAM-1 mutant, which is deficient in its ability to induce 
endothelial cytoskeleton rearrangement [220], also exhibits a deficiency in the ICAM-1- 
and actin-rich endothelial membrane docking structures that help drive transmigration 
[59]. This shows that endothelial membrane protrusions, ICAM-1-enriched 
microdomains, and cytoskeletal rearrangement are necessary for both lateral and 
transversal movement of the leukocyte. 
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Transmigration can occur through two pathways: the paracellular or the 
transcellular route [111]. Paracellular transmigration involves opening of endothelial 
junctions and crossing of the endothelium in between cells, while transcellular 
transmigration involves crossing of the endothelium across the body of a single 
endothelial cell [111]. Although endothelial signaling, cytoskeletal rearrangement, and 
ICAM-1-rich membrane protrusions are needed for both modes of transmigration, it is 
possible that ICAM-1 serves as a regulator between these two routes. For instance, the 
vesicles that form and fuse into the transcellular pore through which leukocytes cross the 
endothelium are enriched in ICAM-1 [121], and ICAM-1 undergoes transcytosis across 
the endothelial cell as leukocytes migrate through this transcellular pore [121]. 
Furthermore, transcellular migration increases upon overexpression of ICAM-1, and 
deletion of its cytoplasmic domain reduces specifically the transcellular route [127]. This 
evidence suggests that ICAM-1-dependent vesicular dynamics and cytoskeletal changes 
are key contributors specifically to transcellular migration. 
Interestingly, the endothelial structures and signaling observed during leukocyte 
transmigration are also present upon ICAM-1-specific engagement by micron-sized inert 
beads coated with antibodies to ICAM-1. This includes the formation of docking-like 
structures [7, 124], Rho-dependent signaling [126], recruitment of tetraspanin domains 
[221], and development of transcellular pore-like invaginations [113]. In addition, these 
inert particles that specifically engage ICAM-1 elicit the pathway known as CAM-
mediated endocytosis, which involves the Na+/H+ exchanger activity of NHE1 and 
ceramide generation by acid sphingomyelinase [6, 7]. The signaling pathways necessary 
for CAM-mediated uptake are similar to those activated during leukocyte transmigration, 
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including the involvement of Rho, Rho-associated kinase, and Src kinase [6]. 
Downstream of these molecules actin rearranges into stress fibers (also seen during 
transmigration) and vesicles form, which allows endothelial cells to internalize objects as 
large as 10 µm in diameter (within the dimensions of a leukocyte) [7, 77]. 
Due to this evidence, it is possible that interaction of leukocyte integrin αLβ2 with 
endothelial ICAM-1 may elicit CAM-mediated endocytosis, which could contribute to 
transmigration, particularly through the transcellular route. The CAM-mediated pathway 
could provide signaling and membrane dynamics that result in formation of docking 
structures, and/or the vesicular events that result in formation of transcellular pores. Thus, 
in this chapter we explore the possible involvement of CAM-mediated endocytosis in 
leukocyte crossing of the endothelium, and regulation of the transmigration route. 
 
5.2. Results 
5.2.1. Contribution of CAM-mediated endocytosis to pre-transmigration interactions 
between lymphocytes and endothelial cells. 
For our studies, the leukocytes used were lymphocytes collected from human 
blood by density-gradient centrifugation and activated with IL-2, and the endothelial cells 
were TNF-α-activated HUVECs. This is a widely used in vitro model of transmigration 
[192]. Previously, we have shown that during CAM-mediated endocytosis, endothelial 
cells form membrane protrusions around anti-ICAM particles that resemble the 
endothelial docking structures seen on leukocytes during transmigration [7]. The 
structures formed during CAM-mediated endocytosis are enriched in ICAM-1, 
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tetraspanin CD9, NHE1, acid sphingomyelinase, and ceramide [7, 113], which are key 
molecular players of CAM-mediated uptake. Although ICAM-1 and tetraspanin CD9 
have been shown to be enriched at sites of leukocyte transmigration [221, 222], it is not 
known if NHE-1, acid sphingomyelinase, or ceramide are associated with transmigration 
events. Thus, we first tested whether these molecules are present at sites of interaction 
between lymphocytes and HUVECs. As shown in Figure 16, immunostaining of ICAM-1 
(as a positive control), NHE-1, acid sphingomyelinase, and ceramide revealed the 
enrichment of these molecules at sites of lymphocyte interaction with endothelial cells 
after a 30-minute incubation. In some cases the enrichment was polarized to sites where 
the lymphocyte appeared to enter the endothelial cell, as estimated by phase-contrast 
(shown by arrows in Figure 16). Although this technique does not allow to distinguish if 
the enriched molecules were endothelial or on the lymphocyte, these results support the 
involvement of CAM-mediated pathway molecular elements in the process of leukocyte 
transmigration. 
 
Figure 16. Enrichment of plasma membrane molecules at sites of interaction between lymphocytes 
and endothelial cells. Activated peripheral-blood lymphocytes were incubated with activated HUVECs 
grown on coverslips for 30 minutes at 37˚C, followed by immunostaining (bottom panels) of VE-cadherin, 
ICAM-1, NHE1, acid sphingomyelinase (ASM), or ceramide. Top panels illustrate phase-contrast. Arrows 
indicate polarized enrichment. Scale bar = 10 µm. 
 
As illustrated by Figure 16 (phase-contrast panels), when lymphocytes interact 
with endothelial cells they can adopt irregular morphologies. Previous studies have 
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shown that leukocytes must change their rounded shape into these spread (also known as 
‘polarized’) morphologies in order to perform sampling on the endothelial surface, which 
is required for transmigration [59, 223, 224]. It is also known that the endothelium plays 
an active role in this morphological change. For example, endothelium-specific inhibition 
of the signaling that regulates endothelial docking structures and invaginations results in 
rounded leukocytes that simply adhere to the endothelial cell and do not spread [59]. 
Thus, if CAM-mediated endocytosis were involved in the generation of pre-
transmigratory cell membrane invaginations and docking structures, it could affect 
leukocyte sampling of the endothelium. 
With this in mind, we first examined the interactions between lymphocytes and 
endothelial cells during the stage of sampling. Lymphocytes and HUVECs were 
incubated for 30 minutes, followed by thorough washing of non-bound lymphocytes. 
Scanning electron microscopy revealed that lymphocytes exhibiting flattened, irregular 
morphologies are associated with the podosomes and interdigitating endothelial 
membrane structures known to result in transmigration (Figure 17A, black arrowheads). 
Meanwhile, lymphocytes with a round morphology are simply (yet firmly) adhered to the 
endothelial cell (Figure 17A, white arrowhead). With this confirmation of historical data 
[59], we used a scoring system in which fluorescently labeled lymphocytes that exhibited 
a round morphology were scored as ‘adhered’, while spread lymphocytes (which may be 
sampling or already undergoing transmigration) were scored as ‘sampling’ to indicate a 
potential transmigratory event (Figure 17B). As shown in Figure 17C, 69.3±2.3% of 
lymphocytes were sampling the surface of HUVECs in this model, while 30.7±2.3% 




Figure 17. Model to examine pre-transmigratory interactions between lymphocytes and endothelial 
cells. Interaction of activated peripheral-blood lymphocytes (WBCs) with activated HUVECs grown on 
coverslips after incubation for 30 minutes at 37˚C. (A) Scanning electron microscopy of WBCs interacting 
with HUVECs. Black closed arrowhead indicates a ‘sampling’ WBC. White arrowhead indicates a simply 
‘adhered’ WBC. Open arrowheads show WBC podosomes and related sampling structures at the interface 
with HUVECs. Scale bars = 10 µm (top) and 2.5 µm (bottom). Nu = Nucleus. (B-D) Activated WBCs pre-
stained with green fluorescent calcein AM and observed by fluorescence microscopy on activated HUVECs 
stained for ICAM-1 (blue). (B) The image shows an example of spread WBCs scored as ‘sampling’ (black 
arrowheads for endothelial cell (EC) body and black arrow for EC border), compared to rounded WBCs 
scored as simply ‘adhered’ (white arrowhead). Cell borders are indicated by dashed lines. Scale bar = 10 
µm. (C) Percent of sampling WBCs on HUVECs with corresponding spatial distribution depending on the 
location of each sampling event (black for HUVEC border and white for HUVEC body). (D) Percent of 
‘sampling’ WBCs (black bars) versus ‘adhered’ WBCs (white bars) out of only the population located on 
the HUVEC body (left) or the HUVEC border (right). Data represent mean ± standard error of the mean. In 
C, error bars correspond (from top to bottom) to Total sampling, Border sampling, and Body sampling, 
respectively. 
 
In order to also examine the potential route of transmigration that may follow 
these sampling interactions, we determined the lymphocyte spatial distribution on the 
endothelial cell surface, thereby scoring ‘sampling’ or ‘adhered’ lymphocytes as being 
directly on the ‘border’ of HUVECs or ≥ 1 µm away from borders (referred to as ‘body’; 
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Figure 17B). This estimation of transcellular versus paracellular events has been used 
previously and is considered acceptable with the understanding that it might 
underestimate transcellular events because a fraction of transcellular transmigration 
occurs within 1 µm of the closest endothelial border without disrupting cell-cell junctions 
[130]. 
This analysis revealed sampling events were equally distributed between the body 
and the border (53.4±4.0% on the body and 46.6±4.0%, respectively; compare white and 
black regions in Figure 17D). Also, from within the population of lymphocytes only 
found on the HUVEC body, 71.2±3.5% were involved in sampling interactions, and a 
similar percentage was observed for the population of lymphocytes only found on the 
HUVEC border (68.0±4.7%; Figure 17D). Thus, these data suggested that under control 
conditions, the initiation of lymphocyte sampling did not exhibit a preference for the 
body or the border of HUVECs. Although sampling leukocytes do not necessarily 
represent those that fully migrate across endothelial cells, our percent sampling rates are 
in agreement with published percentages of leukocyte transmigration [127, 225, 226]. 
Thus, it is possible that most of these sampling interactions between lymphocytes and 
HUVECs may result in successful transmigration, half of which occurs at endothelial 
body locations where transcellular migration can occur. 
With this model in place, we then tested the role of several molecular players of 
the CAM-mediated pathway on pre-transmigratory events using chemical inhibition. In 
addition, we tested the involvement of caveolae-related pathways as some studies suggest 
that caveolae are responsible for the vesicular events that occur during transcellular 
transmigration [138], yet this contribution is controversial [130]. As seen in Figure 18A, 
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methyl-β-cyclodextrin (Cdx), a cholesterol-chelating agent that disrupts lipid raft 
domains, known to affect both CAM-mediated uptake and caveolae-mediated 
endocytosis, inhibited sampling by 19.5±6.8%. However, filipin, which affects caveolae-
mediated endocytosis but not the CAM-mediated pathway [6], had no effect on sampling 
(17.5±9.7% increase, non-significant). This suggested that the integrity of lipid domains 
in CAM-mediated endocytosis is important for the pre-transmigratory interaction 
between leukocytes and endothelial cells, but caveolae may have a less significant role. 
  
Figure 18. Effect of inhibitors on both lymphocytes and endothelial cells during pre-transmigratory 
interactions. Activated HUVECs grown on cover slips were pre-incubated 30 minutes at 37˚C in control 
medium or medium containing filipin (Fili), methyl-β-cyclodextrin (Cdx), amiloride (Ami), EIPA, or 
imipramine (Imi), followed by incubation for 30 minutes with activated peripheral-blood lymphocytes 
(WBCs, pre-stained with green fluorescent calcein AM) in the presence of inhibitors. WBCs not firmly 
bound to HUVECs were washed followed by fixation, immunostaining of ICAM-1, and analysis by 
fluorescence microscopy. (A) Percent of sampling WBCs on HUVECs with corresponding spatial 
distribution (black for HUVEC border and white for HUVEC body). (B) Percent of sampling WBCs (black 
bars) versus simply ‘adhered’ WBCs (white bars) out of only the population located on the HUVEC body. 
(C) Percent of sampling WBCs (black bars) versus simply ‘adhered’ WBCs (white bars) out of only the 
population located on the HUVEC border. In B and C, data are normalized to control values (horizontal 
dashed line). Data represent mean ± standard error of the mean. In A, error bars correspond (from top to 
bottom) to Total sampling, Border sampling, and Body sampling, respectively.* compares total percent 
sampling to control; ^ compares percent body sampling to control, & compares each column to control 
(p<0.05 by Student’s t-test). 
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In support of this, inhibition with amiloride, which disrupts Na+/H+ exchange 
among other cellular processes [227] associated with CAM-mediated uptake [6], led to 
36.2±7.3% inhibition of sampling. Since amiloride can affect other endocytic pathways 
and cellular functions, we also used its analog 5-(N-Ethyl-N-isopropyl)amiloride (EIPA), 
which specifically inhibits NHE1, the exchanger involved CAM-mediated endocytosis 
[8, 228]. This more specific inhibition led to the same effect on lymphocyte sampling as 
amiloride (34.2±6.9% inhibition). Finally, disruption of ceramide production through the 
inhibition of acid sphingomyelinase, a key enzyme that helps differentiate CAM-
mediated uptake from other pathways, inhibited lymphocyte sampling by 49.6±8.2% 
(Figure 18A imipramine). 
More interestingly, in all cases this decrease in sampling was due to a reduction of 
events occurring on the cell body, as opposed to the cell border. As seen in Figure 18A, 
the proportion of sampling occurring on cell borders (black) remained the same in the 
presence of CAM-mediated uptake inhibitors, while the proportion occurring on the 
endothelial cell body (white) decreased (67.5±15.2%, 41.6±20.8%, 37.1±8.6%, and 
15.1±4.7% of control for Cdx, amiloride, EIPA, and imipramine, respectively). 
Confirming this, when we focused only on the population of lymphocytes on the HUVEC 
body, the inhibitors of CAM-mediated endocytosis, but not filipin, decreased percent 
sampling and increased the proportion of ‘adhered’ lymphocytes with respect to control 
(Figure 18B). Meanwhile, when we focused only on the population of lymphocytes on 




Since in the assay described above the inhibitors were present during the 
interaction of lymphocytes with endothelial cells, the effects observed could be due to an 
effect on lymphocytes and not necessarily on HUVECs. In order to clarify our results, we 
repeated the sampling assays by pre-incubating HUVECs with inhibitors, followed by 
washing prior to the addition of lymphocytes. As shown in Figure 19A, inhibitors of the 
CAM-mediated pathway, but not filipin, had a negative effect on total lymphocyte 
sampling (6.9±9.5%, 27.9±9.0%, 25.9±12.35%, 24.3±7.7%, and 20.9±7.3% inhibition for 
filipin, Cdx, amiloride, EIPA, and imipramine, respectively). The effect of imipramine, 
however, was not statistically significant. This pattern of inhibition was similar to our 
previous assay and suggested endothelium-specific CAM-mediated endocytosis 
contributed to the initiation of lymphocyte sampling events. However, a lack of sampling 
inhibition by imipramine suggested that the role of endothelial acid sphingomyelinase in 
this process might not be as important as other molecular elements of CAM-mediated 
uptake, or that acid sphingomyelinase contribution from the lymphocyte might be 







Figure 19. Effect of inhibitors only on endothelial cells during pre-transmigratory interactions with 
lymphocytes. Activated HUVECs grown on cover slips were pre-incubated 30 minutes at 37˚C in control 
medium or medium containing filipin (Fili), methyl-β-cyclodextrin (Cdx), amiloride (Ami), EIPA, or 
imipramine (Imi), followed by washing of inhibitors, and then incubation for 30 minutes with activated 
peripheral-blood lymphocytes (WBCs, pre-stained with green fluorescent calcein AM) in the absence of 
inhibitors. WBCs not firmly bound to HUVECs were washed followed by fixation, immunostaining of 
ICAM-1, and analysis by fluorescence microscopy. (A) Percent of sampling WBCs on HUVECs with 
corresponding spatial distribution (black for HUVEC border and white for HUVEC body). (B) Percent of 
‘sampling’ WBCs (black bars) versus simply ‘adhered’ WBCs (white bars) out of only the population 
located on the HUVEC body. (C) Percent of ‘sampling’ WBCs (black bars) versus simply ‘adhered’ WBCs 
(white bars) out of only the population located on the HUVEC border. In B and C, data are normalized to 
control values (horizontal dashed line). Data represent mean ± standard error of the mean. In C, error bars 
correspond (from top to bottom) to Total sampling, Border sampling, and Body sampling, respectively. * 
compares total percent sampling to control; ^ compares percent body sampling to control, & compares each 
column to control (p<0.05 by Student’s t-test). 
 
In addition to the absolute inhibitory effect on sampling, inhibitors of the CAM-
mediated pathway decreased the percent of sampling events occurring on the HUVEC 
body compared to control without affecting sampling on the HUVEC borders, as seen 
before (compare black and white bars within Figure 19A). The exception to this again 
was imipramine, which did not significantly affect sampling on the endothelial cell body. 
Similarly, when considering only lymphocytes located on the HUVEC body, the 
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inhibitors of CAM-mediated endocytosis except imipramine decreased ‘sampling’ and 
increased ‘adhered’ lymphocytes, as seen in our previous assay (Figure 19B). Also as 
seen in our previous assay, when we focused only on the lymphocyte population on the 
HUVEC border, none of the inhibitors affected ‘sampling’ or ‘adhered’ events (Figure 
19C). 
Curiously, imipramine affected sampling (specifically on the HUVEC body) in 
Figure 18, when the inhibitor was pre-incubated and also present during lymphocyte 
interaction with HUVECs, but this effect was not observed in Figure 19, when the 
inhibitor was only pre-incubated with HUVECs. This could suggest that the activity of 
leukocyte acid sphingomyelinase might be required for sampling, specifically on the 
endothelial cell body. Previous studies indicate that leukocyte-specific sphingomyelinase 
activity contributes to binding to and/or transmigration across the endothelium [229-231]. 
Explaining the location-specific requirement, it is possible that sampling at the 
endothelial cell body has more stringent requirements compared to the endothelial cell 
border. For instance, sampling and probing at the endothelial border could be facilitated 
by the disruption of cell-cell junctions, while the deformability and vesiculation of the 
endothelial membrane on the endothelial cell body might require ceramide production. 
Overall, these data support a role for key players of CAM-mediated endocytosis 
in the generation of morphologies that are indicative of transmigration at the interface 
between leukocytes and endothelial cells, predominantly in areas away from the 
endothelial cell border. Specifically, it appeared that the contribution by this pathway was 
mainly endothelial and not by leukocytes since the inhibitory effects were similar 
regardless of whether HUVECs and lymphocytes versus only HUVECs were exposed to 
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the inhibitors. This suggests that endothelial CAM-mediated endocytosis might have a 
regulatory role in the process of transmigration, specifically through the transcellular 
route. 
 
5.2.2. Contribution of CAM-mediated endocytosis to lymphocyte transmigration across 
endothelial cells. 
Next, we tested a functional role for elements of CAM-mediated uptake in 
leukocyte transmigration. We used a model consisting of a confluent monolayer of TNF-
α-activated HUVECs grown on porous membranes, through which IL-2-activated 
lymphocytes can transmigrate driven by the presence of the chemoattractant SDF-1α in 
the basal chamber [232]. Under control conditions 72.3±3.7% of lymphocytes underwent 
transmigration after 30 minutes, as opposed to 0% transmigration by K562 cells, a non-
migratory erythroid leukemia cell line used as a negative control (Figure 20A). As 
expected, disrupting the interaction between leukocyte integrins and endothelial cell 
surface molecules inhibited transmigration. For instance, blocking antibodies to 
leukocyte integrin αLβ2 (LFA-1), which interacts with endothelial ICAM-1, resulted in 
56.2±12.8% inhibition, and blocking antibodies to leukocyte integrin α4β1 (VLA-4), 
which interacts with endothelial VCAM-1, resulted in 36.8±6.4% inhibition (Figure 
20B). These levels of inhibition were not absolute due to the functional redundancy of 
integrins during leukocyte transmigration [233]. In both cases, blocking antibodies had 
no effect on the ability of leukocytes to move across the porous membrane in the absence 
of a HUVEC monolayer, showing that the effect on transmigration seen with these 





Figure 20. Model to examine transmigration of lymphocytes across endothelial monolayers. Activated 
peripheral-blood lymphocytes or K562 cells were added on top of HUVECs grown on 8-µm pore size 
porous membranes (or porous membranes without HUVECs, when indicated), followed by a 30-minute 
incubation at 37˚C in the absence (control) or presence of antibodies to block integrins VLA-4 or LFA-1. 
Lymphocytes in the basal chamber were collected and counted. (A) Percent transmigration, calculated as 
the number of lymphocytes collected in the basal chamber out of the total lymphocytes initially added the 
top chamber. (B) Percent transmigration of antibody-blocked lymphocytes in the presence (black) or 
absence (white) of a HUVEC monolayer (normalized to non-blocked controls). Data represent mean ± 
standard error of the mean. * compares each column to its respective control (P<0.05 by Student’s t-test). 
 
With this model which showed data consistent with the literature [225, 226], we 
used the series of inhibitors from our microscopy assays to determine the role of elements 
of the CAM-mediated pathway in transmigration. We retained the use of filipin as a 
negative control, shown previously to have no effect on transmigration across porous 
membranes under conditions similar to our model [234], and no role on lymphocyte 
sampling in our previous assays (recall Figures 18 and 19). As seen in Figure 21A, Cdx 
decreased lymphocyte transmigration by 51.9±4.8%. However, filipin had no effect on 
transmigration (12.0±7.7% inhibition, non-significant), supporting previous evidence and 
suggesting that the integrity of lipid domains in CAM-mediated endocytosis is required 
for transmigration, but caveolae may not be crucial to this event. Furthermore, inhibition 
of Na+/H+ exchange with amiloride and EIPA led to 61.4±3.7% and 80.3±1.8% inhibition 
of lymphocyte transmigration, while imipramine inhibited transmigration by 52.1±7.2%. 
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Not only does this pattern of inhibition coincide with that observed in the CAM-mediated 
uptake of anti-ICAM-1-coated particles [6, 7], but it also supports our data on leukocyte 
pre-transmigration sampling (recall Figure 18). 
 
 
Figure 21. Effect of inhibitors on both lymphocytes and endothelial cells during binding and 
transmigration. (A) Activated peripheral-blood lymphocytes (WBC) were added on top of HUVECs 
grown on 8-µm porous membranes (or porous membranes without HUVECs, when indicated), followed by 
a 30-minute incubation at 37˚C in the absence (control) or presence of filipin (Fili), methyl-β-cyclodextrin 
(Cdx), amiloride (Ami), EIPA, or imipramine (Imi). Lymphocytes in the basal chamber were collected and 
counted. Percent transmigration was calculated as the number of lymphocytes collected in the basal 
chamber out of the total lymphocytes initially added to the top chamber. (B) Lymphocytes (pre-stained 
with green fluorescent calcein AM) were added on top of HUVECs grown on coverslips and incubated 
with inhibitors as done in A. Microscopy was used to count total lymphocytes bound per HUVEC. Data 
represent mean ± standard error of the mean. * compares each column to control (P<0.05 by Student’s t-
test). 
 
As addressed in our microscopy sampling assays, the effect of inhibitors in Figure 
21 may have been on either the endothelium, or the lymphocytes, or both cell types. In 
order to clarify the possible role of inhibitors on lymphocytes versus endothelial cells, we 
first tested whether the migratory ability of lymphocytes across a porous membrane was 
affected in presence of inhibitors but the absence of a HUVEC barrier. As shown in 
Figure 21A (white columns), none of the inhibitors used appeared to affect the migratory 
ability of lymphocytes towards a chemokine. In addition, as seen by microscopy, the 
inhibitors used did not affect the levels of lymphocyte binding to HUVECs (Figure 21B), 
with the exception of EIPA, which increased binding by ~2-fold. This ruled out indirect 
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effects by these inhibitors on the lower percent transmigration rates observed compared 
to control. 
To corroborate this, we tested the transmigration of leukocytes by pre-incubating 
HUVECs with each respective inhibitor, followed by washing prior to the transmigration 
assay so that lymphocytes were not directly exposed to the inhibitor. As seen in Figure 
22A, this resulted in similar inhibitory patterns as compared to the presence of inhibitors 
during transmigration (recall Figure 21A), and did not affect leukocyte binding to 
HUVECs (Figure 22B). Thus, it is likely that the effects observed in these assays were 
endothelium-specific, supporting the role of endothelial CAM-mediated uptake in 
leukocyte transmigration. It was interesting to see that the effect of imipramine on 
transmigration was retained even when the inhibitor was only pre-incubated, because this 
was not the case for lymphocyte sampling. This suggests that although endothelial acid 
sphingomyelinase activity might not be necessary for lymphocyte sampling, it is indeed 
required for the downstream event of crossing of the endothelial cell layer. 
 
Figure 22. Effect of inhibitors only on endothelial cells during lymphocyte binding and 
transmigration. (A) Activated HUVECs grown on 8-µm porous membranes were pre-incubated for 30 
minutes in the absence (control) or presence of filipin (Fili), methyl-β-cyclodextrin (Cdx), amiloride (Ami), 
EIPA, or imipramine (Imi). Cells were washed prior to adding activated peripheral-blood lymphocytes 
(WBC) on top of HUVECs, followed by a 30-minute incubation at 37˚C. Lymphocytes in the basal 
chamber were collected and counted. Percent transmigration was calculated as the number of lymphocytes 
collected in the basal chamber out of the total lymphocytes initially added the top chamber. (B) 
Lymphocytes (pre-stained with green fluorescent calcein AM) were added on top of HUVECs grown on 
coverslips and pre-incubated incubated with inhibitors as done in A. Microscopy was used to count total 
lymphocytes bound per HUVEC. Data represent mean ± standard error of the mean. * compares each 




Interestingly, the NHE1-specific inhibitor EIPA resulted in a ~2-fold higher 
inhibition of transmigration when it was present during transmigration as opposed to only 
pre-incubated (compare the EIPA bar in Figures 21A versus 22A). In addition to this, 
EIPA increased binding to HUVECs by 2-fold but only when it was present during 
transmigration (instead of simply pre-incubated; Figures 21B versus 22B). However, 
EIPA did not show different inhibitory effects on lymphocyte sampling when it was 
present during transmigration or simply pre-incubated (recall Figures 18 and 19). Thus, 
this suggested that the activity of lymphocyte NHE1 may be involved in transmigration 
but is not sufficient to maintain this function. Also, the role of leukocyte NHE1 in this 
process may be associated with binding-related mechanisms. For example, NHE1 is 
known to interact with and regulate the actin cytoskeleton [235], which is crucial in the 
regulation of integrin adhesion to endothelial CAMs [236]. Thus, it is possible that EIPA 
caused dysregulation of lymphocyte adhesion to endothelial cells, increasing binding 
strength such that even though a fraction of lymphocytes might have been able sample 
and go across the endothelial cell, they were not able to detach into the basal chamber. 
Indeed, this exchanger protein, which is expressed by leukocytes, has been associated 
with post-transmigratory cell motility [237]. 
Overall, these results agree with previous studies suggesting a role for lipid raft 
domains in leukocyte transmigration, as seen through the inhibition by Cdx [128, 138, 
221]. In addition, an effect due to inhibition of NHE1 and acid sphingomyelinase, but not 
caveolae-related pathways corresponds well with the pattern observed for endocytosis of 
anti-ICAM particles by HUVECs [6], which agrees with a potential role for CAM-
mediated endocytosis in the crossing of endothelial barriers by leukocytes. 
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5.2.3. Contribution of CAM-mediated endocytosis lymphocyte transcellular 
transmigration across endothelial cells. 
Finally, in order to confirm the effect of these inhibitors on transmigration, but 
also explore whether the CAM-mediated pathway has a role determining the routes of 
transmigration, we used established methodologies that allow for the differentiation 
between transcellular versus paracellular transmigration using confocal microscopy 
[192]. This procedure involves staining of actin (Figure 23A, middle panel) in order to 
localize leukocytes and observe their position in the z-axis with respect to the top and 
bottom of the endothelial cell. In addition, staining of VE-cadherin (Figure 23A, bottom 
panel) to observe the integrity of endothelial junctions allows for determination of the 










Figure 23. Confocal microscopy of the route of lymphocyte transmigration across endothelial cells. 
HUVECs growing on glass cover slips were incubated with activated peripheral-blood lymphocytes for 15 
minutes at 37˚C in control medium. Lymphocytes not firmly adhered to HUVECs were washed, followed 
by fixation, staining of actin with red phalloidin, nuclei in blue, and immunostaining of VE-cadherin in 
green. Cells were analyzed by confocal microscopy. (A) Example micrograph of a lymphocyte (red arrow) 
interacting with HUVECs. Scale bar = 20 µm. (B) Sample micrographs of non-transmigrating (either round 
or deformed, to illustrate the simply ‘adhered’ and ‘sampling’ morphologies from previous assays), 
transmigrating, or already transmigrated lymphocytes (red arrows). Top panels show nuclei and bottom 
three panels show z-stack sections from the top of the sample, where only lymphocyte actin is detected, to 
the bottom of the HUVEC monolayer in contact with the cover slip. Transmigration is occurring when 
lymphocyte actin can be observed both on top of and underneath the HUVEC monolayer. (C) Sample of 
three modes of transmigration. Paracellular transmigration occurs on cell borders and disrupts VE-cadherin 
staining. Transcellular transmigration can occur close to cell borders without disrupting VE-cadherin 
staining, or away from cell borders (‘body’). Red lines delineate VE-cadherin staining. Arrowheads 




Figure 23B illustrates that actin staining allows to determine if lymphocytes are in 
the process of transmigration, as the staining can be detected both on the top and the 
bottom of the HUVEC layer. This also allows to observe lymphocytes that are only on 
top of an endothelial cell (not transmigrating), or those that are at the bottom of the 
endothelial layer (already transmigrated). As revealed by this imaging technique, a 
fraction of lymphocytes that exhibit deformed morphologies (i.e.: those scored as 
‘sampling’ in our previous assay) may not be in the act of transmigration. Thus, although 
our previous microscopy assays reveal important information about the pre-
transmigratory interactions between leukocytes and endothelial cells, they do not directly 
reflect transmigration events. Figure 23C also reveals that those leukocytes that are 
transmigrating near the endothelial border can be scored as using the transcellular or 
paracellular route depending on whether or not they disrupt VE-cadherin staining. 
Using this scoring system, we found that under control conditions, 68.1±2.9% of 
leukocytes were undergoing transmigration, and within these transmigratory events 
53.1±2.4% were paracellular, while 46.9±2.4% were transcellular (Figure 24A). These 
route preferences were similar to the percent of lymphocyte sampling on the border 
versus the cell body in our previous assay (recall Figure 17), highlighting the close link 
between sampling and transmigration. In order to only account for inhibition of 
endothelial function, we performed pre-incubation of HUVECs with filipin, Cdx, 
amiloride, EIPA and imipramine, followed by washing of inhibitors before adding 
lymphocytes for the transmigration assay. Supported by our previous assays, inhibition of 
all elements of the CAM-mediated pathway, but not with filipin, decreased the percent of 
transmigrating lymphocytes (Figure 24A). Since imipramine inhibited transmigration in 
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this assay and also in our porous membrane study, but not sampling (recall Figure 19), it 
appears that endothelial ceramide is important in steps downstream of leukocyte 
sampling, possibly in the aperture of transcellular pores, which would pair well with the 
known role of ceramide in vesicular fusion [86, 238]. 
Figure 24. Effect of inhibitors on the route of lymphocyte transmigration across endothelial cells. 
HUVECs growing on glass cover slips were pre-incubated 30 minutes at 37˚C with filipin (Fili), methyl-β-
cyclodextrin (Cdx) amiloride (Ami), EIPA, or imipramine (Imi), followed by washing and incubation with 
activated peripheral-blood lymphocytes for 15 minutes in control medium. Lymphocytes not firmly 
adhered to HUVECs were washed, followed by fixation, staining of actin with red phalloidin, nuclei in 
blue, and immunostaining of VE-cadherin in green. Cells were analyzed by confocal microscopy. (A) 
Quantification of percent transmigration, including route of transmigration (black for paracellular and white 
for transcellular). (B) Assay was performed as A, but using non-confluent HUVECs to only observe 
transcellular events. Bars show quantification of percent transmigration. Data represent mean ± standard 
error of the mean. In A, error bars correspond (from top to bottom) to Total transmigration, Paracellular 
transmigration, and Transcellular transmigration, respectively.* compares percent transmigration, ^ 
compares percent transcellular transmigration, # compares percent paracellular transmigration, each 
compared to respective control (p<0.05 by Student’s t-test).  
 
More importantly, as seen in Figure 24A, this decrease in transmigration by 
inhibiting CAM-mediated endocytosis was due to an inhibition specifically of 
transcellular events, but not paracellular events. The exception to this were Cdx and 
imipramine, both of which affected transcellular and paracellular migration alike, albeit 
the effect on paracellular transmigration was lower (~40-50% inhibition for transcellular 
versus ~8-30% inhibition for paracellular). Recall that Cdx and imipramine had no effect 
on lymphocyte sampling on cell borders in our previous assay, which means that 
cholesterol-dependent lipid domains and acid sphingomyelinase may be important for 
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paracellular transmigration even though lymphocytes can still properly engage by 
probing/sampling at cell borders. This is a significant finding because, to the best of our 
knowledge, it identifies for the first time two endothelial molecular elements that 
differentially regulate the stage of lymphocyte sampling versus the stage of actual 
transmigration. This finding also opens the possibility that CAM-mediated endocytosis 
could be involved in both transcellular and paracellular transmigration, although possibly 
to different extents, reflected by the fact that inhibition of NHE1 exchange only affected 
transcellular transmigration, while inhibition with Cdx and imipramine inhibited both 
routes. Otherwise, it is possible that both routes share similar molecular elements, even if 
they do not share an underlying endocytic mechanism. 
Finally, we also performed transmigration assays using sub-confluent endothelial 
cell cultures in order to exclusively observe transcellular transmigration events, and we 
found similar results as those observed with confluent monolayers. Under control 
conditions and in the presence of filipin, percent transmigration (all transcellular) was 
61.3±19% and 70±20%, respectively, while in the presence of Cdx, amiloride, EIPA, and 
imipramine, it was 20±20%, 20±20%, 6.67±6.67%, and 27.8±18.1%, respectively. Thus, 
these data implicate CAM-mediated endocytosis not only in the process of 
transmigration, as seen using a different technique (Figures 21 and 22), but specifically 
contributing to the transcellular pathway. 
 
5.3. Conclusion 
Leukocyte transmigration depends on membrane and vesicular dynamics 
downstream of ICAM-1 signaling. This includes the formation of endothelial docking 
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structures and invaginations that support leukocyte sampling of the endothelial cell, and 
also endocytic vesicle fusion to form the transcellular pore [121]. Overall, the studies 
presented here expand our current knowledge by supporting a contribution by regulatory 
elements of the CAM-mediated pathway to these events. 
Key molecular elements of the CAM-mediated pathway, NHE1, acid 
sphingomyelinase, and ceramide, are enriched at sites of leukocyte interaction with 
endothelial cells. These molecules as well as cholesterol, in an endothelium-specific 
manner, contribute to the generation of leukocyte sampling events, known to be a 
preliminary step crucial to transmigration. Importantly, this contribution specifically 
occurs at sites away from the endothelial border. Meanwhile, caveolae-mediated 
pathways appear to have a less significant role in sampling. In addition to this, inhibition 
of CAM-mediated endocytosis, but not caveolae-mediated pathways, in the endothelium 
disrupts crossing of leukocytes across endothelial layers, and this inhibition is specifically 
through an effect on the transcellular route of transmigration. 
Since our data showed that CAM-mediated endocytosis is involved in promoting 
lymphocyte sampling, which temporally precedes actual crossing of the endothelial cell, 
we cannot fully determine whether CAM-mediated endocytosis is involved only in 
promoting the sampling of lymphocytes (which in turn affects transmigration) or also 
contributes to opening of the transcellular pore. Such studies prove difficult, as it is still 
unclear whether these two events are discrete in the first place [122]. However, the fact 
that inhibition of endothelial acid sphingomyelinase alone did not disrupt lymphocyte 
sampling but affected transmigration itself, suggests that indeed the CAM-mediated 
pathway may mediate events that occur downstream of lymphocyte sampling, such as 
109 
 
opening of the transcellular pore. Thus, the role of ceramide in transmigration may be an 
important clue regarding the intricacies behind this phenomenon. 
Based on our data from Chapter 4, we have found that CAM-mediated 
endocytosis is capable of mediating transport of micron-sized particles across cells. This 
corresponds well with the apparent physiological function of this pathway in leukocyte 
transmigration across the endothelium, suggesting that the CAM-mediated pathway may 
contribute to the generation of transcellular pores through the formation of vesicles that 
fuse into larger structures through which leukocytes can cross. In addition, our studies 
using particles reveal a potential relationship between ICAM-1 engagement density and 
ceramide enrichment, which in turn can regulate the efficiency of CAM-mediated uptake. 
This may have ramifications in the context of leukocyte transmigration, as is possible that 
leukocytes could potentially modulate the LFA-1 density in their membranes to engage 
ICAM-1 at different extents, ultimately affecting the extent of transmigration, or even the 




Chapter 6: Contribution by the CAM-Mediated Pathway to 
Endothelial Uptake and Degradation of Fibrin Polymers. 
 
6.1. Background 
Coagulation and fibrinolysis are crucial to the maintenance of blood flow within 
the vascular system. The former prevents leakage of blood out of vessels upon injury 
through the formation of a clot, while the latter ensures the fluid state of blood is 
preserved via clot degradation [156]. Proper functioning of this balance requires several 
activators and inhibitors, and involves regulation at the macromolecular and cellular 
levels [239]. For instance, the architecture of a fibrin clot (e.g.: size and polymerization 
density) is affected by its interaction with endothelial cells and can have a significant 
effect on fibrinolysis [182, 196]. In addition, the small peptides produced by fibrinolysis 
can serve as signaling agents upon interaction with cell surface molecules, affecting the 
resolution of a clot [178]. 
Interestingly, these small peptides, which have been well studied, account for only 
a small fraction of the products of fibrinolysis [180]. It is known that dissolution of a 
blood clot depends only on 25% of its degradation, such that fibrinolysis produces many 
large fibrin polymers that become circulating materials [182, 183]. This also means that 
fibrinolysis fragments remain bound to the surface of the endothelium after clot 
dissolution [240]. Since these blood clot fragments (in circulation) and remnants (on the 
endothelial surface) have potential to sustain inflammation and to re-ignite fibrin 
deposition, there must be systems in place to discard these materials in order to prevent 
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the coagulation cascade from being reinitiated. Abnormalities in this clearance might be 
associated with pathological states such as atherosclerosis and thrombosis. 
It is known that macrophages can internalize fibrin and degrade it in their 
lysosomes [241], and hepatic macrophages accumulate fibrin after clot resolution [242]. 
Meanwhile, endothelial cells might use similar mechanisms as phagocytes for removal of 
fibrin blood clot remnants (i.e.: clearance via endocytosis). Indeed, the endothelium is 
adapted to clear particulate materials found in capillaries, including apoptotic cells, sickle 
and parasite-infected erythrocytes, foreign particles, such as asbestos, and pathogens 
[243-245]. Such capabilities for uptake are reflected by endothelial cell display of several 
types of endocytic pathways [246, 247], which could contribute to the uptake of blood 
clot remnants and other forms of fibrin. In fact, recent reports show that endothelial cells 
are capable of engulfing blood clots using membrane protrusions, which leads to their 
removal from the vasculature, yet the mechanism behind this phenomenon remains 
unexplored [22]. 
It is known that fibrinogen and fibrin can interact directly with several molecules 
on the surface of endothelial cells, including VE-cadherin, integrin αVβ3, and ICAM-1 
[145, 147, 149], which could in turn serve as signaling agents to stimulate this uptake and 
transport. Fibrin(ogen) can also indirectly interact with tPA receptor, uPA receptor, and 
thrombomodulin [150, 151], known to mediate endocytosis through clathrin- and 
caveolae-mediated pathways [248]. Although the extent to which these interactions 
contribute to physical retention or potentially uptake of a forming, completed, or partially 
degraded blood clot are not characterized, certain signaling events are known to be 
elicited from these interactions. The majority of these responses are in the context of 
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angiogenesis and cell survival, but in the case of ICAM-1, binding by fibrin can also 
elicit rearrangement the actin cytoskeleton [249], possibly through Rho signaling [250]. 
This outcome is similar to that observed when anti-ICAM particles undergo CAM-
mediated endocytosis, which is not surprising since both anti-ICAM particles and fibrin 
polymers can engage multiple copies of ICAM-1. The endothelial protrusions shown to 
form around blood clots also resemble those observed during the CAM-mediated uptake 
of micron-sized anti-ICAM particles [7, 22]. Furthermore, these signaling events, and 
subsequent CAM-mediated endocytosis also occur when particles are coated with a 
peptide sequence (γ3) corresponding to the ICAM-1-binding region of fibrin(ogen) 
(recall Chapter 4) [216]. Thus, it is possible that this endocytic pathway occurs upon 
interaction of fibrin polymers (such as blood clot remnants) with the endothelium, and 
this may be a mechanism for their clearance. This chapter elaborates on our efforts to 
study the possible link between CAM-mediated endocytosis and endothelial 
internalization of fibrin polymers. 
 
6.2. Results 
6.2.1. Initial interaction between fibrin meshes and endothelial cells. 
In order to mimic the interaction between the blood clot remnants and endothelial 
cells, we used a model consisting of activated HUVEC cultures incubated for 30 minutes 
with purified fluorescently labeled fibrinogen and thrombin to generate artificial fibrin 
meshes. This model is used for studying the interaction between clots and the 
endothelium both cell culture [196] and in vivo [22]. Under the conditions used, fibrin 
meshes of a mean diameter of 1.9±0.6 µm formed on the surface of endothelial cells, with 
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9.4±0.7 objects bound per cell (Figure 25A and B). The thrombin-dependent formation of 
these meshes was confirmed by a reduction in total meshes bound per cell, as well as 
mesh size, in the presence of thrombin inhibitor hirudin (3.7±0.3 objects/cell with 
0.88±0.04 µm mean diameter; Figure 25B and C). In addition, the polymeric nature of 
these meshes was confirmed by a reduction in binding and size in the presence of the 
glycine-proline-arginine-proline (GPRP) peptide, an inhibitor of fibrin polymerization 
(2.2±0.3 objects/cell with 0.9±0.1 µm mean diameter). 
 
Figure 25. Formation of fibrin meshes on the surface of endothelial cells. Activated HUVECs growing 
on coverslips were incubated in the presence of fluorescently labeled fibrinogen with thrombin in the 
absence (control) or presence of hirudin or GPRP for 30 minutes at 37˚C. (A) Sample micrographs of each 
treatment. Left panels are phase-contrast and right panels are fluorescence. Scale bar = 20 µm. (B) 
Quantification of total number of fluorescent fibrin (Fn) meshes bound to HUVECs by microscopy. (C) 
Quantification of fibrin mesh size. Data represent mean ± standard error of the mean. * compares hirudin or 
GPRP to control (p<0.05 by Student’s t-test). 
 
As a preliminary characterization of this model, we determined the kinetics of 
interaction between these micron-sized fibrin meshes and HUVECs to see if we could 
detect evidence their transport across the endothelium, as has been observed previously 
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with injected fibrin emboli in mouse brains in vivo [22]. We tested this by forming fibrin 
meshes on HUVECs monolayers grown on a porous membrane for 30 minutes, followed 
by washing and a chase of different time-points (Figure 26). Confocal analysis showed 
that at initial time-points (1 hour chase), fibrin meshes appeared to be on top of 
HUVECs, as they were detected on planes above cells where nuclei were not detectable. 
Also, at this time-point, some meshes may have been internalized by cells, as they could 
not be seen on top of HUVECs, but only on the same plane as cell nuclei. Meanwhile, no 
fibrin meshes could be detected at the plane of the porous membrane underneath 
HUVECs. At 3 and 5 hours, fibrin meshes could not be detected on top of HUVECs, but 
were abundant on the same plane of nuclei, suggesting possible internalization by cells. 
Meanwhile, at 5 hours there was an increase in detected fibrin meshes beneath HUVECs, 
which would be consistent with transendothelial transport. Although these transport-
specific results will require more scrutinous validation, it appeared this model is suitable 
for studying the mechanisms behind the previously described endothelial transport of 




Figure 26. Kinetics of fibrin mesh interaction with endothelial cells grown on porous membranes. 
Activated HUVECs grown on 3µm-pore size porous membranes were incubated in the presence of 
fluorescently labeled fibrinogen with thrombin for 30 minutes at 37˚C. Apical and basal chambers were 
washed and cells were incubated (chase) for 1, 3 or 5 hours. Confocal micrographs at three planes on the z-
axis are shown. Top panels show a plane above the HUVEC layer, where nuclei cannot be identified. 
Middle panels are at the level of the nuclei plane. Bottom panels show the porous membrane beneath 
HUVECs. Nuclei are blue and fibrin meshes are red. Scale bar = 20 µm. 
 
Using this model, we first characterized the involvement of endothelial cell 
surface molecules on the formation and binding of fibrin meshes using blocking 
antibodies to known binding partners of fibrin(ogen). As seen in Figure 27A, blocking 
antibodies to integrin αVβ3 led to a reduction in the total number of fibrin meshes bound 
to endothelial cells, suggesting that this integrin may be important in the initial deposition 
of fibrin on the activated endothelium. Conversely, antibodies to ICAM-1, VE-cadherin, 
tPA receptor, uPA receptor and thrombomodulin did not significantly affect the total 
number bound fibrin meshes compared to control. However, mesh size was reduced in 
the presence of ICAM-1-blocking antibodies (Figure 27B), suggesting an interaction 
between ICAM-1 and fibrin in this model. Since ICAM-1 blocking did not change the 
116 
 
total number of meshes bound, but decreased their size, it is possible that binding to 
ICAM-1 could serve as a mechanism to support fibrin polymerization on the surface of 
the endothelial cell. 
Figure 27. Effect of blocking antibodies on the binding of fibrin meshes to endothelial cells. Activated 
HUVECs were incubated in the presence of fluorescently labeled fibrinogen with thrombin for 30 minutes 
at 37˚C in the absence (control) or presence of non-specific mouse IgG or blocking antibodies to ICAM-1, 
VE-cadherin (VE-cad), integrin αvβ3, tPA receptor (tPAr), uPA receptor (uPAr), or thrombomodulin 
(Throm). After fixing, cells were analyzed by epifluorescence microscopy. (A) Quantification of fibrin (Fn) 
mesh binding per cell. (B) Quantification of fibrin mesh mean diameter. Data are normalized to non-
blocking control and represent mean ± standard error of the mean. * compares each condition to non-
blocking control (p<0.05 by Student’s t-test). 
 
With this evidence supporting an interaction between ICAM-1 and fibrin meshes, 
we tested the presence of this molecule at sites of fibrin mesh binding to HUVECs. 
Figure 28A illustrates that immunostaining of ICAM-1 followed by microscopy revealed 
ICAM-1 enrichment at these sites. Quantification of the overlap between fluorescent 
fibrin meshes and ICAM-1 immunostaining (calculated as the percent of fibrin mesh 
fluorescent area that overlapped with ICAM-1 fluorescent area above an intensity 
threshold; see Methods, Section 3.14) showed 86.3±2.6% colocalization (Figure 28B). 
This enrichment and substantial percent overlap suggested engagement of multiple copies 
of ICAM-1 by fibrin meshes, which may lead to signaling events observed when anti-
ICAM or γ3 particles that undergo CAM-mediated uptake. Thus, we also tested for the 
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enrichment of molecules associated with CAM-mediated endocytosis. Both NHE1 and 
acid sphingomyelinase were enriched at sites of fibrin mesh binding and showed 
88.5±2.8% and 83.3±4.5% colocalization, respectively (Figure 28B). This, however, was 
not the case for VCAM-1 (30.5±3.9% colocalization), an Ig superfamily endothelial 
surface molecule similar in structure to ICAM-1, but not associated with CAM-mediated 
endocytosis [251], serving as a negative control. Thus, these data supported the specific 
recruitment of elements of the CAM-mediated pathway at sites of interaction between 
fibrin polymers and endothelial cells. 
 
Figure 28. Enrichment of endothelial molecules at sites of fibrin mesh binding to endothelial cells. 
Activated HUVECs were incubated in the presence of fluorescently labeled fibrinogen with thrombin for 
30 minutes at 37˚C, followed by fixation and immunostaining of ICAM-1, NHE1, acid sphingomyelinase 
(ASM) or VCAM-1. (A) Sample micrographs showing fibrin (Fn) meshes (left panels) or each 
immunostained molecule (right panels). Scale bar = 10 µm. (B) Quantification of percent overlap between 
fibrin meshes and each immunostained molecule. Data represent mean ± standard error of the mean. * 




6.2.2. Internalization of fibrin meshes by endothelial cells with contribution by the CAM-
mediated pathway. 
With data supporting an interaction between fibrin meshes and ICAM-1, as well 
as the presence of key molecular players of CAM-mediated uptake at binding sites, we 
tested if these binding interactions are followed by endocytosis. We first determined the 
kinetics of interaction between fluorescent fibrin meshes and HUVECs by incubating 
fibrin mesh mixture for 30 minutes (pulse), followed by washing and a chase of several 
time-points. Following fixation, we immunostained surface-bound, non-internalized 
fibrin to differentiate surface meshes from those inside of cells, which are inaccessible to 
antibodies (Figure 29A). Figure 29B shows that fibrin meshes were internalized by 
endothelial cells, reaching a plateau of ~80% uptake at 3 hours. Note that since this 
treatment had a 30-minute pulse to allow for mesh formation, the 0-minute chase time-
point already showed a degree of internalization. 
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Figure 29. Kinetics of fibrin mesh internalization by endothelial cells. Activated HUVECs were 
incubated in the presence of green fluorescently labeled fibrinogen with thrombin for 30 minutes at 37˚C, 
followed by washing and incubation (chase) for 0, 30 minutes, 1, 3, 5 or 24 hours at 37˚C. After fixation, 
cells were immunostained with anti-fibrin, followed by a red fluorescent secondary antibody. (A) Sample 
micrographs showing fibrin mesh internalization at representative time-points. Green is internalized 
meshes, yellow (red + green) is surface-bound, non-internalized meshes, blue is nuclei (DAPI). Right 
panels show only red fluorescence (surface fibrin meshes). Scale bar = 20 µm. (B) Quantification of percent 
internalization, calculated as internalized/(internalized+surface)×100. (C) Quantification of the mean 
diameter of the surface or the internalized populations of fibrin meshes. (D) Quantification of total (both 
internalized and surface) fibrin meshes bound per cell. Data represent mean ± standard error of the mean. 
 
In order to examine the properties of these internalized fibrin meshes, we 
calculated the mean diameter of both non-internalized (surface-bound) and internalized 
meshes separately (Figure 29C). This revealed that the size of internalized fibrin meshes 
at earlier time-points (white bars between 0 and 1 hour chase), was equal to the original 
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non-internalized mesh size (~1.5-2 µm diameter), which supports the internalization of 
micron-sized fibrin polymers by HUVECs. Furthermore, the size of these internalized 
fibrin meshes decreased between 1 and 3 hours, suggesting distribution of fibrin into 
smaller vesicular compartments and/or intracellular degradation. Indeed, when we 
determined the number of fibrin meshes associated with cells, we observed an increase in 
the number of fibrin meshes over time until 5 hours, likely due to distribution into smaller 
compartments, followed by a dramatic decrease by 24 hours (Figure 29D), possibly due 
to degradation. This increase in number of fibrin meshes accompanied by a decrease in 
mesh size revealed a dynamic internalization and intracellular trafficking of fibrin 
polymers by endothelial cells. 
It was interesting to note that these rates of endocytosis for fibrin meshes over 
time were slower and less efficient compared to those of CAM-mediated endocytosis of 
spherical anti-ICAM particles (Figure 4) [77]. However, they were more similar to the 
CAM-mediated uptake kinetics curve of disk-shaped objects and of γ3 particles (Figure 
7) [77]. Due to the irregular (non-spherical) shape of fibrin meshes, which were mostly in 
the 1-2 µm diameter range, this could be expected if they are internalized by cells using 
this pathway. Indeed, it is a feature of CAM-mediated uptake that it becomes more 
sensitive to irregularities in object shape as object size increases (Muro, unpublished 
data). 
It is known that cultured endothelial cells can produce tPA and uPA, as well as 
proteases, which could drive fibrinolysis and/or non-specific degradation of fibrin meshes 
prior to internalization. This opens the possibility that these extracellular degradation 
events might have a role in the uptake of fibrin meshes. Thus, we determined 
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internalization in the presence of aprotinin and plasminogen activator inhibitor 1 (PAI-1), 
which inhibit endothelium-derived serine proteases and tPA/uPA (thus preventing 
extracellular degradation of fibrin meshes during incubation), respectively. Using these 
inhibitors in an internalization assay had no effect on the endothelial uptake of fibrin 
meshes (102.5±0.3% of control, Figure 30A). 
 
Figure 30. Role of fibrinolysis in the internalization of fibrin meshes by endothelial cells. (A) 
Activated HUVECs were incubated in the presence of green fluorescently labeled fibrinogen with thrombin 
for 30 minutes at 37˚C, followed by washing and incubation (chase) for 3 hours at 37˚C in the absence 
(control) or presence of PAI-1 plus aprotinin. After fixation, cells were immunostained with anti-fibrin, 
followed by a red fluorescent secondary antibody to differentiate non-internalized versus internalized fibrin 
meshes. Graph shows quantification of percent internalization. (B) Green fluorescently labeled fibrinogen 
was incubated with thrombin for 8 hours in control conditions or in the presence of tPA along with PAI-1 
and aprotinin, or tPA alone. Image shows Western blot with an antibody to fibrin, after SDS PAGE. Data 
represent mean ± standard error of the mean. 
 
This confirmed that endothelial cells are equipped to internalize fibrin polymers 
as large as ~2 µm in diameter without depending on fibrinolytic activity. Since the 
inhibitors had no effect on uptake, we confirmed they were active using a test-tube assay 
followed by Western blotting with an antibody to fibrin (see Methods, Section 3.17 for 
details). As Figure 30B shows, under control conditions (left lane) we observed two 
major bands above 130 kDa, while the presence of tPA to induce fibrinolysis (right lane) 
led to a reduction of these bands and appearance of a smaller band below 25 kDa. In the 
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presence of PAI-1 plus aprotinin, tPA lost this effect (middle lane), revealing the 
inhibitory activity. 
In order to further test if endothelial cells internalized full fibrin meshes instead of 
extracellular degradation products, we performed an internalization assay as done 
previously (recall Figure 28) but prior to immunostaining, we permeabilized cells. This 
allows for anti-fibrin to access both the surface and the inside of cells, and thus 
immunodetection does not discriminate between internalized or surface-bound fibrin. As 
shown in Figure 31A (top panels), in the absence of permeabilization, there was a 
decrease over time in the number of immunodetectable fibrin meshes, as expected from 
their internalization by HUVECs. At 0 and 1 hours, when cells were permeabilized, there 
was an increase in immunodetection of fibrin compared to non-permeabilized cells 
(Figure 31B). This indicates that when antibodies could access the inside of cells, they 
were able to recognize fibrin, supporting the idea that HUVECs are able to internalize 




Figure 31. Immunodetectability of endothelium-internalized fibrin meshes after permeabilization. 
Activated HUVECs were incubated in the presence of green fluorescently labeled fibrinogen with thrombin 
for 30 minutes at 37˚C, followed by washing and incubation (chase) for 0, 1, 3 or 5 hours at 37˚C. After 
fixation, cells were either permeabilized or not prior to immunostaining with anti-fibrin, followed by a red 
fluorescent secondary antibody. (A) Sample micrographs showing fibrin (Fn) mesh immunostaining in the 
absence (top panels) or presence (bottom panels) of permeabilization. Green is non-immunodetectable Fn, 
yellow (red + green) is immunodetectable Fn, blue is nuclei (DAPI). Scale bar = 20 µm. (B) Quantification 
of immunodetected (yellow) fibrin meshes per cell. (C). Quantification of total (includes green-only and 
yellow) fibrin meshes per cell. Data represent mean ± standard error of the mean. 
 
Interestingly, after 3 and 5 hours, permeabilization did not increase the level of 
immunodetected fibrin. Instead, it drastically reduced the detected green (non-
immunodetectable) fluorescence at these two time-points (compare top to bottom 3- and 
5-hour panels in Figure 31A; Figure 31C). This suggests that at these time-points 
permeabilization led to washing off of non-immunostained objects. Thus, as our size data 
suggested previously (recall Figure 29C showing a reduction of internalized fibrin mesh 
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size), it is possible that that between 1 and 5 hours after internalization, fibrin meshes 
were intracellularly degraded into molecular species small enough to diffuse out of the 
cell upon permeabilization. 
In order to determine the possible uptake mechanism used by endothelial cells, we 
incubated fibrin meshes and HUVECs in the presence of a series of chemical inhibitors, 
including those disrupt CAM-mediated endocytosis. As seen in Figure 32, inhibition with 
filipin, which affects caveolae-mediated endocytosis, had no effect on the internalization 
of fibrin meshes (97.1±3.0% of control). Meanwhile, all other inhibitors used had a 
significant negative effect on fibrin mesh uptake. Monodansylcadaverine and 
wortmannin, which affect clathrin-mediated uptake and PI3K-dependent 
macropinocytosis/phagocytosis, respectively, had a mild effect on endocytosis 
(84.4±5.4% and 85.0±4.4% of control, respectively). Amiloride and imipramine, which 
affect CAM-mediated uptake through their inhibition of Na+/H+ exchange and acid 
sphingomyelinase, respectively, had a more drastic effect on the uptake fibrin meshes 






Figure 32. Mechanism of fibrin mesh internalization by endothelial cells. Activated HUVECs were 
incubated in the presence of green fluorescently labeled fibrinogen with thrombin for 30 minutes at 37˚C, 
followed by washing and incubation (chase) for 3 hours at 37˚C in the absence (control) or presence of 
filipin, monodansylcadaverine (MDC), amiloride, imipramine, or wortmannin. After fixation, cells were 
immunostained with anti-fibrin, followed by a red fluorescent secondary antibody to distinguish between 
non-internalized and internalized fibrin meshes. Microscopy was used to quantify percent internalization, 
shown in the graph. Data represent mean ± standard error of the mean. * compares each inhibitor to control 
(p<0.05 by Student’s t-test). 
 
The effect by inhibitors of different pathways is suggestive of overlapping 
mechanisms of uptake. This is feasible due to the variety of potential binding partners for 
fibrin on the surface of endothelial cells, including VE-cadherin, known to be associated 
with clathrin-mediated endocytosis [252], and αVβ3, which regulates actin-dependent 
uptake of fibrinogen in epithelial cells [253]. However, it appears from these inhibition 
data that ICAM-1-dependent CAM-mediated endocytosis is a major contributor to this 
uptake in activated endothelial cells. This is supported by the role of ICAM-1 we 
observed in our binding studies, and also the enrichment of this molecule, NHE1 and acid 




6.2.3. Intracellular trafficking of fibrin meshes and contribution of lysosomes to fibrin 
mesh degradation. 
We next examined the kinetics of fibrin mesh intracellular trafficking using 
microscopy. Analysis of the spatial distribution of fibrin meshes interacting with 
HUVECs revealed a tendency of migration toward the perinuclear region over time 
(percent perinuclear localization rose from 15.6±6.4% to 70.6±4.2% between 0 minutes 
and 3 hours; Figure 33A and B), suggesting trafficking to lysosomes, as seen with anti-
ICAM and γ3 particles targeted to CAM-mediated endocytosis (recall Figures 12 and 13).  
 
Figure 33. Intracellular trafficking of fibrin meshes in endothelial cells. Activated HUVECs were 
incubated in the presence of green fluorescently labeled fibrinogen with thrombin for 30 minutes at 37˚C, 
followed by washing and incubation (chase) for 0, 30 minutes, 1, 3, 5 or 24 hours at 37˚C. For C and D, 
HUVECs were pre-incubated for 45 minutes with Texas Red-labeled dextran, followed by a 45 minutes 
chase to label lysosomes. (A) Sample micrographs showing green fibrin (Fn) meshes and nuclei (blue). (B) 
Quantification of percent perinuclear localization, defined as a region ~5 µm surrounding the nucleus. (C). 
Sample micrographs showing green Fn meshes and red lysosomes. Colocalization is yellow. (D) 
Quantification of percent colocalization between Fn meshes and lysosomes. Scale bars = 20 µm. Data 




To validate this, we pre-incubated HUVECs with Texas Red-labeled dextran for 
45 minutes, followed by a 45-minute chase. This ensures that dextran has fully trafficked 
to and labels lysosomes, a technique shown to be a suitable alternative to immunostaining 
of LAMP-1 [9, 193]. Then, we determined the colocalization between these 
compartments and internalized fibrin meshes over time (Figure 33C). This revealed that 
the percent of fibrin mesh objects internalized by endothelial cells colocalizing with 
Texas Red-labeled lysosomes increased until 3 hours, indicating trafficking to these 
compartments. The percent colocalization then declined after 5 and 24 hours, suggesting 
that at later time-points, lysosome-resident fibrin meshes were degraded. This is 
supported by our previous observation that between 5 and 24 hours, the number of fibrin 
meshes detected on HUVECs was greatly reduced (recall Figure 29D; also see Figure 
32A and C, bottom right panels). 
In order to examine the role of lysosomes in this later decrease of colocalization, 
we determined colocalization in the presence of chloroquine, a lysosomotropic base that 
inhibits lysosome hydrolases [254]. As seen in Figure 34, at 5 hours the presence of 
chloroquine did not affect fibrin mesh colocalization with lysosomes compared to 
control. However, at 24 hours chloroquine elicited an increase in colocalization. Also, in 
the presence of chloroquine, the percent colocalization between fibrin and lysosomes 
increased over time (while it decreased in control conditions), possibly due to continued 
trafficking and accumulation of fibrin in lysosomes in the absence of degradation. This 
suggests that inhibition with chloroquine prevented degradation of fibrin, supporting a 




Figure 34. Effect of chloroquine on fibrin mesh colocalization with lysosomes in endothelial cells. 
Activated HUVECs were pre-incubated for 45 minutes with Texas Red-labeled dextran, followed by a 45-
minute chase to label lysosomes. Cells were incubated in the presence of green fluorescently labeled 
fibrinogen with thrombin for 30 minutes at 37˚C, followed by washing and incubation (chase) for 5 or 24 
hours at 37˚C in the absence (control) or presence of chloroquine (A) Sample micrographs for each 
condition. Fibrin (Fn) meshes are green and lysosomes are red. Colocalization is yellow. Scale bar = 20 
µm. (B) Quantification of percent colocalization between fibrin meshes and lysosomes. Data represent 
mean ± standard error of the mean. * compares chloroquine to control within each time-point (p<0.05 by 
Student’s t-test). 
 
Despite our inability to detect chloroquine-sensitive degradation at 5 hours with 
this colocalization assay, our previous permeabilization assay showed that even at this 
time-point, internalized fibrin meshes appeared to be degraded (recall that for the 5-hour 
time-point, after permeabilization internalized green fluorescent objects diffused out of 
cells in Figure 31). Thus, it is possible that although we did not see a change in 
colocalization due to the presence of chloroquine at 5 hours, the composition of 
lysosome-resident fibrin was different between control and chloroquine conditions. To 
test this, we compared the immunodetectability of internalized fibrin meshes in the 
presence or absence of chloroquine, using cell permeabilization prior to staining with 
antibodies to fibrin (Figure 35A). This assay uses the same concept as seen in Figure 31: 
Total fluorescent objects are either fibrin meshes or fibrin derivatives that still retain the 
green fluorophore. Objects that are green and red (yellow) are those immunodetected by 
anti-fibrin, and thus must consist of protein intact enough to retain the antibody-binding 
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epitope. Finally, non-immunodetectable objects (those that are only green), still retain the 
fluorophore, but must consist of degraded fibrin derivatives that do not have the anti-
fibrin epitope. 
Figure 35. Role of lysosomes in fibrin mesh degradation by endothelial cells. Activated HUVECs were 
incubated in the presence of green fluorescently labeled fibrinogen with thrombin for 30 minutes at 37˚C, 
followed by washing and incubation (chase) for 5 hours at 37˚C in the absence (control) or presence of 
chloroquine (Chloro), PAI-1 plus aprotinin, or Chloro plus PAI-1 plus aprotinin. After fixation, cells were 
permeabilized prior to immunostaining with anti-fibrin, followed by a red fluorescent secondary antibody. 
(A) Sample micrographs showing non-immunodetectable (green only) or immunodetectable (yellow) 
fibrin. (B) Columns show quantification of immunostained (yellow) or non-immunostained (green only) 
fibrin. Data represent mean ± standard error of the mean. * compares each column to its respective control 
(p<0.05 by Student’s t-test). 
 
As shown in Figure 35B, the presence of chloroquine increased the number of 
both immunodetectable and non-immunodetectable fibrin (by 2- and 2.5-fold, 
respectively). This suggests that lysosomes contribute to the degradation of both intact 
fibrin, and also fibrin derivatives. Although we already observed that endothelial uptake 
of fibrin meshes did not depend on fibrinolysis, it was possible that fibrinolytic activity 
could affect their degradation. Suggesting otherwise, the presence of PAI-1 and aprotinin 
did not significantly increase immunodetectable or non-immunodetectable fibrin. 
However, since there was a slight increase in the presence of these inhibitors, we tested 
the effect of inhibiting both lysosomes and fibrinolysis concomitantly. As illustrated by 
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Figure 35B, co-incubation with chloroquine and PAI-1 plus aprotinin increased the 
number of immunodetectable and non-immunodetectable fibrin to a greater extent than 
chloroquine alone (2.7-fold and 3.1-fold, respectively). Due to this additive effect, it 
seems that fibrinolysis of fibrin meshes occurred upstream of, and could facilitate, their 
subsequent degradation in lysosomes. 
In order to corroborate these results, we used protein gel electrophoresis. We 
repeated the incubation of fluorescent fibrin mesh mixture with HUVECs for 30 minutes, 
followed by a 5-hour chase in the presence of degradation inhibitors. Then, we 
characterized HUVEC lysates using SDS-PAGE followed by Western blotting with an 
antibody to the β chain of fibrin. As shown in Figure 36A, immunodetection of cell 
lysates allowed us to distinguish a major band corresponding to the intact β chain of 
fibrin (~55 kDa). We were also able to detect a smaller band of ~22 kDa, which is the 
same size as the band observed upon tPA-stimulated degradation seen previously (recall 
Figure 30). Densitometry analysis showed that the ratio between the 22 kDa and the 55 
kDa bands was larger for cells incubated for 5 hours versus those incubated for 0 hours 
after fibrin mesh binding (Figure 36A). This suggested that the lower band was a product 
of degradation over time. Although we detected several bands between 55 and 22 kDa, 
also suggestive of degradation, these were difficult to quantify. Thus, we used the 22/55 
band ratio as an estimation of the effect of inhibitors on fibrin degradation. 
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Figure 36. SDS-PAGE and Western blot characterization of fibrin mesh interaction with endothelial 
cells. Activated HUVECs were incubated in the presence of red fluorescently labeled fibrinogen with 
thrombin for 30 minutes at 37˚C, followed by washing and incubation (chase) for 0 or 5 hours at 37˚C in 
the absence (control) or presence of chloroquine (Chloro), PAI-1 plus aprotinin, amiloride (Ami), or 
different combinations, as detailed in each panel. Cell lysates were processed for SDS-PAGE (A) Western 
blotting with an antibody to fibrin (bottom) and analysis by densitometry (top). Columns represent the ratio 
of intensities between the lower (~22 kDa) band and the upper (~55 kDa) band. (B) Direct fluorescence 
imaging after SDS-PAGE (bottom) and analysis by densitometry (top). Columns represent the intensity of 
the ~22 kDa band after normalization to a non-specific protein from Ponceau staining. Data represent mean 
± standard error of the mean. 
 
As seen in Figure 36A, the presence of amiloride, which disrupts internalization 
of fibrin meshes (recall Figure 32), appeared to fully inhibit degradation, suggesting that 
the detected fibrin degradation was intracellular and associated with the CAM-mediated 
pathway. Incubation with chloroquine also inhibited degradation, suggesting a role by 
lysosomes in this intracellular degradation, and validating our microscopy data However, 
this inhibition was lower than that of amiloride, suggesting that other factors contributed 
to intracellular degradation of fibrin meshes or that degradation products (of fibrinolysis) 
were also internalized. Indeed, incubation with PAI-1 plus aprotinin, to inhibit 
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fibrinolysis, also inhibited degradation. Finally, similar to our microscopy data, co-
incubation with chloroquine and PAI-1 appeared to have an additive effect on this 
inhibition. 
Alternatively, we directly imaged gels by fluorescence in order to detect fibrin 
regardless of its immunodetectability by anti-fibrin. This revealed one main band at ~22 
kDa (Figure 36B). Although we observed a 55 kDa band using this technique, its signal 
was much weaker compared to the 22 kDa band and, thus, it cannot be observed in Figure 
36B. Densitometry analysis of the 22 kDa band revealed that this band appeared to be a 
degradation product, as its intensity increased between 0 and 5 h. The presence of 
amiloride inhibited this degradation (suggesting intracellular degradation), as also 
occurred with chloroquine (suggesting lysosomal degradation). Contrary to our 
observation with Western blotting, chloroquine was sufficient to inhibit degradation to 
the same level as amiloride, while PAI-1 had very low (if any) effect on degradation. 
Thus, it seems that this band was the product of non-specific proteolysis in lysosomes, 
instead of the site-specific cleavage by plasmin, which retains antibody-binding sites on 
the fibrin chains. However, co-incubation with chloroquine and PAI-1 appeared to have 
an additive effect on this inhibition, as we previously observed by microscopy. 
Thus, overall, these data support a contribution by lysosomes in the degradation 
of internalized fibrin meshes. Meanwhile, fibrinolysis may help this degradation, possibly 
by cleaving fibrin meshes into smaller fragments upstream of their arrival to lysosomes. 
While these assays do not reveal whether fibrinolysis occurred prior to fibrin mesh 
uptake or inside of cells, our internalization data showing that endothelial cells internalize 
full-sized fibrin meshes that are immunodetectable by anti-fibrin, suggest that at least a 
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fraction of this fibrinolysis activity occurs within cells. It is likely that in a physiological 
setting, fibrinolysis inside and outside of endothelial cells helps to make lysosomal 
degradation of blood clot remnants more efficient. 
 
6.2.4. Characterization of model fibrin microemboli for in vivo studies. 
After describing the internalization of fibrin meshes by endothelial cells, followed 
by degradation in lysosomes, we next studied these interactions in vivo. To do this, we 
aimed at injecting pre-formed fibrin meshes in mice intravenously, a model previously 
used for studying blood clot interaction with the endothelium [22, 255]. Since injected 
pre-formed fibrin meshes (hereby referred to as fibrin microemboli) bind to the 
endothelium instead of forming directly on it, we first characterized their binding and 
endocytosis in cell culture. As seen in Figure 37A, fibrin microemboli showed similar 
dimensions as those seen with fibrin meshes (1.56±0.7 µm diameter, compared to 1.9±0.6 
µm for fibrin meshes), although they bound at lower numbers (2.36±0.1 fibrin 
microemboli per cell, compared to 9.4±0.7 fibrin meshes per cell). 
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Figure 37. Binding and internalization of fibrin microemboli by endothelial cells. Activated HUVECs 
were incubated in the presence pre-formed fluorescent fibrin microemboli pre-formed in test tubes and then 
added to cells for 30 minutes at 37˚C in the absence (control) or presence of non-specific mouse IgG or 
blocking antibodies to ICAM-1, VE-cadherin (VE-cad), integrin αvβ3, tPA receptor (tPAr), uPA receptor 
(uPAr), or thrombomodulin (Throm), or different concentrations of γ3 peptide or scrambled γ3 (γ3S). (A) 
Sample micrograph of fibrin microemboli (green) bound to endothelial cells (blue nuclei). Scale bar = 20 
µm (B) Quantification of fibrin microemboli binding per cell by microscopy, expressed as a percent of 
binding in the absence of antibodies (B) Quantification of fibrin microemboli binding per cell by 
microscopy, expressed as a percent of binding in the absence of peptides. (D) After the 30-minute binding 
period, HUVECs were incubated (chase) for 0, 30 minutes, 1, 3, 5 or 24 hours at 37˚C. After fixation, cells 
were immunostained with anti-fibrin, followed by a red fluorescent secondary antibody to differentiate 
non-internalized fibrin microemboli from internalized counterparts. Graph shows quantification of percent 
internalization by microscopy. In B and C, data are normalized to non-blocking control. Data represent 
mean ± standard error of the mean. * compares each condition to non-blocking control (p<0.05 by 
Student’s t-test). 
 
We determined the contribution of cell surface molecules to binding of fibrin 
microemboli to endothelial cells, as done with fibrin meshes (recall Figure 27). As shown 
in Figure 37B, blocking antibodies to ICAM-1 and VE-cadherin led to a reduction in 
binding of fibrin microemboli, while antibodies to the other molecules had no effect. The 
role of ICAM-1 in binding of fibrin microemboli was confirmed by a similar inhibitory 
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effect in the presence of γ3, the peptide derived from the fibrin(ogen) ICAM-1-binding 
region, in a concentration-dependent manner and also compared to compared to a 
scrambled γ3 (γ3S) control (Figure 37C). While VE-cadherin is highly localized to cell-
cell junctions, these results are in agreement with previous data that show a contribution 
by VE-cadherin to fibrin binding to endothelial monolayers [147]. Meanwhile, these data 
support the idea that ICAM-1 could also be a key molecule during the interaction of clot 
microemboli with the endothelium, possibly inducing CAM-mediated uptake as seen 
with fibrin meshes. Indeed, internalization assays with fibrin microemboli by HUVECs 
revealed similar kinetics compared to fibrin meshes (recall Figure 29B), with a slightly 
lower plateau at ~75% internalization around 3 hours (Figure 37D). 
 
6.2.5. Contribution by the CAM-mediated pathway to endothelial uptake of fibrin 
microemboli in vivo. 
Our results show a contribution by ICAM-1 to binding of both fibrin meshes 
formed on the endothelial cell surface and fibrin microemboli added to endothelial cells, 
followed by uptake and intracellular degradation. The endocytosis of fibrin polymers by 
the endothelium may be a mechanism to remove clot fragments from the endothelial 
surface, preventing sustained inflammation and reocclusion after fibrinolysis. To test this, 
we proceeded with in vivo studies. In order to examine possible uptake of fibrin 
microemboli in the context of CAM-mediated endocytosis, we compared wild-type mice 
to ICAM-1 or acid sphingomyelinase (ASM) knockout strains, both of which are 
deficient in this endocytic pathway [7]. We injected green fluorescent fibrin microemboli 
into mice and allowed sufficient time for internalization (1.5 hours), based on uptake 
136 
 
kinetics from our microscopy studies. Since we observed that the highest accumulation 
occurred in lung tissue, we performed confocal microscopy of lung capillaries to 
facilitate imaging. Here, we observed that in wild-type mice, injected fluorescent fibrin 
microemboli appeared to be surrounding the perinuclear region of cells, and they were 
found to be in the same z-plane as cell nuclei (Figure 38A). Meanwhile, in ICAM-1 and 
ASM knockout strains, fibrin microemboli remained on z-planes on top nuclei, 
suggesting that they were possibly found on the surface of the cell, and thus, not 





Figure 38. Confocal analysis of fibrin microemboli interaction with cells in mouse lungs. Wild-type, 
ICAM-1 knockout (-/-), or ASM knockout mice were injected with AF488 (green fluorescently labeled) 
fibrin microemboli (FnMe), followed by a 1.5-hour incubation. In (B) mice were then injected with AF594 
(red fluorescently labeled) fibrinogen. (A) Z-sections of FnMe associated with alveolar cells from the top 
of cells, where nuclei are not visible, to the plane where nuclei are visible. Bottom panels show a 
maximum-intensity composite and a reconstruction of the z-axis at the site indicated by a red horizontal 
line. Scale bar = 30 µm. (B) Maximum-intensity composite showing green FnMe and red fibrinogen (which 
appear as yellow when colocalizing). 
 
To corroborate this, we injected green fibrin microemboli for 1.5 hours, followed 
by injection of red fibrinogen. This circulating red fibrinogen could potentially be 
incorporated into green microemboli adhered to the endothelial surface. As seen in Figure 
38B, in wild-type mice, green microemboli did not overlap with red, suggesting that 
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microemboli were internalized and not accessible to circulating fibrinogen. Meanwhile, 
in both knockout strains there was colocalization of green microemboli and injected red 
fibrin(ogen). This supported the lack of internalization of these materials ICAM-1 and 
ASM knockout mice, which may possibly reignite fibrin formation from the injected 
fibrinogen. 
Although this technique does not provide sufficient resolution to confirm a 
deficiency in fibrin microemboli internalization for CAM-mediated pathway-deficient 
mice, other members of our group have validated these results using electron microscopy. 
These data show that in wild-type mice endothelial cells exhibit fibrous structures on 
their surface 30 minutes after injection with fibrin microemboli. These structures 
disappear from the endothelial surface at 3 hours, while electron dense vesicles appear 
inside the endothelium. In contrast, in ICAM-1 knockout mice, fibrin microemboli 
remain as fibrous structures on the surface of the cell even at 3 hours. (Muro, unpublished 
data). 
With this evidence that CAM-mediated uptake of fibrin microemboli may occur 
in vivo, we explored a possible physiological function of this endocytosis. As mentioned 
previously, it is possible that endothelial uptake of blood clot fragments/remnants on the 
endothelial surface could serve to prevent re-initiation of clotting. Not only would this be 
relevant in the natural resolution of clotting after wound healing, but could also have 
implications in the context of vessel re-occlusion following induced thrombolysis in a 
clinical context [256]. Thus, we tested this in mouse brains because clot-related 
pathologies in this organ have high clinical significance (e.g.: a major cause of stroke is 
brain embolism). We injected mice with different formulations as will be described 
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below, and used two-photon microscopy to image and quantify the number of fibrin 
microemboli found in 400×400 µm2 regions of post-mortem brain tissue (see Methods, 
Section 3.18 for details). 
To test for re-initiation of clotting after induced thrombolysis, we designed the 
following treatment consisting of three injections: First, inject non-fluorescent fibrin 
microemboli, such that they would accumulate in mouse brain tissue. Then, inject tPA in 
order to induce fibrinolysis, which, as speculated, still leaves fibrin remnants on the 
endothelial surface that could re-initiate clotting if not internalized by the endothelium. 
Finally, inject fluorescent fibrinogen, which would serve as a detectable circulating pool 
of monomer for new clotting if this occurs. 
Prior to this experiment, we confirmed its feasibility by characterizing our model 
in wild-type mice. As shown in Figure 39, injection of (red) fluorescent fibrin 
microemboli led to accumulation of 28.9±4.0 microemboli per field (2.3±0.1 µm in 
diameter, similar to dimensions observed in cell culture). Furthermore, injection of non-
fluorescent microemboli followed by (red) fluorescent fibrinogen led to the detection of 
23.7±3.5 microemboli. This showed that injected microemboli can accumulate in mouse 
brains, and also that injected circulating fibrinogen could interact with endothelium-
adhered fibrin materials. 
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Figure 39. Model to study fibrin microemboli in the brain in vivo. Two-photon microscopy was used to 
observe mouse brain tissue after injection of several formulations of fibrin microemboli (FnMe). 
Formulations are detailed in Methods, Section 3.18. In short, from left to right: AF594 fluorescent (red) 
FnMe; non-fluorescent (NF) FnMe followed by red fibrinogen (Fg); red fibrinogen; red FnMe followed by 
tPA. (A) Sample micrographs for each treatment. Scale bar = 100 µm (B) Quantification of FnMe per field 
for each treatment. Data represent mean ± standard error of the mean. 
 
Meanwhile, injection of only fluorescent fibrinogen into wild-type mice resulted 
in detection of 3.14±2.1 microemboli, which possibly corresponds to background levels 
of fibrinogen deposition on the endothelium, or background coagulation. This shows that 
in this model, mice were not prone to accumulate injected fibrinogen or form clots unless 
previously injected with microemboli. Finally, injection of fluorescent microemboli 
followed by tPA injection revealed 0.94±0.3 microemboli, showing that tPA injection 
could induce microemboli fibrinolysis. Although we were not able to directly detect the 
presence of remnants after tPA-induced fibrinolysis using this technique, other members 




We next tested our model in ICAM-1 knockout or ASM knockout mice. First, we 
compared fibrin microemboli accumulation in wild-type versus ICAM-1 knockout brains 
because our cell culture experiments showed that ICAM-1 was important in fibrin 
microemboli binding (Figure 40A). However, our in vivo data showed no difference in 
fibrin microemboli accumulation in mouse brains (26.9±2.5 microemboli in ICAM-1 
knockout brains versus 28.9±4.0 in wild-type). Since we did not induce inflammation to 
overexpress ICAM-1 in our mouse model and other endothelial molecules could 
contribute to binding, this result is reasonable. Also, mechanical entrapment could be 





Figure 40. Role of CAM-mediated endocytosis in fibrin microemboli clearance in vivo. Two-photon 
microscopy was used to observe mouse brain tissue after injection of several formulations of fibrin 
microemboli (FnMe; as detailed in Methods, Section 3.18) in wild-type, ICAM-1 knockout (-/-), or ASM 
knockout mice. (A) Micrographs after injection of AF594 fluorescent (red) FnMe. (B-D) Micrographs and 
quantification of FnMe per field after injection of red fibrinogen (Fg; B), red FnMe followed by tPA (C), or 
non-fluorescent (NF) FnMe followed by tPA, followed by red fibrinogen (D). Scale bars = 100 µm Data 
represent mean ± standard error of the mean. and are normalized to wild-type in B and C. * compares each 
value to wild-type (p<0.05 by Student’s t-test). 
 
Next, we compared injection of (red) fluorescent fibrinogen, to determine the 
basal levels of fibrinogen accumulation on the endothelium or background clotting in 
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knockout mice. As shown in Figure 40B, both knockout mouse strains showed similar 
basal levels of detected fibrin microemboli to wild-type, suggesting that the knockout 
strains did not have a predisposition for fibrin(ogen) deposition/clotting compared to 
wild-type. Then, we injected of (red) fluorescent fibrin microemboli followed by tPA in 
both knockout strains to determine the levels of fibrinolysis in these strains. This revealed 
low accumulation of microemboli similar to wild-type background (Figure 40C), 
indicating tPA-induced fibrinolysis was successful in both knockout strains. 
With these controls in place, we injected non-fluorescent fibrin microemboli 
(which would accumulate in brain tissue, as seen with fluorescent microemboli), 
followed by tPA (to induce fibrinolysis), and finally (red) fluorescent fibrinogen (which 
could potentially be incorporated into new clots, and allow for their detection). As shown 
in Figure 40D, after this treatment, wild-type mice showed 8.0±0.9 microemboli per 
field, while ICAM-1 knockout and ASM knockout mice showed 17.0±1.7 and 29.6±2.7 
microemboli, respectively. With our compounded data, this result suggests that in the 
absence of ICAM-1 and key elements of CAM-mediated endocytosis (acid 
sphingomyelinase), there was no endothelial uptake of tPA-induced fibrin microemboli 
remnants, leading to re-clotting, which could be detected upon injection of fluorescent 
fibrinogen. Thus, these in vivo data support a role for CAM-mediated endocytosis in the 
internalization of fibrin remnants by endothelial cells, effectively clearing from the 





The interaction between blood clots and endothelial cells evidently involves more 
than mechanical adherence, as several signaling mechanisms are activated once 
fibrinogen or fibrin materials interact with the endothelium [20, 72, 174, 257]. Beyond 
induction of angiogenesis and endothelial cytoskeleton rearrangement, previous studies 
show that this interaction can also prompt endothelial cells to engulf and transport clots 
out of the vasculature [22]. Expanding this current knowledge, our studies presented here 
show that endothelial cells can use the ICAM-1-dependent CAM-mediated pathway for 
internalization and intracellular degradation of fibrin polymers. 
We show that fibrin meshes and microemboli, a model for blood clot 
remnants/fragments, interact with endothelial cells in an ICAM-1-dependent manner, 
leading to enrichment of this molecule at binding sites, and also accompanied by 
enrichment of molecular players of CAM-mediated endocytosis, NHE1 and acid 
sphingomyelinase. Following binding, these fibrin materials are internalized by 
endothelial cells in a manner consistent with CAM-mediated endocytosis, both through 
its kinetics and its sensitivity to chemical inhibitors. After internalization, fibrin meshes 
follow a trafficking itinerary similar to that observed after CAM-mediated uptake of 
polystyrene-latex particles. This involves trafficking to lysosomes, where fibrin meshes 
are degraded. These results are supported by in vivo data that suggest uptake of injected 
fibrin microemboli occurs in wild-type mice, but not in ICAM-1 and ASM knockout 
mice, both of which are deficient in CAM-mediated uptake. Importantly, this endocytic 
pathway appears to be involved in maintaining the effective clearance of clots or clot 
remnants after fibrinolysis. 
145 
 
Based on our findings from Chapter 4, it might be possible that CAM-mediated 
endocytosis is also used for the transcellular transport of internalized fibrin materials. 
Indeed, colocalization of γ3 particles (which bind using the same peptide sequence as 
fibrin) with lysosomes is only partial (~70% colocalization) and these particles exhibit 
transport across endothelial monolayers. The similarly partial colocalization percentages 
found with our fibrin mesh model (~60% at maximum levels), may be an indication that a 
fraction of internalized fibrin polymers are also transported across cells. Thus, it is 
plausible that physiologically, a certain fraction of clot remnants are degraded in 
lysosomes, while another fraction undergo transcytosis and are degraded outside of the 
vasculature possibly by resident macrophages [241]. Our data from Chapter 4 suggesting 
that micron-sized objects are transported more efficiently than nanometer-sized 
counterparts may hold a key to understanding this potential divergent trafficking. Indeed, 
the extravasation observed in previous reports was observed for large clot fragments 




Chapter 7: Overall Conclusions 
 
7.1. Summary of Results, Significance, and Novelty 
CAM-mediated endocytosis is a pathway elicited when drug carriers bind 
multiple copies of ICAM-1 on the cell surface. Signaling events associated with this 
binding culminate in the uptake of drug carriers of a wide range of sizes [6, 77], which 
can be used as a strategy for delivery of therapeutics into cells. Despite significant efforts 
at characterizing ICAM-1-dependent CAM-mediated endocytosis for drug delivery [6-9, 
77, 101, 258-260], some of the regulatory mechanisms behind this pathway have not been 
fully elucidated. Furthermore, the possible physiological role of this endocytic pathway 
in endothelial cells remains unexplored. Motivated by these gaps in knowledge, the 
studies presented in this dissertation provide insight into the regulation of CAM-mediated 
drug delivery and the possible biological significance of this endocytic pathway. In short, 
this work expands our ability to optimize the design of drug carriers targeted to CAM-
mediated endocytosis by changing ICAM-1-targeted particle size and targeting moiety. In 
addition, this work provides significant evidence to assign a link between CAM-mediated 





7.1.1. Role of drug carrier size and targeting moiety on the outcomes of ICAM-1-
mediated endocytosis. 
First, we show through the use of ICAM-1-targeted particles of different sizes and 
coated with different targeting moieties (anti-ICAM versus γ3 peptide), that these two 
parameters can significantly affect the outcomes of CAM-mediated endocytosis. Anti-
ICAM particles bind to ICAM-1 on cells with higher efficiency than γ3 counterparts, 
although concomitant endocytosis can mitigate this difference. Increasing the size of 
ICAM-1-targeted particles lowers the initial efficiency of their uptake, yet after sufficient 
time, endothelial cells can endocytose particles of a wide range of sizes. Although this 
holds true for both anti-ICAM and γ3 particles, it appears that internalization of γ3 
particles is less efficient as particle size increases. Helping explain this, we provide data 
suggesting that higher ceramide production during CAM-mediated endocytosis is 
required as particle size increases. This is in agreement with other studies showing that 
ceramide is particularly suited to generate large membrane compartments and vesicular 
fusion [83, 86, 238]. Since γ3 particles appear to elicit low ceramide levels regardless of 
their size, they show consistently lower rates of CAM-mediated uptake. After 
internalization, micron-sized particles have a tendency to avoid lysosomes and be 
transported across cells more readily compared to nanoparticles. Meanwhile, γ3 
nanoparticles elicit lower lysosome trafficking and higher transport across cells compared 
to anti-ICAM particles of the same size. 
Overall, these results confirm previous reports by showing that the size and 
coating of ICAM-1-targeted particles can be manipulated to modulate the behavior of 
CAM-mediated endocytosis [77, 101]. However, the data presented here provide new 
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knowledge regarding the involvement of ceramide during this regulation, information 
about the use of γ3 particles specifically, and novel findings regarding transport across 
cell barriers. This knowledge will prove useful to preferentially regulate CAM-mediated 
drug carrier uptake rates, trafficking to lysosomes, and transport across cells. 
Furthermore, it is possible that these findings can have implications in the 
physiological function of CAM-mediated endocytosis, or other endocytic pathways. For 
example, although the concept of endocytosis and trafficking regulation due to ligand 
geometry has been considered in the past [96, 261-263], this is, to our knowledge, the 
first study to suggest a relationship between particle size, internalization, and the level of 
sphingomyelinase-driven ceramide enrichment. Since ceramide is gaining recognition as 
an important modulator of endocytosis, our results could have implications in this 
context. Indeed, the variety of materials internalized in a ceramide-dependent manner 
present a considerably wide range of sizes (from micron-sized Trypanosoma cruzi [264] 
to nanometer-sized viruses [13]). 
 
7.1.2. Role of ICAM-1-mediated endocytosis in leukocyte transmigration. 
Next, we show that the processes that precede lymphocyte transmigration as well 
as transmigration itself are dependent on key molecules of the CAM-mediated pathway. 
Using chemical inhibition, we see that NHE1 and acid sphingomyelinase, but not 
caveolae, are needed for the development of lymphocyte sampling. Furthermore, these 
molecules are required for transmigration of lymphocytes across HUVECs on porous 
membranes. Finally, inhibition of these molecules specifically disrupts the transcellular 
route of transmigration without affecting paracellular events. 
149 
 
These findings are supported by the fact that inhibition of NHE1 prevents 
accumulation of leukocytes at inflammatory sites in mice [265], while NHE1 null mice 
are protected from inflammation-related injuries [266]. Our results also highlight for the 
first time a mechanistic link between ceramide production by endothelial acid 
sphingomyelinase and transmigration, which helps explain previous findings that link 
ceramide to the inflammatory response. This includes events such as decreased leukocyte 
influx into alveolar space in acid sphingomyelinase knockout mice [229], and higher 
levels of leukocytes in tissue under metabolic imbalances that cause high levels of 
ceramide [267]. 
It is believed that although paracellular transmigration is tightly regulated, it 
might be used under scenarios in which the integrity of the endothelium is not of prime 
importance or is already compromised, such as pathological states and inflammation. 
Conversely, transcellular migration is thought to be more prevalent for surveillance 
functions, and also at specific sites such as the blood-brain barrier and lymph nodes [17]. 
Our findings presented here open new avenues of study to examine whether CAM-
mediated endocytosis is preferentially activated in these conditions or by these specific 
cell types, and if so, what drives this preferential activation. In turn, this knowledge will 
be useful in the development of clinical interventions during situations where the 
regulation between paracellular and transcellular transmigration might be disrupted, 
causing excessive opening of the endothelial monolayer [268, 269]. 
In addition to ICAM-1, when antibody-coated drug carriers bind multiple copies 
of PECAM-1, CAM-mediated uptake is activated. Since PECAM-1 is also a major 
contributor to leukocyte transmigration, it is possible that the mechanisms through which 
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this molecule contributes to transmigration also relate to CAM-mediated endocytosis. 
Most recent data on leukocyte transmigration show that vesicular dynamics associated 
with PECAM-1 are involved in transcellular transmigration, supporting this idea [130, 
131]. This opens the possibility that other CAMs may be associated with CAM-mediated 
endocytosis and help regulated leukocyte transmigration. Indeed, activated leukocyte cell 
adhesion molecule (ALCAM), CD47 and ICAM-2 have been implicated in specialized 
forms of transmigration [270-272]. Whether the engagement of these molecules by 
leukocytes directly elicits the signaling responses and morphological changes seen with 
ICAM-1 remains to be determined. However, our data encourage study of the 
involvement of other CAMs in transmigration within the context of CAM-mediated 
uptake. 
 
7.1.3. Role of ICAM-1-mediated endocytosis in clearance of blood clot 
fragments/remnants. 
Finally, our data also show that fibrin polymers (mimicking the 
remnants/fragments or clot fibrinolysis) bind do endothelial cells at sites enriched in 
ICAM-1, NHE1 and acid sphingomyelinase. After binding of fibrin meshes/microemboli, 
endothelial cells can internalize these micron-sized fibrin polymers without requiring 
their extracellular degradation. This uptake is dependent on regulatory elements of the 
CAM-mediated pathway, although other internalization mechanisms may also contribute 
to uptake. Finally, after internalization, fibrin meshes traffic to lysosomes, where fibrin is 
degraded. In mice, this endocytosis appears to protect the endothelium from re-initiation 
of clot growth. 
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Our studies shed light on the possible mechanism used for the recently described 
novel endothelial function of clot extravasation [22], which here we show may 
correspond to CAM-mediated endocytosis. Indeed, using porous membranes, we show 
that these clot-fragment mimicking fibrin meshes appear to be transported across cells. In 
our case, we also identify that a fraction of internalized fibrin meshes colocalizes with 
lysosomes, which is followed by lysosomal degradation of internalized fibrin objects. 
However, this colocalization is partial, and may be affected by factors such as fibrin mesh 
size and the fact that our studies were done on coverslips. Thus, it is possible that 
endothelial cells are equipped to both transport clots into tissue, and also degrade them in 
lysosomes. This clearance by the endothelium might be a mechanism for prevention of 
recurrent formation of clots after fibrinolysis, or housekeeping maintenance of the basal 
liquid state of blood. Abnormalities in ICAM-1-dependent uptake may be a cause for 
clot-related pathologies, bringing important clinical significance to our results. Indeed, 
thrombosis and vessel re-occlusion represent one of the most common causes of 
disability and mortality in certain countries such as the USA, associated to acute and 
chronic vascular pathologies [161]. Our findings could serve for development of 
interventions for thrombosis-associated conditions, such as ischemic stroke, deep vein 
thrombosis, atherosclerosis, hypertension, and diabetes. 
Overall, the findings explored in this dissertation contribute to the field of carrier-
assisted drug delivery through a better understanding of how endothelial cells respond to 
objects with different physical properties. Furthermore, they shed light on the function of 




7.2. Future Directions 
Beyond the contributions of this work to the understanding of CAM-mediated 
endocytosis and endothelial function, a variety of potential studies emerge from our data 
and interpretations. 
In the context of drug delivery, future studies should be performed in order to 
more systematically understand the role of particle size and valency on the outcomes of 
CAM-mediated endocytosis. This could be done by using particles of different sizes as 
done in these studies, but also coated with different densities of anti-ICAM or γ3 on their 
surface. Antibody coating densities on the surface of particles could be matched for 
different sizes in order to determine the extent of binding, ceramide enrichment, 
internalization, lysosome trafficking, and transport. In this context, it will be important to 
determine the avidity of each particle formulation and relate this parameter to the 
outcomes of the CAM-mediated pathway. Our experimental design did not compare the 
trafficking and transport rates of γ3 particles of different sizes. However, as seen with 
anti-ICAM particles, size is an important parameter defining the outcomes of CAM-
mediated uptake. Future work should aim at studying this size relationship by coating 
particles of different sizes with γ3 and comparing their trafficking to lysosomes and 
transport across cells. Not only would this be significant in the context of drug delivery, 
but it could also serve as a preliminary model to understand how binding of ICAM-1 by 
fibrin polymers (such as clot fragments) of different sizes can affect binding, 
internalization and intracellular trafficking of these physiologically relevant materials. 
Finally, it is known that anti-ICAM clone R6.5 used in our studies and γ3 bind to 
different epitopes of ICAM-1. However, any epitope-related effects that may have been 
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manifested in our studies were potentially confounded by other differences between anti-
ICAM and γ3. For instance, since anti-ICAM is a full antibody, it contains an Fc region 
that may bind to Fc receptors on endothelial cells and elicit additional responses. 
Previous data suggest that this is unlikely since the interaction between IgG-coated 
particles and endothelial cells does not involve significant binding or induce substantial 
endocytosis [189, 190]. However, this may be addressed by coating particles only with 
the F(ab’)2 region of anti-ICAM. Furthermore, anti-ICAM and γ3 have different 
affinities to ICAM-1. Thus, it will be interesting, thus, to coat particles with targeting 
moieties that bind different epitopes of ICAM-1 with similar affinity (including a variety 
of available antibodies to ICAM-1) and determine if and how this affects the outcomes of 
CAM-mediated uptake. 
In the context of leukocyte transmigration, it will be important to perform similar 
sampling and transmigration assays using genetic models in order to validate the role of 
CAM-mediated endocytosis. For example, transmigration assays should be repeated 
using wild-type leukocytes incubated with ICAM-1, NHE1 and acid sphingomyelinase 
knockout or knockdown endothelial cells. Meanwhile, using ICAM-1, NHE1 and acid 
sphingomyelinase knockout or knockdown lymphocytes with wild-type endothelial cells 
will further help elucidate the role of endothelial CAM-mediated endocytosis in 
transmigration. 
Time-lapse imaging of leukocyte transmigration in vivo after staining endothelial 
junctions will allow for more physiologically relevant exploration of these phenomena 
and account for the role of blood flow and other factors. Such in vivo experiments could 
be performed using the aforementioned mouse knockout strains, if budget permits, after 
154 
 
bone-marrow transplantation to allow the in vivo interaction between wild-type 
leukocytes and knockout endothelium. 
As mentioned earlier, leukocyte transmigration rates differ depending on the 
endothelial cell type, the leukocyte type, and the activation conditions. Thus, it will be 
important to extend these studies to other leukocytes, including macrophages and 
neutrophils. Also, future work should look at other endothelial cell types, such as brain 
endothelial cells and endothelial cells from high endothelial venules, which are thought to 
exhibit higher rates of transcellular transmigration. Furthermore, it known that leukocytes 
can migrate across non-endothelial cells, and it has been recently shown that they can 
migrate transcellularly across fibroblasts [273]. The mechanisms behind these events, and 
whether or not they relate to CAM-mediated endocytosis, will be important to consider, 
particularly with the knowledge that the CAM-mediated pathway occurs in other cell 
types including fibroblasts [274] and epithelial cells [10]. 
Regarding clot remnant uptake, our model did not vary the properties of fibrin 
meshes, which could affect clot resolution, degradation and trafficking itinerary. Thus, 
future studies could observe fibrin mesh endocytosis using different ratios of thrombin to 
fibrinogen to vary mesh size, density and level of cross-linking. In particular, our data 
suggest that particles directed to the epitope on ICAM-1 bound by fibrin (γ3 particles) 
could be internalized in a size-restrictive manner. Furthermore, we have observed that 
particle size can regulate lysosome trafficking versus transport across cells. Thus, 
developing a system that permits systematic probing of different clot fragment sizes and 
how this might affect their uptake, degradation and possible transport across the 
endothelium, will be important. Finally, it will be crucial to determine the functional 
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significance of CAM-mediated clearance of blood clot remnants in mouse models by 
performing time-lapse experiments that measure blood flow as an indicator of vessel 
blockade, and also in well-established mouse models of clot-related pathologies, such as 
ischemia-reperfusion, deep-vein thrombosis, and atherosclerosis. In addition to this, our 
experimental design was such that mice were injected with thrombin-containing fibrin 
microemboli formulations, which may have affected the integrity of the endothelium and 
confounded our results [275]. Thus, future work should account for this by measuring 
endothelial permeability under the thrombin concentrations found in our fibrin 
microemboli formulations, or add thrombin-inhibiting agents to the formulation prior to 
injection. 
It is possible that ICAM-1-triggered CAM-mediated endocytosis has other 
functions beyond those explored in this dissertation. Primarily, some pathogens bind to 
ICAM-1, including rhinovirus, poliovirus, HIV [276], and Plasmodium falciparum-
infected erythrocytes during malarial infection [277]. In addition, some bacteria may bind 
to glycosylated residues of ICAM-1 [278] and exploit CAM-mediated transcytosis across 
the gastrointestinal or lung epithelium. Future work should address potential subversion 
of CAM-mediated endocytosis by these pathogens for cell/tissue invasion, eventually 
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